#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Disrupted modulation of thalamus activation and thalamocortical connectivity during dual task performance in schizophrenia
#Text=Despite considerable evidence showing thalamus anatomy and connectivity abnormalities in schizophrenia, how these abnormalities are reflected in thalamus function during cognition is relatively understudied.
1-1	0-9	Disrupted	_	
1-2	10-20	modulation	_	
1-3	21-23	of	_	
1-4	24-32	thalamus	_	
1-5	33-43	activation	_	
1-6	44-47	and	_	
1-7	48-63	thalamocortical	_	
1-8	64-76	connectivity	_	
1-9	77-83	during	_	
1-10	84-88	dual	_	
1-11	89-93	task	_	
1-12	94-105	performance	_	
1-13	106-108	in	_	
1-14	109-122	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-15	123-130	Despite	_	
1-16	131-143	considerable	_	
1-17	144-152	evidence	_	
1-18	153-160	showing	_	
1-19	161-169	thalamus	_	
1-20	170-177	anatomy	_	
1-21	178-181	and	_	
1-22	182-194	connectivity	_	
1-23	195-208	abnormalities	_	
1-24	209-211	in	_	
1-25	212-225	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-26	225-226	,	_	
1-27	227-230	how	_	
1-28	231-236	these	_	
1-29	237-250	abnormalities	_	
1-30	251-254	are	_	
1-31	255-264	reflected	_	
1-32	265-267	in	_	
1-33	268-276	thalamus	_	
1-34	277-285	function	_	
1-35	286-292	during	_	
1-36	293-302	cognition	_	
1-37	303-305	is	_	
1-38	306-316	relatively	_	
1-39	317-329	understudied	_	
1-40	329-330	.	_	

#Text=Modulation of thalamic connectivity with the prefrontal cortex (PFC) is required for higher-order cognitive processes, which are often impaired in schizophrenia.
2-1	331-341	Modulation	_	
2-2	342-344	of	_	
2-3	345-353	thalamic	_	
2-4	354-366	connectivity	_	
2-5	367-371	with	_	
2-6	372-375	the	_	
2-7	376-386	prefrontal	_	
2-8	387-393	cortex	_	
2-9	394-395	(	_	
2-10	395-398	PFC	_	
2-11	398-399	)	_	
2-12	400-402	is	_	
2-13	403-411	required	_	
2-14	412-415	for	_	
2-15	416-428	higher-order	_	
2-16	429-438	cognitive	_	
2-17	439-448	processes	_	
2-18	448-449	,	_	
2-19	450-455	which	_	
2-20	456-459	are	_	
2-21	460-465	often	_	
2-22	466-474	impaired	_	
2-23	475-477	in	_	
2-24	478-491	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-25	491-492	.	_	

#Text=To address this gap, we investigated how thalamus function and thalamus-PFC connectivity under different levels of cognitive demand may be disrupted in schizophrenia.
3-1	493-495	To	_	
3-2	496-503	address	_	
3-3	504-508	this	_	
3-4	509-512	gap	_	
3-5	512-513	,	_	
3-6	514-516	we	_	
3-7	517-529	investigated	_	
3-8	530-533	how	_	
3-9	534-542	thalamus	_	
3-10	543-551	function	_	
3-11	552-555	and	_	
3-12	556-568	thalamus-PFC	_	
3-13	569-581	connectivity	_	
3-14	582-587	under	_	
3-15	588-597	different	_	
3-16	598-604	levels	_	
3-17	605-607	of	_	
3-18	608-617	cognitive	_	
3-19	618-624	demand	_	
3-20	625-628	may	_	
3-21	629-631	be	_	
3-22	632-641	disrupted	_	
3-23	642-644	in	_	
3-24	645-658	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
3-25	658-659	.	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	

#Text=Participants underwent fMRI scanning while performing an event-related two-alternative forced choice task under Single and Dual task conditions.
4-1	660-672	Participants	_	
4-2	673-682	underwent	_	
4-3	683-687	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-4	688-696	scanning	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-5	697-702	while	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-6	703-713	performing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-7	714-716	an	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-8	717-730	event-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-9	731-746	two-alternative	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-10	747-753	forced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-11	754-760	choice	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-12	761-765	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-13	766-771	under	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-14	772-778	Single	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-15	779-782	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-16	783-787	Dual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-17	788-792	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-18	793-803	conditions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-19	803-804	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	

#Text=In the Single task condition, participants responded either to a visual cue with a well-learned motor response, or an audio cue with a well-learned vocal response.
5-1	805-807	In	_	
5-2	808-811	the	_	
5-3	812-818	Single	_	
5-4	819-823	task	_	
5-5	824-833	condition	_	
5-6	833-834	,	_	
5-7	835-847	participants	_	
5-8	848-857	responded	_	
5-9	858-864	either	_	
5-10	865-867	to	_	
5-11	868-869	a	_	
5-12	870-876	visual	_	
5-13	877-880	cue	_	
5-14	881-885	with	_	
5-15	886-887	a	_	
5-16	888-900	well-learned	_	
5-17	901-906	motor	_	
5-18	907-915	response	_	
5-19	915-916	,	_	
5-20	917-919	or	_	
5-21	920-922	an	_	
5-22	923-928	audio	_	
5-23	929-932	cue	_	
5-24	933-937	with	_	
5-25	938-939	a	_	
5-26	940-952	well-learned	_	
5-27	953-958	vocal	_	
5-28	959-967	response	_	
5-29	967-968	.	_	

#Text=In the Dual task condition, participants performed both tasks.
6-1	969-971	In	_	
6-2	972-975	the	_	
6-3	976-980	Dual	_	
6-4	981-985	task	_	
6-5	986-995	condition	_	
6-6	995-996	,	_	
6-7	997-1009	participants	_	
6-8	1010-1019	performed	_	
6-9	1020-1024	both	_	
6-10	1025-1030	tasks	_	
6-11	1030-1031	.	_	

#Text=Thalamic connectivity with task relevant regions of the PFC for each condition was measured using beta-series correlation.
7-1	1032-1040	Thalamic	_	
7-2	1041-1053	connectivity	_	
7-3	1054-1058	with	_	
7-4	1059-1063	task	_	
7-5	1064-1072	relevant	_	
7-6	1073-1080	regions	_	
7-7	1081-1083	of	_	
7-8	1084-1087	the	_	
7-9	1088-1091	PFC	_	
7-10	1092-1095	for	_	
7-11	1096-1100	each	_	
7-12	1101-1110	condition	_	
7-13	1111-1114	was	_	
7-14	1115-1123	measured	_	
7-15	1124-1129	using	_	
7-16	1130-1141	beta-series	_	
7-17	1142-1153	correlation	_	
7-18	1153-1154	.	_	

#Text=Individuals with schizophrenia demonstrated less modulation of both mediodorsal thalamus activation and thalamus-PFC connectivity with increased cognitive demand.
8-1	1155-1166	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
8-2	1167-1171	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
8-3	1172-1185	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
8-4	1186-1198	demonstrated	_	
8-5	1199-1203	less	_	
8-6	1204-1214	modulation	_	
8-7	1215-1217	of	_	
8-8	1218-1222	both	_	
8-9	1223-1234	mediodorsal	_	
8-10	1235-1243	thalamus	_	
8-11	1244-1254	activation	_	
8-12	1255-1258	and	_	
8-13	1259-1271	thalamus-PFC	_	
8-14	1272-1284	connectivity	_	
8-15	1285-1289	with	_	
8-16	1290-1299	increased	_	
8-17	1300-1309	cognitive	_	
8-18	1310-1316	demand	_	
8-19	1316-1317	.	_	

#Text=In contrast, their ability to modulate PFC function during task performance was maintained.
9-1	1318-1320	In	_	
9-2	1321-1329	contrast	_	
9-3	1329-1330	,	_	
9-4	1331-1336	their	_	
9-5	1337-1344	ability	_	
9-6	1345-1347	to	_	
9-7	1348-1356	modulate	_	
9-8	1357-1360	PFC	_	
9-9	1361-1369	function	_	
9-10	1370-1376	during	_	
9-11	1377-1381	task	_	
9-12	1382-1393	performance	_	
9-13	1394-1397	was	_	
9-14	1398-1408	maintained	_	
9-15	1408-1409	.	_	

#Text=These results suggest that the pathophysiology of cognitive impairment in schizophrenia is associated with thalamus-PFC circuitry and suggests that the thalamus, along with the PFC, should be a focus of investigation.
10-1	1410-1415	These	_	
10-2	1416-1423	results	_	
10-3	1424-1431	suggest	_	
10-4	1432-1436	that	_	
10-5	1437-1440	the	_	
10-6	1441-1456	pathophysiology	_	
10-7	1457-1459	of	_	
10-8	1460-1469	cognitive	_	
10-9	1470-1480	impairment	_	
10-10	1481-1483	in	_	
10-11	1484-1497	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
10-12	1498-1500	is	_	
10-13	1501-1511	associated	_	
10-14	1512-1516	with	_	
10-15	1517-1529	thalamus-PFC	_	
10-16	1530-1539	circuitry	_	
10-17	1540-1543	and	_	
10-18	1544-1552	suggests	_	
10-19	1553-1557	that	_	
10-20	1558-1561	the	_	
10-21	1562-1570	thalamus	_	
10-22	1570-1571	,	_	
10-23	1572-1577	along	_	
10-24	1578-1582	with	_	
10-25	1583-1586	the	_	
10-26	1587-1590	PFC	_	
10-27	1590-1591	,	_	
10-28	1592-1598	should	_	
10-29	1599-1601	be	_	
10-30	1602-1603	a	_	
10-31	1604-1609	focus	_	
10-32	1610-1612	of	_	
10-33	1613-1626	investigation	_	
10-34	1626-1627	.	_	

#Text=Introduction
#Text=Abnormal function of the thalamus and thalamic connectivity with the prefrontal cortex (PFC) is thought to be fundamental to cognitive impairment in schizophrenia.
11-1	1628-1640	Introduction	_	
11-2	1641-1649	Abnormal	_	
11-3	1650-1658	function	_	
11-4	1659-1661	of	_	
11-5	1662-1665	the	_	
11-6	1666-1674	thalamus	_	
11-7	1675-1678	and	_	
11-8	1679-1687	thalamic	_	
11-9	1688-1700	connectivity	_	
11-10	1701-1705	with	_	
11-11	1706-1709	the	_	
11-12	1710-1720	prefrontal	_	
11-13	1721-1727	cortex	_	
11-14	1728-1729	(	_	
11-15	1729-1732	PFC	_	
11-16	1732-1733	)	_	
11-17	1734-1736	is	_	
11-18	1737-1744	thought	_	
11-19	1745-1747	to	_	
11-20	1748-1750	be	_	
11-21	1751-1762	fundamental	_	
11-22	1763-1765	to	_	
11-23	1766-1775	cognitive	_	
11-24	1776-1786	impairment	_	
11-25	1787-1789	in	_	
11-26	1790-1803	schizophrenia	_	
11-27	1803-1804	.	_	

#Text=There is considerable evidence that the structure and connectivity of the thalamus is abnormal in schizophrenia.
12-1	1805-1810	There	_	
12-2	1811-1813	is	_	
12-3	1814-1826	considerable	_	
12-4	1827-1835	evidence	_	
12-5	1836-1840	that	_	
12-6	1841-1844	the	_	
12-7	1845-1854	structure	_	
12-8	1855-1858	and	_	
12-9	1859-1871	connectivity	_	
12-10	1872-1874	of	_	
12-11	1875-1878	the	_	
12-12	1879-1887	thalamus	_	
12-13	1888-1890	is	_	
12-14	1891-1899	abnormal	_	
12-15	1900-1902	in	_	
12-16	1903-1916	schizophrenia	_	
12-17	1916-1917	.	_	

#Text=However, few studies have investigated thalamic dysfunction during cognitive tasks.
13-1	1918-1925	However	_	
13-2	1925-1926	,	_	
13-3	1927-1930	few	_	
13-4	1931-1938	studies	_	
13-5	1939-1943	have	_	
13-6	1944-1956	investigated	_	
13-7	1957-1965	thalamic	_	
13-8	1966-1977	dysfunction	_	
13-9	1978-1984	during	_	
13-10	1985-1994	cognitive	_	
13-11	1995-2000	tasks	_	
13-12	2000-2001	.	_	

#Text=Several early studies found thalamic hypofunction in schizophrenia while performing verbal and spatial working memory tasks, attention tasks, prepulse inhibition and oddball tasks, though other studies have found thalamus hyperfunction while performing sensory gating tasks, word encoding tasks and target detection.
14-1	2002-2009	Several	_	
14-2	2010-2015	early	_	
14-3	2016-2023	studies	_	
14-4	2024-2029	found	_	
14-5	2030-2038	thalamic	_	
14-6	2039-2051	hypofunction	_	
14-7	2052-2054	in	_	
14-8	2055-2068	schizophrenia	_	
14-9	2069-2074	while	_	
14-10	2075-2085	performing	_	
14-11	2086-2092	verbal	_	
14-12	2093-2096	and	_	
14-13	2097-2104	spatial	_	
14-14	2105-2112	working	_	
14-15	2113-2119	memory	_	
14-16	2120-2125	tasks	_	
14-17	2125-2126	,	_	
14-18	2127-2136	attention	_	
14-19	2137-2142	tasks	_	
14-20	2142-2143	,	_	
14-21	2144-2152	prepulse	_	
14-22	2153-2163	inhibition	_	
14-23	2164-2167	and	_	
14-24	2168-2175	oddball	_	
14-25	2176-2181	tasks	_	
14-26	2181-2182	,	_	
14-27	2183-2189	though	_	
14-28	2190-2195	other	_	
14-29	2196-2203	studies	_	
14-30	2204-2208	have	_	
14-31	2209-2214	found	_	
14-32	2215-2223	thalamus	_	
14-33	2224-2237	hyperfunction	_	
14-34	2238-2243	while	_	
14-35	2244-2254	performing	_	
14-36	2255-2262	sensory	_	
14-37	2263-2269	gating	_	
14-38	2270-2275	tasks	_	
14-39	2275-2276	,	_	
14-40	2277-2281	word	_	
14-41	2282-2290	encoding	_	
14-42	2291-2296	tasks	_	
14-43	2297-2300	and	_	
14-44	2301-2307	target	_	
14-45	2308-2317	detection	_	
14-46	2317-2318	.	_	

#Text=These studies typically examined thalamic function during a cognitive task compared to baseline, rather than modulation by cognitive demand.
15-1	2319-2324	These	_	
15-2	2325-2332	studies	_	
15-3	2333-2342	typically	_	
15-4	2343-2351	examined	_	
15-5	2352-2360	thalamic	_	
15-6	2361-2369	function	_	
15-7	2370-2376	during	_	
15-8	2377-2378	a	_	
15-9	2379-2388	cognitive	_	
15-10	2389-2393	task	_	
15-11	2394-2402	compared	_	
15-12	2403-2405	to	_	
15-13	2406-2414	baseline	_	
15-14	2414-2415	,	_	
15-15	2416-2422	rather	_	
15-16	2423-2427	than	_	
15-17	2428-2438	modulation	_	
15-18	2439-2441	by	_	
15-19	2442-2451	cognitive	_	
15-20	2452-2458	demand	_	
15-21	2458-2459	.	_	

#Text=Thalamic hypofunction was more prominent during tasks with higher cognitive demand, such as tasks requiring mental updating or manipulation.
16-1	2460-2468	Thalamic	_	
16-2	2469-2481	hypofunction	_	
16-3	2482-2485	was	_	
16-4	2486-2490	more	_	
16-5	2491-2500	prominent	_	
16-6	2501-2507	during	_	
16-7	2508-2513	tasks	_	
16-8	2514-2518	with	_	
16-9	2519-2525	higher	_	
16-10	2526-2535	cognitive	_	
16-11	2536-2542	demand	_	
16-12	2542-2543	,	_	
16-13	2544-2548	such	_	
16-14	2549-2551	as	_	
16-15	2552-2557	tasks	_	
16-16	2558-2567	requiring	_	
16-17	2568-2574	mental	_	
16-18	2575-2583	updating	_	
16-19	2584-2586	or	_	
16-20	2587-2599	manipulation	_	
16-21	2599-2600	.	_	

#Text=In a modified Sternberg task, thalamic hypofunction was observed when manipulation of maintained information was required, but not while passively maintaining information.
17-1	2601-2603	In	_	
17-2	2604-2605	a	_	
17-3	2606-2614	modified	_	
17-4	2615-2624	Sternberg	_	
17-5	2625-2629	task	_	
17-6	2629-2630	,	_	
17-7	2631-2639	thalamic	_	
17-8	2640-2652	hypofunction	_	
17-9	2653-2656	was	_	
17-10	2657-2665	observed	_	
17-11	2666-2670	when	_	
17-12	2671-2683	manipulation	_	
17-13	2684-2686	of	_	
17-14	2687-2697	maintained	_	
17-15	2698-2709	information	_	
17-16	2710-2713	was	_	
17-17	2714-2722	required	_	
17-18	2722-2723	,	_	
17-19	2724-2727	but	_	
17-20	2728-2731	not	_	
17-21	2732-2737	while	_	
17-22	2738-2747	passively	_	
17-23	2748-2759	maintaining	_	
17-24	2760-2771	information	_	
17-25	2771-2772	.	_	

#Text=A recent study found thalamic hypofunction during encoding and maintenance, but not retrieval of spatial information.
18-1	2773-2774	A	_	
18-2	2775-2781	recent	_	
18-3	2782-2787	study	_	
18-4	2788-2793	found	_	
18-5	2794-2802	thalamic	_	
18-6	2803-2815	hypofunction	_	
18-7	2816-2822	during	_	
18-8	2823-2831	encoding	_	
18-9	2832-2835	and	_	
18-10	2836-2847	maintenance	_	
18-11	2847-2848	,	_	
18-12	2849-2852	but	_	
18-13	2853-2856	not	_	
18-14	2857-2866	retrieval	_	
18-15	2867-2869	of	_	
18-16	2870-2877	spatial	_	
18-17	2878-2889	information	_	
18-18	2889-2890	.	_	

#Text=In contrast, thalamic hyperfunction was observed during sensory tasks.
19-1	2891-2893	In	_	
19-2	2894-2902	contrast	_	
19-3	2902-2903	,	_	
19-4	2904-2912	thalamic	_	
19-5	2913-2926	hyperfunction	_	
19-6	2927-2930	was	_	
19-7	2931-2939	observed	_	
19-8	2940-2946	during	_	
19-9	2947-2954	sensory	_	
19-10	2955-2960	tasks	_	
19-11	2960-2961	.	_	

#Text=These thalamic findings are consistent with PFC dysfunction in schizophrenia, where a shifted inverted-U shaped curve is observed in patients, such that PFC hyperfunction is observed in high performing patients, or during easier tasks, and PFC hypofunction is observed in low performing patients, or during difficult tasks.
20-1	2962-2967	These	_	
20-2	2968-2976	thalamic	_	
20-3	2977-2985	findings	_	
20-4	2986-2989	are	_	
20-5	2990-3000	consistent	_	
20-6	3001-3005	with	_	
20-7	3006-3009	PFC	_	
20-8	3010-3021	dysfunction	_	
20-9	3022-3024	in	_	
20-10	3025-3038	schizophrenia	_	
20-11	3038-3039	,	_	
20-12	3040-3045	where	_	
20-13	3046-3047	a	_	
20-14	3048-3055	shifted	_	
20-15	3056-3066	inverted-U	_	
20-16	3067-3073	shaped	_	
20-17	3074-3079	curve	_	
20-18	3080-3082	is	_	
20-19	3083-3091	observed	_	
20-20	3092-3094	in	_	
20-21	3095-3103	patients	_	
20-22	3103-3104	,	_	
20-23	3105-3109	such	_	
20-24	3110-3114	that	_	
20-25	3115-3118	PFC	_	
20-26	3119-3132	hyperfunction	_	
20-27	3133-3135	is	_	
20-28	3136-3144	observed	_	
20-29	3145-3147	in	_	
20-30	3148-3152	high	_	
20-31	3153-3163	performing	_	
20-32	3164-3172	patients	_	
20-33	3172-3173	,	_	
20-34	3174-3176	or	_	
20-35	3177-3183	during	_	
20-36	3184-3190	easier	_	
20-37	3191-3196	tasks	_	
20-38	3196-3197	,	_	
20-39	3198-3201	and	_	
20-40	3202-3205	PFC	_	
20-41	3206-3218	hypofunction	_	
20-42	3219-3221	is	_	
20-43	3222-3230	observed	_	
20-44	3231-3233	in	_	
20-45	3234-3237	low	_	
20-46	3238-3248	performing	_	
20-47	3249-3257	patients	_	
20-48	3257-3258	,	_	
20-49	3259-3261	or	_	
20-50	3262-3268	during	_	
20-51	3269-3278	difficult	_	
20-52	3279-3284	tasks	_	
20-53	3284-3285	.	_	

#Text=In this study, we investigated modulation of thalamic function by cognitive demand in schizophrenia.
21-1	3286-3288	In	_	
21-2	3289-3293	this	_	
21-3	3294-3299	study	_	
21-4	3299-3300	,	_	
21-5	3301-3303	we	_	
21-6	3304-3316	investigated	_	
21-7	3317-3327	modulation	_	
21-8	3328-3330	of	_	
21-9	3331-3339	thalamic	_	
21-10	3340-3348	function	_	
21-11	3349-3351	by	_	
21-12	3352-3361	cognitive	_	
21-13	3362-3368	demand	_	
21-14	3369-3371	in	_	
21-15	3372-3385	schizophrenia	_	
21-16	3385-3386	.	_	

#Text=The thalamus is composed of multiple nuclei, with differentiable structure, function and connectivity patterns.
22-1	3387-3390	The	_	
22-2	3391-3399	thalamus	_	
22-3	3400-3402	is	_	
22-4	3403-3411	composed	_	
22-5	3412-3414	of	_	
22-6	3415-3423	multiple	_	
22-7	3424-3430	nuclei	_	
22-8	3430-3431	,	_	
22-9	3432-3436	with	_	
22-10	3437-3451	differentiable	_	
22-11	3452-3461	structure	_	
22-12	3461-3462	,	_	
22-13	3463-3471	function	_	
22-14	3472-3475	and	_	
22-15	3476-3488	connectivity	_	
22-16	3489-3497	patterns	_	
22-17	3497-3498	.	_	

#Text=Two thalamic nuclei have been particularly implicated during cognitive function; the mediodorsal nucleus (MD) and pulvinar (PUL).
23-1	3499-3502	Two	_	
23-2	3503-3511	thalamic	_	
23-3	3512-3518	nuclei	_	
23-4	3519-3523	have	_	
23-5	3524-3528	been	_	
23-6	3529-3541	particularly	_	
23-7	3542-3552	implicated	_	
23-8	3553-3559	during	_	
23-9	3560-3569	cognitive	_	
23-10	3570-3578	function	_	
23-11	3578-3579	;	_	
23-12	3580-3583	the	_	
23-13	3584-3595	mediodorsal	_	
23-14	3596-3603	nucleus	_	
23-15	3604-3605	(	_	
23-16	3605-3607	MD	_	
23-17	3607-3608	)	_	
23-18	3609-3612	and	_	
23-19	3613-3621	pulvinar	_	
23-20	3622-3623	(	_	
23-21	3623-3626	PUL	_	
23-22	3626-3627	)	_	
23-23	3627-3628	.	_	

#Text=The MD has prominent anatomical connectivity with the PFC, and is central to various cognitive processes including working memory, attention and adaptive decision making (see for reviews).
24-1	3629-3632	The	_	
24-2	3633-3635	MD	_	
24-3	3636-3639	has	_	
24-4	3640-3649	prominent	_	
24-5	3650-3660	anatomical	_	
24-6	3661-3673	connectivity	_	
24-7	3674-3678	with	_	
24-8	3679-3682	the	_	
24-9	3683-3686	PFC	_	
24-10	3686-3687	,	_	
24-11	3688-3691	and	_	
24-12	3692-3694	is	_	
24-13	3695-3702	central	_	
24-14	3703-3705	to	_	
24-15	3706-3713	various	_	
24-16	3714-3723	cognitive	_	
24-17	3724-3733	processes	_	
24-18	3734-3743	including	_	
24-19	3744-3751	working	_	
24-20	3752-3758	memory	_	
24-21	3758-3759	,	_	
24-22	3760-3769	attention	_	
24-23	3770-3773	and	_	
24-24	3774-3782	adaptive	_	
24-25	3783-3791	decision	_	
24-26	3792-3798	making	_	
24-27	3799-3800	(	_	
24-28	3800-3803	see	_	
24-29	3804-3807	for	_	
24-30	3808-3815	reviews	_	
24-31	3815-3816	)	_	
24-32	3816-3817	.	_	

#Text=The PUL shows extensive connectivity with the posterior parietal cortex and is implicated in visual attention processes (see for review).
25-1	3818-3821	The	_	
25-2	3822-3825	PUL	_	
25-3	3826-3831	shows	_	
25-4	3832-3841	extensive	_	
25-5	3842-3854	connectivity	_	
25-6	3855-3859	with	_	
25-7	3860-3863	the	_	
25-8	3864-3873	posterior	_	
25-9	3874-3882	parietal	_	
25-10	3883-3889	cortex	_	
25-11	3890-3893	and	_	
25-12	3894-3896	is	_	
25-13	3897-3907	implicated	_	
25-14	3908-3910	in	_	
25-15	3911-3917	visual	_	
25-16	3918-3927	attention	_	
25-17	3928-3937	processes	_	
25-18	3938-3939	(	_	
25-19	3939-3942	see	_	
25-20	3943-3946	for	_	
25-21	3947-3953	review	_	
25-22	3953-3954	)	_	
25-23	3954-3955	.	_	

#Text=Few functional studies of thalamic function in schizophrenia have investigated different regions of the thalamus during cognitive tasks.
26-1	3956-3959	Few	_	
26-2	3960-3970	functional	_	
26-3	3971-3978	studies	_	
26-4	3979-3981	of	_	
26-5	3982-3990	thalamic	_	
26-6	3991-3999	function	_	
26-7	4000-4002	in	_	
26-8	4003-4016	schizophrenia	_	
26-9	4017-4021	have	_	
26-10	4022-4034	investigated	_	
26-11	4035-4044	different	_	
26-12	4045-4052	regions	_	
26-13	4053-4055	of	_	
26-14	4056-4059	the	_	
26-15	4060-4068	thalamus	_	
26-16	4069-4075	during	_	
26-17	4076-4085	cognitive	_	
26-18	4086-4091	tasks	_	
26-19	4091-4092	.	_	

#Text=One study parcellated the thalamus into 7 regions of interest (ROIs) and investigated differential thalamic function of these regions during a visual working memory, intentional encoding and recognition tasks.
27-1	4093-4096	One	_	
27-2	4097-4102	study	_	
27-3	4103-4114	parcellated	_	
27-4	4115-4118	the	_	
27-5	4119-4127	thalamus	_	
27-6	4128-4132	into	_	
27-7	4133-4134	7	_	
27-8	4135-4142	regions	_	
27-9	4143-4145	of	_	
27-10	4146-4154	interest	_	
27-11	4155-4156	(	_	
27-12	4156-4160	ROIs	_	
27-13	4160-4161	)	_	
27-14	4162-4165	and	_	
27-15	4166-4178	investigated	_	
27-16	4179-4191	differential	_	
27-17	4192-4200	thalamic	_	
27-18	4201-4209	function	_	
27-19	4210-4212	of	_	
27-20	4213-4218	these	_	
27-21	4219-4226	regions	_	
27-22	4227-4233	during	_	
27-23	4234-4235	a	_	
27-24	4236-4242	visual	_	
27-25	4243-4250	working	_	
27-26	4251-4257	memory	_	
27-27	4257-4258	,	_	
27-28	4259-4270	intentional	_	
27-29	4271-4279	encoding	_	
27-30	4280-4283	and	_	
27-31	4284-4295	recognition	_	
27-32	4296-4301	tasks	_	
27-33	4301-4302	.	_	

#Text=This study found task-related thalamic hypofunction in the anterior and MD thalamus, but not similar changes in the PUL.
28-1	4303-4307	This	_	
28-2	4308-4313	study	_	
28-3	4314-4319	found	_	
28-4	4320-4332	task-related	_	
28-5	4333-4341	thalamic	_	
28-6	4342-4354	hypofunction	_	
28-7	4355-4357	in	_	
28-8	4358-4361	the	_	
28-9	4362-4370	anterior	_	
28-10	4371-4374	and	_	
28-11	4375-4377	MD	_	
28-12	4378-4386	thalamus	_	
28-13	4386-4387	,	_	
28-14	4388-4391	but	_	
28-15	4392-4395	not	_	
28-16	4396-4403	similar	_	
28-17	4404-4411	changes	_	
28-18	4412-4414	in	_	
28-19	4415-4418	the	_	
28-20	4419-4422	PUL	_	
28-21	4422-4423	.	_	

#Text=In recent years, there has been increasing evidence of reduced thalamus-PFC structural and functional connectivity at rest in schizophrenia (; see for review).
29-1	4424-4426	In	_	
29-2	4427-4433	recent	_	
29-3	4434-4439	years	_	
29-4	4439-4440	,	_	
29-5	4441-4446	there	_	
29-6	4447-4450	has	_	
29-7	4451-4455	been	_	
29-8	4456-4466	increasing	_	
29-9	4467-4475	evidence	_	
29-10	4476-4478	of	_	
29-11	4479-4486	reduced	_	
29-12	4487-4499	thalamus-PFC	_	
29-13	4500-4510	structural	_	
29-14	4511-4514	and	_	
29-15	4515-4525	functional	_	
29-16	4526-4538	connectivity	_	
29-17	4539-4541	at	_	
29-18	4542-4546	rest	_	
29-19	4547-4549	in	_	
29-20	4550-4563	schizophrenia	_	
29-21	4564-4565	(	_	
29-22	4565-4566	;	_	
29-23	4567-4570	see	_	
29-24	4571-4574	for	_	
29-25	4575-4581	review	_	
29-26	4581-4582	)	_	
29-27	4582-4583	.	_	

#Text=In contrast, few studies have investigated task related connectivity changes in schizophrenia, though these studies have reported increased connectivity between the thalamus and PFC during verbal working memory.
30-1	4584-4586	In	_	
30-2	4587-4595	contrast	_	
30-3	4595-4596	,	_	
30-4	4597-4600	few	_	
30-5	4601-4608	studies	_	
30-6	4609-4613	have	_	
30-7	4614-4626	investigated	_	
30-8	4627-4631	task	_	
30-9	4632-4639	related	_	
30-10	4640-4652	connectivity	_	
30-11	4653-4660	changes	_	
30-12	4661-4663	in	_	
30-13	4664-4677	schizophrenia	_	
30-14	4677-4678	,	_	
30-15	4679-4685	though	_	
30-16	4686-4691	these	_	
30-17	4692-4699	studies	_	
30-18	4700-4704	have	_	
30-19	4705-4713	reported	_	
30-20	4714-4723	increased	_	
30-21	4724-4736	connectivity	_	
30-22	4737-4744	between	_	
30-23	4745-4748	the	_	
30-24	4749-4757	thalamus	_	
30-25	4758-4761	and	_	
30-26	4762-4765	PFC	_	
30-27	4766-4772	during	_	
30-28	4773-4779	verbal	_	
30-29	4780-4787	working	_	
30-30	4788-4794	memory	_	
30-31	4794-4795	.	_	

#Text=Both of these studies investigated the effect of task compared to baseline, and differences in methods used to calculate connectivity make it difficult to reconcile resting state related reduced and task related increased thalamus-PFC connectivity.
31-1	4796-4800	Both	_	
31-2	4801-4803	of	_	
31-3	4804-4809	these	_	
31-4	4810-4817	studies	_	
31-5	4818-4830	investigated	_	
31-6	4831-4834	the	_	
31-7	4835-4841	effect	_	
31-8	4842-4844	of	_	
31-9	4845-4849	task	_	
31-10	4850-4858	compared	_	
31-11	4859-4861	to	_	
31-12	4862-4870	baseline	_	
31-13	4870-4871	,	_	
31-14	4872-4875	and	_	
31-15	4876-4887	differences	_	
31-16	4888-4890	in	_	
31-17	4891-4898	methods	_	
31-18	4899-4903	used	_	
31-19	4904-4906	to	_	
31-20	4907-4916	calculate	_	
31-21	4917-4929	connectivity	_	
31-22	4930-4934	make	_	
31-23	4935-4937	it	_	
31-24	4938-4947	difficult	_	
31-25	4948-4950	to	_	
31-26	4951-4960	reconcile	_	
31-27	4961-4968	resting	_	
31-28	4969-4974	state	_	
31-29	4975-4982	related	_	
31-30	4983-4990	reduced	_	
31-31	4991-4994	and	_	
31-32	4995-4999	task	_	
31-33	5000-5007	related	_	
31-34	5008-5017	increased	_	
31-35	5018-5030	thalamus-PFC	_	
31-36	5031-5043	connectivity	_	
31-37	5043-5044	.	_	

#Text=The present study used a dual task paradigm requiring participants to perform either one two-alternative forced choice task or two tasks simultaneously to investigate modulation of thalamic function and connectivity by cognitive demand in individuals with schizophrenia compared to healthy individuals.
32-1	5045-5048	The	_	
32-2	5049-5056	present	_	
32-3	5057-5062	study	_	
32-4	5063-5067	used	_	
32-5	5068-5069	a	_	
32-6	5070-5074	dual	_	
32-7	5075-5079	task	_	
32-8	5080-5088	paradigm	_	
32-9	5089-5098	requiring	_	
32-10	5099-5111	participants	_	
32-11	5112-5114	to	_	
32-12	5115-5122	perform	_	
32-13	5123-5129	either	_	
32-14	5130-5133	one	_	
32-15	5134-5149	two-alternative	_	
32-16	5150-5156	forced	_	
32-17	5157-5163	choice	_	
32-18	5164-5168	task	_	
32-19	5169-5171	or	_	
32-20	5172-5175	two	_	
32-21	5176-5181	tasks	_	
32-22	5182-5196	simultaneously	_	
32-23	5197-5199	to	_	
32-24	5200-5211	investigate	_	
32-25	5212-5222	modulation	_	
32-26	5223-5225	of	_	
32-27	5226-5234	thalamic	_	
32-28	5235-5243	function	_	
32-29	5244-5247	and	_	
32-30	5248-5260	connectivity	_	
32-31	5261-5263	by	_	
32-32	5264-5273	cognitive	_	
32-33	5274-5280	demand	_	
32-34	5281-5283	in	_	
32-35	5284-5295	individuals	_	
32-36	5296-5300	with	_	
32-37	5301-5314	schizophrenia	_	
32-38	5315-5323	compared	_	
32-39	5324-5326	to	_	
32-40	5327-5334	healthy	_	
32-41	5335-5346	individuals	_	
32-42	5346-5347	.	_	

#Text=We examined activation and connectivity from the MD, PUL and the ventrolateral thalamus (VL), a thalamic region that is part of the striato-thalamo-frontal network involved in motor function.
33-1	5348-5350	We	_	
33-2	5351-5359	examined	_	
33-3	5360-5370	activation	_	
33-4	5371-5374	and	_	
33-5	5375-5387	connectivity	_	
33-6	5388-5392	from	_	
33-7	5393-5396	the	_	
33-8	5397-5399	MD	_	
33-9	5399-5400	,	_	
33-10	5401-5404	PUL	_	
33-11	5405-5408	and	_	
33-12	5409-5412	the	_	
33-13	5413-5426	ventrolateral	_	
33-14	5427-5435	thalamus	_	
33-15	5436-5437	(	_	
33-16	5437-5439	VL	_	
33-17	5439-5440	)	_	
33-18	5440-5441	,	_	
33-19	5442-5443	a	_	
33-20	5444-5452	thalamic	_	
33-21	5453-5459	region	_	
33-22	5460-5464	that	_	
33-23	5465-5467	is	_	
33-24	5468-5472	part	_	
33-25	5473-5475	of	_	
33-26	5476-5479	the	_	
33-27	5480-5503	striato-thalamo-frontal	_	
33-28	5504-5511	network	_	
33-29	5512-5520	involved	_	
33-30	5521-5523	in	_	
33-31	5524-5529	motor	_	
33-32	5530-5538	function	_	
33-33	5538-5539	.	_	

#Text=Importantly, we investigated thalamus-PFC connectivity modulation by different levels of cognitive demand in the same task, allowing us to use the same method for calculating connectivity.
34-1	5540-5551	Importantly	_	
34-2	5551-5552	,	_	
34-3	5553-5555	we	_	
34-4	5556-5568	investigated	_	
34-5	5569-5581	thalamus-PFC	_	
34-6	5582-5594	connectivity	_	
34-7	5595-5605	modulation	_	
34-8	5606-5608	by	_	
34-9	5609-5618	different	_	
34-10	5619-5625	levels	_	
34-11	5626-5628	of	_	
34-12	5629-5638	cognitive	_	
34-13	5639-5645	demand	_	
34-14	5646-5648	in	_	
34-15	5649-5652	the	_	
34-16	5653-5657	same	_	
34-17	5658-5662	task	_	
34-18	5662-5663	,	_	
34-19	5664-5672	allowing	_	
34-20	5673-5675	us	_	
34-21	5676-5678	to	_	
34-22	5679-5682	use	_	
34-23	5683-5686	the	_	
34-24	5687-5691	same	_	
34-25	5692-5698	method	_	
34-26	5699-5702	for	_	
34-27	5703-5714	calculating	_	
34-28	5715-5727	connectivity	_	
34-29	5727-5728	.	_	

#Text=We hypothesized that patients would should show reduced modulation of PFC and thalamus activation, and thalamus-PFC connectivity by cognitive demand.
35-1	5729-5731	We	_	
35-2	5732-5744	hypothesized	_	
35-3	5745-5749	that	_	
35-4	5750-5758	patients	_	
35-5	5759-5764	would	_	
35-6	5765-5771	should	_	
35-7	5772-5776	show	_	
35-8	5777-5784	reduced	_	
35-9	5785-5795	modulation	_	
35-10	5796-5798	of	_	
35-11	5799-5802	PFC	_	
35-12	5803-5806	and	_	
35-13	5807-5815	thalamus	_	
35-14	5816-5826	activation	_	
35-15	5826-5827	,	_	
35-16	5828-5831	and	_	
35-17	5832-5844	thalamus-PFC	_	
35-18	5845-5857	connectivity	_	
35-19	5858-5860	by	_	
35-20	5861-5870	cognitive	_	
35-21	5871-5877	demand	_	
35-22	5877-5878	.	_	

#Text=Method
#Text=Participants
#Text=Twenty-two patients with schizophrenia and 24 healthy individuals matched for age, gender, ethnicity and parental education participated in this study. 6 subjects (4 healthy; 2 schizophrenia) were excluded for incomplete data and one healthy individual was removed for excessive head motion.
36-1	5879-5885	Method	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
36-2	5886-5898	Participants	_	
36-3	5899-5909	Twenty-two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-4	5910-5918	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-5	5919-5923	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-6	5924-5937	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
36-7	5938-5941	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-8	5942-5944	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-9	5945-5952	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
36-10	5953-5964	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
36-11	5965-5972	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-12	5973-5976	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-13	5977-5980	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-14	5980-5981	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-15	5982-5988	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-16	5988-5989	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-17	5990-5999	ethnicity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-18	6000-6003	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-19	6004-6012	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-20	6013-6022	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-21	6023-6035	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-22	6036-6038	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-23	6039-6043	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-24	6044-6049	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-25	6049-6050	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-26	6051-6052	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-27	6053-6061	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-28	6062-6063	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-29	6063-6064	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-30	6065-6072	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-31	6072-6073	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-32	6074-6075	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-33	6076-6089	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
36-34	6089-6090	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-35	6091-6095	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-36	6096-6104	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-37	6105-6108	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-38	6109-6119	incomplete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-39	6120-6124	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-40	6125-6128	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-41	6129-6132	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-42	6133-6140	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-43	6141-6151	individual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-44	6152-6155	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-45	6156-6163	removed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-46	6164-6167	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-47	6168-6177	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-48	6178-6182	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-49	6183-6189	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-50	6189-6190	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Thus, the final sample included 20 schizophrenia patients and 19 healthy individuals.
37-1	6191-6195	Thus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-2	6195-6196	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-3	6197-6200	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-4	6201-6206	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-5	6207-6213	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-6	6214-6222	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-7	6223-6225	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-8	6226-6239	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
37-9	6240-6248	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-10	6249-6252	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-11	6253-6255	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-12	6256-6263	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
37-13	6264-6275	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
37-14	6275-6276	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Demographics for subjects included in the analyses are presented in Table 1.
38-1	6277-6289	Demographics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-2	6290-6293	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-3	6294-6302	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-4	6303-6311	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-5	6312-6314	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-6	6315-6318	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-7	6319-6327	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-8	6328-6331	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-9	6332-6341	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-10	6342-6344	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-11	6345-6350	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-12	6351-6352	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-13	6352-6353	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Schizophrenia participants were recruited from inpatient and outpatient services at the Vanderbilt Psychiatric Hospital in Nashville, Tennessee, and healthy participants were recruited from Nashville and the surrounding area through advertisement and word-of-mouth.
39-1	6354-6367	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
39-2	6368-6380	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-3	6381-6385	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-4	6386-6395	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-5	6396-6400	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-6	6401-6410	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-7	6411-6414	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-8	6415-6425	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-9	6426-6434	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-10	6435-6437	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-11	6438-6441	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-12	6442-6452	Vanderbilt	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-13	6453-6464	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-14	6465-6473	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-15	6474-6476	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-16	6477-6486	Nashville	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-17	6486-6487	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-18	6488-6497	Tennessee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-19	6497-6498	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-20	6499-6502	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-21	6503-6510	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-22	6511-6523	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-23	6524-6528	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-24	6529-6538	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-25	6539-6543	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-26	6544-6553	Nashville	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-27	6554-6557	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-28	6558-6561	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-29	6562-6573	surrounding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-30	6574-6578	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-31	6579-6586	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-32	6587-6600	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-33	6601-6604	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-34	6605-6618	word-of-mouth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-35	6618-6619	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Our schizophrenia sample consisted of 17 outpatients and 2 inpatients (data from 1 participant was not available).
40-1	6620-6623	Our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-2	6624-6637	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[16]	
40-3	6638-6644	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-4	6645-6654	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-5	6655-6657	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-6	6658-6660	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-7	6661-6672	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-8	6673-6676	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-9	6677-6678	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-10	6679-6689	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-11	6690-6691	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-12	6691-6695	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-13	6696-6700	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-14	6701-6702	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-15	6703-6714	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-16	6715-6718	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-17	6719-6722	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-18	6723-6732	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-19	6732-6733	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-20	6733-6734	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=One patient was unmedicated and 2 were not receiving any antipsychotic medications.
41-1	6735-6738	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-2	6739-6746	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-3	6747-6750	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-4	6751-6762	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-5	6763-6766	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-6	6767-6768	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-7	6769-6773	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-8	6774-6777	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-9	6778-6787	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-10	6788-6791	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-11	6792-6805	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-12	6806-6817	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-13	6817-6818	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=This study was approved by the Vanderbilt University Institutional Review Board and all participants provided written informed consent prior to participating in this study.
42-1	6819-6823	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-2	6824-6829	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-3	6830-6833	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-4	6834-6842	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-5	6843-6845	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-6	6846-6849	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-7	6850-6860	Vanderbilt	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-8	6861-6871	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-9	6872-6885	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-10	6886-6892	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-11	6893-6898	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-12	6899-6902	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-13	6903-6906	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-14	6907-6919	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-15	6920-6928	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-16	6929-6936	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-17	6937-6945	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-18	6946-6953	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-19	6954-6959	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-20	6960-6962	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-21	6963-6976	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-22	6977-6979	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-23	6980-6984	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-24	6985-6990	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-25	6990-6991	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=All participants were administered the Structured Clinical Interview for Diagnosing DSM-IV Disorders (SCID:) to confirm diagnosis in patients and rule out current or past psychiatric illness in control subjects.
43-1	6992-6995	All	_	
43-2	6996-7008	participants	_	
43-3	7009-7013	were	_	
43-4	7014-7026	administered	_	
43-5	7027-7030	the	_	
43-6	7031-7041	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-7	7042-7050	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-8	7051-7060	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-9	7061-7064	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-10	7065-7075	Diagnosing	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-11	7076-7082	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-12	7083-7092	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-13	7093-7094	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-14	7094-7098	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-15	7098-7099	:	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-16	7099-7100	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[19]	
43-17	7101-7103	to	_	
43-18	7104-7111	confirm	_	
43-19	7112-7121	diagnosis	_	
43-20	7122-7124	in	_	
43-21	7125-7133	patients	_	
43-22	7134-7137	and	_	
43-23	7138-7142	rule	_	
43-24	7143-7146	out	_	
43-25	7147-7154	current	_	
43-26	7155-7157	or	_	
43-27	7158-7162	past	_	
43-28	7163-7174	psychiatric	_	
43-29	7175-7182	illness	_	
43-30	7183-7185	in	_	
43-31	7186-7193	control	_	
43-32	7194-7202	subjects	_	
43-33	7202-7203	.	_	

#Text=Clinical symptoms in patients were quantified with the Positive and Negative Syndrome Scale (PANSS:).
44-1	7204-7212	Clinical	_	
44-2	7213-7221	symptoms	_	
44-3	7222-7224	in	_	
44-4	7225-7233	patients	_	
44-5	7234-7238	were	_	
44-6	7239-7249	quantified	_	
44-7	7250-7254	with	_	
44-8	7255-7258	the	_	
44-9	7259-7267	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-10	7268-7271	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-11	7272-7280	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-12	7281-7289	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-13	7290-7295	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-14	7296-7297	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-15	7297-7302	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-16	7302-7303	:	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-17	7303-7304	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
44-18	7304-7305	.	_	

#Text=Premorbid IQ was estimated using the Wechsler Test of Adult Reading (WTAR:).
45-1	7306-7315	Premorbid	_	
45-2	7316-7318	IQ	_	
45-3	7319-7322	was	_	
45-4	7323-7332	estimated	_	
45-5	7333-7338	using	_	
45-6	7339-7342	the	_	
45-7	7343-7351	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-8	7352-7356	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-9	7357-7359	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-10	7360-7365	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-11	7366-7373	Reading	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-12	7374-7375	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-13	7375-7379	WTAR	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-14	7379-7380	:	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-15	7380-7381	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]	
45-16	7381-7382	.	_	

#Text=Exclusion criteria included an estimated premorbid IQ of less than 70, age less than 18 or greater than 60, presence of a systemic medical illness (i.e. diabetes, cardiovascular or central nervous system disorder that would affect study participation, history of significant head trauma, reported pregnancy or lactation, history of substance abuse/dependence (3-months in patients; lifetime in controls), psychotropic drug use (in healthy individuals), and any MRI contraindications (e.g. metal implants, claustrophobia).
46-1	7383-7392	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-2	7393-7401	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-3	7402-7410	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-4	7411-7413	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-5	7414-7423	estimated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-6	7424-7433	premorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-7	7434-7436	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-8	7437-7439	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-9	7440-7444	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-10	7445-7449	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-11	7450-7452	70	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-12	7452-7453	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-13	7454-7457	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-14	7458-7462	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-15	7463-7467	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-16	7468-7470	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-17	7471-7473	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-18	7474-7481	greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-19	7482-7486	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-20	7487-7489	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-21	7489-7490	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-22	7491-7499	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-23	7500-7502	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-24	7503-7504	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-25	7505-7513	systemic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-26	7514-7521	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-27	7522-7529	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-28	7530-7531	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-29	7531-7534	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-30	7534-7535	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-31	7536-7544	diabetes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-32	7544-7545	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-33	7546-7560	cardiovascular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-34	7561-7563	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-35	7564-7571	central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-36	7572-7579	nervous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-37	7580-7586	system	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-38	7587-7595	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-39	7596-7600	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-40	7601-7606	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-41	7607-7613	affect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-42	7614-7619	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-43	7620-7633	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-44	7633-7634	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-45	7635-7642	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-46	7643-7645	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-47	7646-7657	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-48	7658-7662	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-49	7663-7669	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-50	7669-7670	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-51	7671-7679	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-52	7680-7689	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-53	7690-7692	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-54	7693-7702	lactation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-55	7702-7703	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-56	7704-7711	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-57	7712-7714	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-58	7715-7724	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-59	7725-7730	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-60	7730-7731	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-61	7731-7741	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-62	7742-7743	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-63	7743-7744	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-64	7744-7745	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-65	7745-7751	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-66	7752-7754	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-67	7755-7763	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-68	7763-7764	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-69	7765-7773	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-70	7774-7776	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-71	7777-7785	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-72	7785-7786	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-73	7786-7787	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-74	7788-7800	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-75	7801-7805	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-76	7806-7809	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-77	7810-7811	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-78	7811-7813	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-79	7814-7821	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-80	7822-7833	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-81	7833-7834	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-82	7834-7835	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-83	7836-7839	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-84	7840-7843	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-85	7844-7847	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-86	7848-7865	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-87	7866-7867	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-88	7867-7870	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-89	7870-7871	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-90	7872-7877	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-91	7878-7886	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-92	7886-7887	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-93	7888-7902	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-94	7902-7903	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
46-95	7903-7904	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=Task
#Text=On each trial, participants performed either a visuo-motor task where a visual cue was mapped to a motor response, or an audio-vocal task where an audio cue was mapped to a vocal response (Single task condition), or both tasks with a 0 ms stimulus onset asynchrony (Dual task condition).
47-1	7905-7909	Task	_	
47-2	7910-7912	On	_	
47-3	7913-7917	each	_	
47-4	7918-7923	trial	_	
47-5	7923-7924	,	_	
47-6	7925-7937	participants	_	
47-7	7938-7947	performed	_	
47-8	7948-7954	either	_	
47-9	7955-7956	a	_	
47-10	7957-7968	visuo-motor	_	
47-11	7969-7973	task	_	
47-12	7974-7979	where	_	
47-13	7980-7981	a	_	
47-14	7982-7988	visual	_	
47-15	7989-7992	cue	_	
47-16	7993-7996	was	_	
47-17	7997-8003	mapped	_	
47-18	8004-8006	to	_	
47-19	8007-8008	a	_	
47-20	8009-8014	motor	_	
47-21	8015-8023	response	_	
47-22	8023-8024	,	_	
47-23	8025-8027	or	_	
47-24	8028-8030	an	_	
47-25	8031-8042	audio-vocal	_	
47-26	8043-8047	task	_	
47-27	8048-8053	where	_	
47-28	8054-8056	an	_	
47-29	8057-8062	audio	_	
47-30	8063-8066	cue	_	
47-31	8067-8070	was	_	
47-32	8071-8077	mapped	_	
47-33	8078-8080	to	_	
47-34	8081-8082	a	_	
47-35	8083-8088	vocal	_	
47-36	8089-8097	response	_	
47-37	8098-8099	(	_	
47-38	8099-8105	Single	_	
47-39	8106-8110	task	_	
47-40	8111-8120	condition	_	
47-41	8120-8121	)	_	
47-42	8121-8122	,	_	
47-43	8123-8125	or	_	
47-44	8126-8130	both	_	
47-45	8131-8136	tasks	_	
47-46	8137-8141	with	_	
47-47	8142-8143	a	_	
47-48	8144-8145	0	_	
47-49	8146-8148	ms	_	
47-50	8149-8157	stimulus	_	
47-51	8158-8163	onset	_	
47-52	8164-8174	asynchrony	_	
47-53	8175-8176	(	_	
47-54	8176-8180	Dual	_	
47-55	8181-8185	task	_	
47-56	8186-8195	condition	_	
47-57	8195-8196	)	_	
47-58	8196-8197	.	_	

#Text=Both visuo-motor and audio-vocal tasks were two-alternative forced choice tasks, mapping two stimuli to two responses.
48-1	8198-8202	Both	_	
48-2	8203-8214	visuo-motor	_	
48-3	8215-8218	and	_	
48-4	8219-8230	audio-vocal	_	
48-5	8231-8236	tasks	_	
48-6	8237-8241	were	_	
48-7	8242-8257	two-alternative	_	
48-8	8258-8264	forced	_	
48-9	8265-8271	choice	_	
48-10	8272-8277	tasks	_	
48-11	8277-8278	,	_	
48-12	8279-8286	mapping	_	
48-13	8287-8290	two	_	
48-14	8291-8298	stimuli	_	
48-15	8299-8301	to	_	
48-16	8302-8305	two	_	
48-17	8306-8315	responses	_	
48-18	8315-8316	.	_	

#Text=The visual stimuli were two greyscale male faces controlled for skin tone, hair color, neutral facial expression and hairline on a grey background.
49-1	8317-8320	The	_	
49-2	8321-8327	visual	_	
49-3	8328-8335	stimuli	_	
49-4	8336-8340	were	_	
49-5	8341-8344	two	_	
49-6	8345-8354	greyscale	_	
49-7	8355-8359	male	_	
49-8	8360-8365	faces	_	
49-9	8366-8376	controlled	_	
49-10	8377-8380	for	_	
49-11	8381-8385	skin	_	
49-12	8386-8390	tone	_	
49-13	8390-8391	,	_	
49-14	8392-8396	hair	_	
49-15	8397-8402	color	_	
49-16	8402-8403	,	_	
49-17	8404-8411	neutral	_	
49-18	8412-8418	facial	_	
49-19	8419-8429	expression	_	
49-20	8430-8433	and	_	
49-21	8434-8442	hairline	_	
49-22	8443-8445	on	_	
49-23	8446-8447	a	_	
49-24	8448-8452	grey	_	
49-25	8453-8463	background	_	
49-26	8463-8464	.	_	

#Text=Participants responded to each face by pressing a button with either their right index or middle finger.
50-1	8465-8477	Participants	_	
50-2	8478-8487	responded	_	
50-3	8488-8490	to	_	
50-4	8491-8495	each	_	
50-5	8496-8500	face	_	
50-6	8501-8503	by	_	
50-7	8504-8512	pressing	_	
50-8	8513-8514	a	_	
50-9	8515-8521	button	_	
50-10	8522-8526	with	_	
50-11	8527-8533	either	_	
50-12	8534-8539	their	_	
50-13	8540-8545	right	_	
50-14	8546-8551	index	_	
50-15	8552-8554	or	_	
50-16	8555-8561	middle	_	
50-17	8562-8568	finger	_	
50-18	8568-8569	.	_	

#Text=The audio-vocal task consisted of two easily discriminable sounds (a complex tone and an edited natural sound) used previously in, each paired with a “Tay” or a “Koo” vocal response.
51-1	8570-8573	The	_	
51-2	8574-8585	audio-vocal	_	
51-3	8586-8590	task	_	
51-4	8591-8600	consisted	_	
51-5	8601-8603	of	_	
51-6	8604-8607	two	_	
51-7	8608-8614	easily	_	
51-8	8615-8628	discriminable	_	
51-9	8629-8635	sounds	_	
51-10	8636-8637	(	_	
51-11	8637-8638	a	_	
51-12	8639-8646	complex	_	
51-13	8647-8651	tone	_	
51-14	8652-8655	and	_	
51-15	8656-8658	an	_	
51-16	8659-8665	edited	_	
51-17	8666-8673	natural	_	
51-18	8674-8679	sound	_	
51-19	8679-8680	)	_	
51-20	8681-8685	used	_	
51-21	8686-8696	previously	_	
51-22	8697-8699	in	_	
51-23	8699-8700	,	_	
51-24	8701-8705	each	_	
51-25	8706-8712	paired	_	
51-26	8713-8717	with	_	
51-27	8718-8719	a	_	
51-28	8720-8721	“	_	
51-29	8721-8724	Tay	_	
51-30	8724-8725	”	_	
51-31	8726-8728	or	_	
51-32	8729-8730	a	_	
51-33	8731-8732	“	_	
51-34	8732-8735	Koo	_	
51-35	8735-8736	”	_	
51-36	8737-8742	vocal	_	
51-37	8743-8751	response	_	
51-38	8751-8752	.	_	

#Text=On Single trials, one visual or auditory stimulus was presented for 200 ms, on Dual trials, both the visual and auditory stimuli were presented simultaneously.
52-1	8753-8755	On	_	
52-2	8756-8762	Single	_	
52-3	8763-8769	trials	_	
52-4	8769-8770	,	_	
52-5	8771-8774	one	_	
52-6	8775-8781	visual	_	
52-7	8782-8784	or	_	
52-8	8785-8793	auditory	_	
52-9	8794-8802	stimulus	_	
52-10	8803-8806	was	_	
52-11	8807-8816	presented	_	
52-12	8817-8820	for	_	
52-13	8821-8824	200	_	
52-14	8825-8827	ms	_	
52-15	8827-8828	,	_	
52-16	8829-8831	on	_	
52-17	8832-8836	Dual	_	
52-18	8837-8843	trials	_	
52-19	8843-8844	,	_	
52-20	8845-8849	both	_	
52-21	8850-8853	the	_	
52-22	8854-8860	visual	_	
52-23	8861-8864	and	_	
52-24	8865-8873	auditory	_	
52-25	8874-8881	stimuli	_	
52-26	8882-8886	were	_	
52-27	8887-8896	presented	_	
52-28	8897-8911	simultaneously	_	
52-29	8911-8912	.	_	

#Text=All trials were preceded by a 200 ms warning fixation and followed by a 12000 ms inter-trial interval (see Figure 1A for schematic).
53-1	8913-8916	All	_	
53-2	8917-8923	trials	_	
53-3	8924-8928	were	_	
53-4	8929-8937	preceded	_	
53-5	8938-8940	by	_	
53-6	8941-8942	a	_	
53-7	8943-8946	200	_	
53-8	8947-8949	ms	_	
53-9	8950-8957	warning	_	
53-10	8958-8966	fixation	_	
53-11	8967-8970	and	_	
53-12	8971-8979	followed	_	
53-13	8980-8982	by	_	
53-14	8983-8984	a	_	
53-15	8985-8990	12000	_	
53-16	8991-8993	ms	_	
53-17	8994-9005	inter-trial	_	
53-18	9006-9014	interval	_	
53-19	9015-9016	(	_	
53-20	9016-9019	see	_	
53-21	9020-9026	Figure	_	
53-22	9027-9029	1A	_	
53-23	9030-9033	for	_	
53-24	9034-9043	schematic	_	
53-25	9043-9044	)	_	
53-26	9044-9045	.	_	

#Text=Participants completed a total of 5 runs while undergoing fMRI scanning with each run consisting of 12 Single (6 visuomotor and 6 audio-vocal) and 12 Dual trials.
54-1	9046-9058	Participants	_	
54-2	9059-9068	completed	_	
54-3	9069-9070	a	_	
54-4	9071-9076	total	_	
54-5	9077-9079	of	_	
54-6	9080-9081	5	_	
54-7	9082-9086	runs	_	
54-8	9087-9092	while	_	
54-9	9093-9103	undergoing	_	
54-10	9104-9108	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
54-11	9109-9117	scanning	_	
54-12	9118-9122	with	_	
54-13	9123-9127	each	_	
54-14	9128-9131	run	_	
54-15	9132-9142	consisting	_	
54-16	9143-9145	of	_	
54-17	9146-9148	12	_	
54-18	9149-9155	Single	_	
54-19	9156-9157	(	_	
54-20	9157-9158	6	_	
54-21	9159-9169	visuomotor	_	
54-22	9170-9173	and	_	
54-23	9174-9175	6	_	
54-24	9176-9187	audio-vocal	_	
54-25	9187-9188	)	_	
54-26	9189-9192	and	_	
54-27	9193-9195	12	_	
54-28	9196-9200	Dual	_	
54-29	9201-9207	trials	_	
54-30	9207-9208	.	_	

#Text=Data acquisition
#Text=Imaging data were collected on a 3T Philips Intera Achieva scanner located at the Vanderbilt University Institute of Imaging Science.
55-1	9209-9213	Data	_	
55-2	9214-9225	acquisition	_	
55-3	9226-9233	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[23]	
55-4	9234-9238	data	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[23]	
55-5	9239-9243	were	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[23]	
55-6	9244-9253	collected	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[23]	
55-7	9254-9256	on	_	
55-8	9257-9258	a	_	
55-9	9259-9261	3T	_	
55-10	9262-9269	Philips	_	
55-11	9270-9276	Intera	_	
55-12	9277-9284	Achieva	_	
55-13	9285-9292	scanner	_	
55-14	9293-9300	located	_	
55-15	9301-9303	at	_	
55-16	9304-9307	the	_	
55-17	9308-9318	Vanderbilt	_	
55-18	9319-9329	University	_	
55-19	9330-9339	Institute	_	
55-20	9340-9342	of	_	
55-21	9343-9350	Imaging	_	
55-22	9351-9358	Science	_	
55-23	9358-9359	.	_	

#Text=High resolution T1 structural scans were collected with a 4.5 minute 3D T1 fast field echo sequence (170 slices, TR/TE = 8.9/4.6, FOV = 256 × 256 × 170 mm, matrix = 256 × 256 × 170, flip angle = 8°).
56-1	9360-9364	High	_	
56-2	9365-9375	resolution	_	
56-3	9376-9378	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
56-4	9379-9389	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
56-5	9390-9395	scans	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
56-6	9396-9400	were	_	
56-7	9401-9410	collected	_	
56-8	9411-9415	with	_	
56-9	9416-9417	a	_	
56-10	9418-9421	4.5	_	
56-11	9422-9428	minute	_	
56-12	9429-9431	3D	_	
56-13	9432-9434	T1	_	
56-14	9435-9439	fast	_	
56-15	9440-9445	field	_	
56-16	9446-9450	echo	_	
56-17	9451-9459	sequence	_	
56-18	9460-9461	(	_	
56-19	9461-9464	170	_	
56-20	9465-9471	slices	_	
56-21	9471-9472	,	_	
56-22	9473-9475	TR	_	
56-23	9475-9476	/	_	
56-24	9476-9478	TE	_	
56-25	9479-9480	=	_	
56-26	9481-9484	8.9	_	
56-27	9484-9485	/	_	
56-28	9485-9488	4.6	_	
56-29	9488-9489	,	_	
56-30	9490-9493	FOV	_	
56-31	9494-9495	=	_	
56-32	9496-9499	256	_	
56-33	9500-9501	×	_	
56-34	9502-9505	256	_	
56-35	9506-9507	×	_	
56-36	9508-9511	170	_	
56-37	9512-9514	mm	_	
56-38	9514-9515	,	_	
56-39	9516-9522	matrix	_	
56-40	9523-9524	=	_	
56-41	9525-9528	256	_	
56-42	9529-9530	×	_	
56-43	9531-9534	256	_	
56-44	9535-9536	×	_	
56-45	9537-9540	170	_	
56-46	9540-9541	,	_	
56-47	9542-9546	flip	_	
56-48	9547-9552	angle	_	
56-49	9553-9554	=	_	
56-50	9555-9556	8	_	
56-51	9556-9557	°	_	
56-52	9557-9558	)	_	
56-53	9558-9559	.	_	

#Text=Echo-planar imaging functional scans were collected while participants performed the behavioral task (38 slices, TR/TE = 2000/25 ms, FOV = 240 × 240 mm, matrix = 80 × 80, slice thickness = 3 mm with 0.3 mm gap, flip angle = 90°, volumes = 203).
57-1	9560-9571	Echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
57-2	9572-9579	imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
57-3	9580-9590	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
57-4	9591-9596	scans	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
57-5	9597-9601	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-6	9602-9611	collected	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-7	9612-9617	while	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-8	9618-9630	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-9	9631-9640	performed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-10	9641-9644	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-11	9645-9655	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-12	9656-9660	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-13	9661-9662	(	_	
57-14	9662-9664	38	_	
57-15	9665-9671	slices	_	
57-16	9671-9672	,	_	
57-17	9673-9675	TR	_	
57-18	9675-9676	/	_	
57-19	9676-9678	TE	_	
57-20	9679-9680	=	_	
57-21	9681-9685	2000	_	
57-22	9685-9686	/	_	
57-23	9686-9688	25	_	
57-24	9689-9691	ms	_	
57-25	9691-9692	,	_	
57-26	9693-9696	FOV	_	
57-27	9697-9698	=	_	
57-28	9699-9702	240	_	
57-29	9703-9704	×	_	
57-30	9705-9708	240	_	
57-31	9709-9711	mm	_	
57-32	9711-9712	,	_	
57-33	9713-9719	matrix	_	
57-34	9720-9721	=	_	
57-35	9722-9724	80	_	
57-36	9725-9726	×	_	
57-37	9727-9729	80	_	
57-38	9729-9730	,	_	
57-39	9731-9736	slice	_	
57-40	9737-9746	thickness	_	
57-41	9747-9748	=	_	
57-42	9749-9750	3	_	
57-43	9751-9753	mm	_	
57-44	9754-9758	with	_	
57-45	9759-9762	0.3	_	
57-46	9763-9765	mm	_	
57-47	9766-9769	gap	_	
57-48	9769-9770	,	_	
57-49	9771-9775	flip	_	
57-50	9776-9781	angle	_	
57-51	9782-9783	=	_	
57-52	9784-9786	90	_	
57-53	9786-9787	°	_	
57-54	9787-9788	,	_	
57-55	9789-9796	volumes	_	
57-56	9797-9798	=	_	
57-57	9799-9802	203	_	
57-58	9802-9803	)	_	
57-59	9803-9804	.	_	

#Text=Data analyses
#Text=Neuroimaging preprocessing and subsequent analyses were carried out using SPM12 (version 7219) in Matlab (R2017b; MathWorks, USA).
58-1	9805-9809	Data	_	
58-2	9810-9818	analyses	_	
58-3	9819-9831	Neuroimaging	_	
58-4	9832-9845	preprocessing	_	
58-5	9846-9849	and	_	
58-6	9850-9860	subsequent	_	
58-7	9861-9869	analyses	_	
58-8	9870-9874	were	_	
58-9	9875-9882	carried	_	
58-10	9883-9886	out	_	
58-11	9887-9892	using	_	
58-12	9893-9898	SPM12	_	
58-13	9899-9900	(	_	
58-14	9900-9907	version	_	
58-15	9908-9912	7219	_	
58-16	9912-9913	)	_	
58-17	9914-9916	in	_	
58-18	9917-9923	Matlab	_	
58-19	9924-9925	(	_	
58-20	9925-9931	R2017b	_	
58-21	9931-9932	;	_	
58-22	9933-9942	MathWorks	_	
58-23	9942-9943	,	_	
58-24	9944-9947	USA	_	
58-25	9947-9948	)	_	
58-26	9948-9949	.	_	

#Text=T1 structural images were skull stripped then segmented into grey and white matter tissue classes and normalized to MNI space using the CAT12 computational anatomy toolbox for SPM with default settings.
59-1	9950-9952	T1	_	
59-2	9953-9963	structural	_	
59-3	9964-9970	images	_	
59-4	9971-9975	were	_	
59-5	9976-9981	skull	_	
59-6	9982-9990	stripped	_	
59-7	9991-9995	then	_	
59-8	9996-10005	segmented	_	
59-9	10006-10010	into	_	
59-10	10011-10015	grey	_	
59-11	10016-10019	and	_	
59-12	10020-10025	white	_	
59-13	10026-10032	matter	_	
59-14	10033-10039	tissue	_	
59-15	10040-10047	classes	_	
59-16	10048-10051	and	_	
59-17	10052-10062	normalized	_	
59-18	10063-10065	to	_	
59-19	10066-10069	MNI	_	
59-20	10070-10075	space	_	
59-21	10076-10081	using	_	
59-22	10082-10085	the	_	
59-23	10086-10091	CAT12	_	
59-24	10092-10105	computational	_	
59-25	10106-10113	anatomy	_	
59-26	10114-10121	toolbox	_	
59-27	10122-10125	for	_	
59-28	10126-10129	SPM	_	
59-29	10130-10134	with	_	
59-30	10135-10142	default	_	
59-31	10143-10151	settings	_	
59-32	10151-10152	.	_	

#Text=Functional data underwent slice timing correction, motion correction followed by co-registration to the grey matter tissue segmentation.
60-1	10153-10163	Functional	_	
60-2	10164-10168	data	_	
60-3	10169-10178	underwent	_	
60-4	10179-10184	slice	_	
60-5	10185-10191	timing	_	
60-6	10192-10202	correction	_	
60-7	10202-10203	,	_	
60-8	10204-10210	motion	_	
60-9	10211-10221	correction	_	
60-10	10222-10230	followed	_	
60-11	10231-10233	by	_	
60-12	10234-10249	co-registration	_	
60-13	10250-10252	to	_	
60-14	10253-10256	the	_	
60-15	10257-10261	grey	_	
60-16	10262-10268	matter	_	
60-17	10269-10275	tissue	_	
60-18	10276-10288	segmentation	_	
60-19	10288-10289	.	_	

#Text=Deformation parameters from the structural normalization were then applied to all functional images, which were then smoothed with a 6 mm Gaussian kernel.
61-1	10290-10301	Deformation	_	
61-2	10302-10312	parameters	_	
61-3	10313-10317	from	_	
61-4	10318-10321	the	_	
61-5	10322-10332	structural	_	
61-6	10333-10346	normalization	_	
61-7	10347-10351	were	_	
61-8	10352-10356	then	_	
61-9	10357-10364	applied	_	
61-10	10365-10367	to	_	
61-11	10368-10371	all	_	
61-12	10372-10382	functional	_	
61-13	10383-10389	images	_	
61-14	10389-10390	,	_	
61-15	10391-10396	which	_	
61-16	10397-10401	were	_	
61-17	10402-10406	then	_	
61-18	10407-10415	smoothed	_	
61-19	10416-10420	with	_	
61-20	10421-10422	a	_	
61-21	10423-10424	6	_	
61-22	10425-10427	mm	_	
61-23	10428-10436	Gaussian	_	
61-24	10437-10443	kernel	_	
61-25	10443-10444	.	_	

#Text=For each subject, runs with motion larger than 3 mm in the x, y or z dimensions relative to the first volume in each run were excluded from further analysis.
62-1	10445-10448	For	_	
62-2	10449-10453	each	_	
62-3	10454-10461	subject	_	
62-4	10461-10462	,	_	
62-5	10463-10467	runs	_	
62-6	10468-10472	with	_	
62-7	10473-10479	motion	_	
62-8	10480-10486	larger	_	
62-9	10487-10491	than	_	
62-10	10492-10493	3	_	
62-11	10494-10496	mm	_	
62-12	10497-10499	in	_	
62-13	10500-10503	the	_	
62-14	10504-10505	x	_	
62-15	10505-10506	,	_	
62-16	10507-10508	y	_	
62-17	10509-10511	or	_	
62-18	10512-10513	z	_	
62-19	10514-10524	dimensions	_	
62-20	10525-10533	relative	_	
62-21	10534-10536	to	_	
62-22	10537-10540	the	_	
62-23	10541-10546	first	_	
62-24	10547-10553	volume	_	
62-25	10554-10556	in	_	
62-26	10557-10561	each	_	
62-27	10562-10565	run	_	
62-28	10566-10570	were	_	
62-29	10571-10579	excluded	_	
62-30	10580-10584	from	_	
62-31	10585-10592	further	_	
62-32	10593-10601	analysis	_	
62-33	10601-10602	.	_	

#Text=A total of 12 runs were excluded for excessive motion, with no subject having more than 2 of their 5 runs removed.
63-1	10603-10604	A	_	
63-2	10605-10610	total	_	
63-3	10611-10613	of	_	
63-4	10614-10616	12	_	
63-5	10617-10621	runs	_	
63-6	10622-10626	were	_	
63-7	10627-10635	excluded	_	
63-8	10636-10639	for	_	
63-9	10640-10649	excessive	_	
63-10	10650-10656	motion	_	
63-11	10656-10657	,	_	
63-12	10658-10662	with	_	
63-13	10663-10665	no	_	
63-14	10666-10673	subject	_	
63-15	10674-10680	having	_	
63-16	10681-10685	more	_	
63-17	10686-10690	than	_	
63-18	10691-10692	2	_	
63-19	10693-10695	of	_	
63-20	10696-10701	their	_	
63-21	10702-10703	5	_	
63-22	10704-10708	runs	_	
63-23	10709-10716	removed	_	
63-24	10716-10717	.	_	

#Text=A General Linear Model (GLM) was created for each subject with regressors defined separately for correct and incorrect Single and Dual trial onsets, convolved to a canonical hemodynamic response function.
64-1	10718-10719	A	_	
64-2	10720-10727	General	_	
64-3	10728-10734	Linear	_	
64-4	10735-10740	Model	_	
64-5	10741-10742	(	_	
64-6	10742-10745	GLM	_	
64-7	10745-10746	)	_	
64-8	10747-10750	was	_	
64-9	10751-10758	created	_	
64-10	10759-10762	for	_	
64-11	10763-10767	each	_	
64-12	10768-10775	subject	_	
64-13	10776-10780	with	_	
64-14	10781-10791	regressors	_	
64-15	10792-10799	defined	_	
64-16	10800-10810	separately	_	
64-17	10811-10814	for	_	
64-18	10815-10822	correct	_	
64-19	10823-10826	and	_	
64-20	10827-10836	incorrect	_	
64-21	10837-10843	Single	_	
64-22	10844-10847	and	_	
64-23	10848-10852	Dual	_	
64-24	10853-10858	trial	_	
64-25	10859-10865	onsets	_	
64-26	10865-10866	,	_	
64-27	10867-10876	convolved	_	
64-28	10877-10879	to	_	
64-29	10880-10881	a	_	
64-30	10882-10891	canonical	_	
64-31	10892-10903	hemodynamic	_	
64-32	10904-10912	response	_	
64-33	10913-10921	function	_	
64-34	10921-10922	.	_	

#Text=In addition, the model included covariates of no interest to account for the effect of 6 motion parameters (x, y, z, translation and roll, yaw and pitch).
65-1	10923-10925	In	_	
65-2	10926-10934	addition	_	
65-3	10934-10935	,	_	
65-4	10936-10939	the	_	
65-5	10940-10945	model	_	
65-6	10946-10954	included	_	
65-7	10955-10965	covariates	_	
65-8	10966-10968	of	_	
65-9	10969-10971	no	_	
65-10	10972-10980	interest	_	
65-11	10981-10983	to	_	
65-12	10984-10991	account	_	
65-13	10992-10995	for	_	
65-14	10996-10999	the	_	
65-15	11000-11006	effect	_	
65-16	11007-11009	of	_	
65-17	11010-11011	6	_	
65-18	11012-11018	motion	_	
65-19	11019-11029	parameters	_	
65-20	11030-11031	(	_	
65-21	11031-11032	x	_	
65-22	11032-11033	,	_	
65-23	11034-11035	y	_	
65-24	11035-11036	,	_	
65-25	11037-11038	z	_	
65-26	11038-11039	,	_	
65-27	11040-11051	translation	_	
65-28	11052-11055	and	_	
65-29	11056-11060	roll	_	
65-30	11060-11061	,	_	
65-31	11062-11065	yaw	_	
65-32	11066-11069	and	_	
65-33	11070-11075	pitch	_	
65-34	11075-11076	)	_	
65-35	11076-11077	.	_	

#Text=Vocal artifacts are limited to the first couple of seconds of responding and has limited effect on later hemodynamic response.
66-1	11078-11083	Vocal	_	
66-2	11084-11093	artifacts	_	
66-3	11094-11097	are	_	
66-4	11098-11105	limited	_	
66-5	11106-11108	to	_	
66-6	11109-11112	the	_	
66-7	11113-11118	first	_	
66-8	11119-11125	couple	_	
66-9	11126-11128	of	_	
66-10	11129-11136	seconds	_	
66-11	11137-11139	of	_	
66-12	11140-11150	responding	_	
66-13	11151-11154	and	_	
66-14	11155-11158	has	_	
66-15	11159-11166	limited	_	
66-16	11167-11173	effect	_	
66-17	11174-11176	on	_	
66-18	11177-11182	later	_	
66-19	11183-11194	hemodynamic	_	
66-20	11195-11203	response	_	
66-21	11203-11204	.	_	

#Text=For each individual, estimated parameters of the regressors (beta weights) were calculated for each voxel using the GLM and were used in t-tests to assess the main effect of correct Dual>Single trials.
67-1	11205-11208	For	_	
67-2	11209-11213	each	_	
67-3	11214-11224	individual	_	
67-4	11224-11225	,	_	
67-5	11226-11235	estimated	_	
67-6	11236-11246	parameters	_	
67-7	11247-11249	of	_	
67-8	11250-11253	the	_	
67-9	11254-11264	regressors	_	
67-10	11265-11266	(	_	
67-11	11266-11270	beta	_	
67-12	11271-11278	weights	_	
67-13	11278-11279	)	_	
67-14	11280-11284	were	_	
67-15	11285-11295	calculated	_	
67-16	11296-11299	for	_	
67-17	11300-11304	each	_	
67-18	11305-11310	voxel	_	
67-19	11311-11316	using	_	
67-20	11317-11320	the	_	
67-21	11321-11324	GLM	_	
67-22	11325-11328	and	_	
67-23	11329-11333	were	_	
67-24	11334-11338	used	_	
67-25	11339-11341	in	_	
67-26	11342-11349	t-tests	_	
67-27	11350-11352	to	_	
67-28	11353-11359	assess	_	
67-29	11360-11363	the	_	
67-30	11364-11368	main	_	
67-31	11369-11375	effect	_	
67-32	11376-11378	of	_	
67-33	11379-11386	correct	_	
67-34	11387-11391	Dual	_	
67-35	11391-11392	>	_	
67-36	11392-11398	Single	_	
67-37	11399-11405	trials	_	
67-38	11405-11406	.	_	

#Text=Within group analyses were conducted separately for healthy and schizophrenia groups using subject level Dual>Single contrast images.
68-1	11407-11413	Within	_	
68-2	11414-11419	group	_	
68-3	11420-11428	analyses	_	
68-4	11429-11433	were	_	
68-5	11434-11443	conducted	_	
68-6	11444-11454	separately	_	
68-7	11455-11458	for	_	
68-8	11459-11466	healthy	_	
68-9	11467-11470	and	_	
68-10	11471-11484	schizophrenia	_	
68-11	11485-11491	groups	_	
68-12	11492-11497	using	_	
68-13	11498-11505	subject	_	
68-14	11506-11511	level	_	
68-15	11512-11516	Dual	_	
68-16	11516-11517	>	_	
68-17	11517-11523	Single	_	
68-18	11524-11532	contrast	_	
68-19	11533-11539	images	_	
68-20	11539-11540	.	_	

#Text=Between group analyses were investigated for the Dual>Single contrast images from each individual using subject as a random effect.
69-1	11541-11548	Between	_	
69-2	11549-11554	group	_	
69-3	11555-11563	analyses	_	
69-4	11564-11568	were	_	
69-5	11569-11581	investigated	_	
69-6	11582-11585	for	_	
69-7	11586-11589	the	_	
69-8	11590-11594	Dual	_	
69-9	11594-11595	>	_	
69-10	11595-11601	Single	_	
69-11	11602-11610	contrast	_	
69-12	11611-11617	images	_	
69-13	11618-11622	from	_	
69-14	11623-11627	each	_	
69-15	11628-11638	individual	_	
69-16	11639-11644	using	_	
69-17	11645-11652	subject	_	
69-18	11653-11655	as	_	
69-19	11656-11657	a	_	
69-20	11658-11664	random	_	
69-21	11665-11671	effect	_	
69-22	11671-11672	.	_	

#Text=This analysis identifies regions that show a condition by group interaction.
70-1	11673-11677	This	_	
70-2	11678-11686	analysis	_	
70-3	11687-11697	identifies	_	
70-4	11698-11705	regions	_	
70-5	11706-11710	that	_	
70-6	11711-11715	show	_	
70-7	11716-11717	a	_	
70-8	11718-11727	condition	_	
70-9	11728-11730	by	_	
70-10	11731-11736	group	_	
70-11	11737-11748	interaction	_	
70-12	11748-11749	.	_	

#Text=As we were interested in how the two groups differ in task relevant brain regions, whole brain group comparisons were masked for the Dual>Single contrast, collapsed across all subjects (thresholded at p<0.05, uncorrected).
71-1	11750-11752	As	_	
71-2	11753-11755	we	_	
71-3	11756-11760	were	_	
71-4	11761-11771	interested	_	
71-5	11772-11774	in	_	
71-6	11775-11778	how	_	
71-7	11779-11782	the	_	
71-8	11783-11786	two	_	
71-9	11787-11793	groups	_	
71-10	11794-11800	differ	_	
71-11	11801-11803	in	_	
71-12	11804-11808	task	_	
71-13	11809-11817	relevant	_	
71-14	11818-11823	brain	_	
71-15	11824-11831	regions	_	
71-16	11831-11832	,	_	
71-17	11833-11838	whole	_	
71-18	11839-11844	brain	_	
71-19	11845-11850	group	_	
71-20	11851-11862	comparisons	_	
71-21	11863-11867	were	_	
71-22	11868-11874	masked	_	
71-23	11875-11878	for	_	
71-24	11879-11882	the	_	
71-25	11883-11887	Dual	_	
71-26	11887-11888	>	_	
71-27	11888-11894	Single	_	
71-28	11895-11903	contrast	_	
71-29	11903-11904	,	_	
71-30	11905-11914	collapsed	_	
71-31	11915-11921	across	_	
71-32	11922-11925	all	_	
71-33	11926-11934	subjects	_	
71-34	11935-11936	(	_	
71-35	11936-11947	thresholded	_	
71-36	11948-11950	at	_	
71-37	11951-11952	p	_	
71-38	11952-11953	<	_	
71-39	11953-11957	0.05	_	
71-40	11957-11958	,	_	
71-41	11959-11970	uncorrected	_	
71-42	11970-11971	)	_	
71-43	11971-11972	.	_	

#Text=For all masked analyses, we used small volume correction (SVC) to define cluster level significance.
72-1	11973-11976	For	_	
72-2	11977-11980	all	_	
72-3	11981-11987	masked	_	
72-4	11988-11996	analyses	_	
72-5	11996-11997	,	_	
72-6	11998-12000	we	_	
72-7	12001-12005	used	_	
72-8	12006-12011	small	_	
72-9	12012-12018	volume	_	
72-10	12019-12029	correction	_	
72-11	12030-12031	(	_	
72-12	12031-12034	SVC	_	
72-13	12034-12035	)	_	
72-14	12036-12038	to	_	
72-15	12039-12045	define	_	
72-16	12046-12053	cluster	_	
72-17	12054-12059	level	_	
72-18	12060-12072	significance	_	
72-19	12072-12073	.	_	

#Text=All contrasts used a voxel wise threshold of p<0.005 to detect cluster level significance.
73-1	12074-12077	All	_	
73-2	12078-12087	contrasts	_	
73-3	12088-12092	used	_	
73-4	12093-12094	a	_	
73-5	12095-12100	voxel	_	
73-6	12101-12105	wise	_	
73-7	12106-12115	threshold	_	
73-8	12116-12118	of	_	
73-9	12119-12120	p	_	
73-10	12120-12121	<	_	
73-11	12121-12126	0.005	_	
73-12	12127-12129	to	_	
73-13	12130-12136	detect	_	
73-14	12137-12144	cluster	_	
73-15	12145-12150	level	_	
73-16	12151-12163	significance	_	
73-17	12163-12164	.	_	

#Text=Region-of-Interest Analysis: PFC and Thalamus
#Text=To further investigate PFC activation and thalamus-PFC connectivity, we defined 4 PFC regions of interest (ROIs) based on task activations.
74-1	12165-12183	Region-of-Interest	_	
74-2	12184-12192	Analysis	_	
74-3	12192-12193	:	_	
74-4	12194-12197	PFC	_	
74-5	12198-12201	and	_	
74-6	12202-12210	Thalamus	_	
74-7	12211-12213	To	_	
74-8	12214-12221	further	_	
74-9	12222-12233	investigate	_	
74-10	12234-12237	PFC	_	
74-11	12238-12248	activation	_	
74-12	12249-12252	and	_	
74-13	12253-12265	thalamus-PFC	_	
74-14	12266-12278	connectivity	_	
74-15	12278-12279	,	_	
74-16	12280-12282	we	_	
74-17	12283-12290	defined	_	
74-18	12291-12292	4	_	
74-19	12293-12296	PFC	_	
74-20	12297-12304	regions	_	
74-21	12305-12307	of	_	
74-22	12308-12316	interest	_	
74-23	12317-12318	(	_	
74-24	12318-12322	ROIs	_	
74-25	12322-12323	)	_	
74-26	12324-12329	based	_	
74-27	12330-12332	on	_	
74-28	12333-12337	task	_	
74-29	12338-12349	activations	_	
74-30	12349-12350	.	_	

#Text=First, a prefrontal cortex mask was created using the frontal pole, superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus pars triangularis and pars opercularis ROIs from the Harvard-Oxford cortical atlas (; https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases).
75-1	12351-12356	First	_	
75-2	12356-12357	,	_	
75-3	12358-12359	a	_	
75-4	12360-12370	prefrontal	_	
75-5	12371-12377	cortex	_	
75-6	12378-12382	mask	_	
75-7	12383-12386	was	_	
75-8	12387-12394	created	_	
75-9	12395-12400	using	_	
75-10	12401-12404	the	_	
75-11	12405-12412	frontal	_	
75-12	12413-12417	pole	_	
75-13	12417-12418	,	_	
75-14	12419-12427	superior	_	
75-15	12428-12435	frontal	_	
75-16	12436-12441	gyrus	_	
75-17	12441-12442	,	_	
75-18	12443-12449	middle	_	
75-19	12450-12457	frontal	_	
75-20	12458-12463	gyrus	_	
75-21	12463-12464	,	_	
75-22	12465-12473	inferior	_	
75-23	12474-12481	frontal	_	
75-24	12482-12487	gyrus	_	
75-25	12488-12492	pars	_	
75-26	12493-12505	triangularis	_	
75-27	12506-12509	and	_	
75-28	12510-12514	pars	_	
75-29	12515-12526	opercularis	_	
75-30	12527-12531	ROIs	_	
75-31	12532-12536	from	_	
75-32	12537-12540	the	_	
75-33	12541-12555	Harvard-Oxford	_	
75-34	12556-12564	cortical	_	
75-35	12565-12570	atlas	_	
75-36	12571-12572	(	_	
75-37	12572-12573	;	_	
75-38	12574-12579	https	_	
75-39	12579-12580	:	_	
75-40	12580-12581	/	_	
75-41	12581-12582	/	_	
75-42	12582-12600	fsl.fmrib.ox.ac.uk	_	
75-43	12600-12601	/	_	
75-44	12601-12604	fsl	_	
75-45	12604-12605	/	_	
75-46	12605-12612	fslwiki	_	
75-47	12612-12613	/	_	
75-48	12613-12620	Atlases	_	
75-49	12620-12621	)	_	
75-50	12621-12622	.	_	

#Text=All significant clusters in the Dual>Single contrast (collapsed across all subjects, p<0.05, FDRSVC) falling within this PFC mask were extracted.
76-1	12623-12626	All	_	
76-2	12627-12638	significant	_	
76-3	12639-12647	clusters	_	
76-4	12648-12650	in	_	
76-5	12651-12654	the	_	
76-6	12655-12659	Dual	_	
76-7	12659-12660	>	_	
76-8	12660-12666	Single	_	
76-9	12667-12675	contrast	_	
76-10	12676-12677	(	_	
76-11	12677-12686	collapsed	_	
76-12	12687-12693	across	_	
76-13	12694-12697	all	_	
76-14	12698-12706	subjects	_	
76-15	12706-12707	,	_	
76-16	12708-12709	p	_	
76-17	12709-12710	<	_	
76-18	12710-12714	0.05	_	
76-19	12714-12715	,	_	
76-20	12716-12722	FDRSVC	_	
76-21	12722-12723	)	_	
76-22	12724-12731	falling	_	
76-23	12732-12738	within	_	
76-24	12739-12743	this	_	
76-25	12744-12747	PFC	_	
76-26	12748-12752	mask	_	
76-27	12753-12757	were	_	
76-28	12758-12767	extracted	_	
76-29	12767-12768	.	_	

#Text=A total of 4 ROIs were defined this way.
77-1	12769-12770	A	_	
77-2	12771-12776	total	_	
77-3	12777-12779	of	_	
77-4	12780-12781	4	_	
77-5	12782-12786	ROIs	_	
77-6	12787-12791	were	_	
77-7	12792-12799	defined	_	
77-8	12800-12804	this	_	
77-9	12805-12808	way	_	
77-10	12808-12809	.	_	

#Text=They included the midline (pre) supplementary motor area (pre-SMA/SMA; −4, 10, 56; 357 voxels), left frontal eye fields (FEF; −32, 0, 52; 367 voxels), right lateral PFC (LPFC; 42, 10, 24; 402 voxels) and the left LPFC (40, 15, 22; 97 voxels).
78-1	12810-12814	They	_	
78-2	12815-12823	included	_	
78-3	12824-12827	the	_	
78-4	12828-12835	midline	_	
78-5	12836-12837	(	_	
78-6	12837-12840	pre	_	
78-7	12840-12841	)	_	
78-8	12842-12855	supplementary	_	
78-9	12856-12861	motor	_	
78-10	12862-12866	area	_	
78-11	12867-12868	(	_	
78-12	12868-12875	pre-SMA	_	
78-13	12875-12876	/	_	
78-14	12876-12879	SMA	_	
78-15	12879-12880	;	_	
78-16	12881-12882	−	_	
78-17	12882-12883	4	_	
78-18	12883-12884	,	_	
78-19	12885-12887	10	_	
78-20	12887-12888	,	_	
78-21	12889-12891	56	_	
78-22	12891-12892	;	_	
78-23	12893-12896	357	_	
78-24	12897-12903	voxels	_	
78-25	12903-12904	)	_	
78-26	12904-12905	,	_	
78-27	12906-12910	left	_	
78-28	12911-12918	frontal	_	
78-29	12919-12922	eye	_	
78-30	12923-12929	fields	_	
78-31	12930-12931	(	_	
78-32	12931-12934	FEF	_	
78-33	12934-12935	;	_	
78-34	12936-12937	−	_	
78-35	12937-12939	32	_	
78-36	12939-12940	,	_	
78-37	12941-12942	0	_	
78-38	12942-12943	,	_	
78-39	12944-12946	52	_	
78-40	12946-12947	;	_	
78-41	12948-12951	367	_	
78-42	12952-12958	voxels	_	
78-43	12958-12959	)	_	
78-44	12959-12960	,	_	
78-45	12961-12966	right	_	
78-46	12967-12974	lateral	_	
78-47	12975-12978	PFC	_	
78-48	12979-12980	(	_	
78-49	12980-12984	LPFC	_	
78-50	12984-12985	;	_	
78-51	12986-12988	42	_	
78-52	12988-12989	,	_	
78-53	12990-12992	10	_	
78-54	12992-12993	,	_	
78-55	12994-12996	24	_	
78-56	12996-12997	;	_	
78-57	12998-13001	402	_	
78-58	13002-13008	voxels	_	
78-59	13008-13009	)	_	
78-60	13010-13013	and	_	
78-61	13014-13017	the	_	
78-62	13018-13022	left	_	
78-63	13023-13027	LPFC	_	
78-64	13028-13029	(	_	
78-65	13029-13031	40	_	
78-66	13031-13032	,	_	
78-67	13033-13035	15	_	
78-68	13035-13036	,	_	
78-69	13037-13039	22	_	
78-70	13039-13040	;	_	
78-71	13041-13043	97	_	
78-72	13044-13050	voxels	_	
78-73	13050-13051	)	_	
78-74	13051-13052	.	_	

#Text=For the all PFC ROI analyses, reported p-values were adjusted for Bonferroni corrected values based on 4 tests conducted.
79-1	13053-13056	For	_	
79-2	13057-13060	the	_	
79-3	13061-13064	all	_	
79-4	13065-13068	PFC	_	
79-5	13069-13072	ROI	_	
79-6	13073-13081	analyses	_	
79-7	13081-13082	,	_	
79-8	13083-13091	reported	_	
79-9	13092-13100	p-values	_	
79-10	13101-13105	were	_	
79-11	13106-13114	adjusted	_	
79-12	13115-13118	for	_	
79-13	13119-13129	Bonferroni	_	
79-14	13130-13139	corrected	_	
79-15	13140-13146	values	_	
79-16	13147-13152	based	_	
79-17	13153-13155	on	_	
79-18	13156-13157	4	_	
79-19	13158-13163	tests	_	
79-20	13164-13173	conducted	_	
79-21	13173-13174	.	_	

#Text=For the thalamus, the voxel-wise between groups analysis was masked with a bilateral thalamus mask composed of the left and right thalamus from the Harvard-Oxford atlas.
80-1	13175-13178	For	_	
80-2	13179-13182	the	_	
80-3	13183-13191	thalamus	_	
80-4	13191-13192	,	_	
80-5	13193-13196	the	_	
80-6	13197-13207	voxel-wise	_	
80-7	13208-13215	between	_	
80-8	13216-13222	groups	_	
80-9	13223-13231	analysis	_	
80-10	13232-13235	was	_	
80-11	13236-13242	masked	_	
80-12	13243-13247	with	_	
80-13	13248-13249	a	_	
80-14	13250-13259	bilateral	_	
80-15	13260-13268	thalamus	_	
80-16	13269-13273	mask	_	
80-17	13274-13282	composed	_	
80-18	13283-13285	of	_	
80-19	13286-13289	the	_	
80-20	13290-13294	left	_	
80-21	13295-13298	and	_	
80-22	13299-13304	right	_	
80-23	13305-13313	thalamus	_	
80-24	13314-13318	from	_	
80-25	13319-13322	the	_	
80-26	13323-13337	Harvard-Oxford	_	
80-27	13338-13343	atlas	_	
80-28	13343-13344	.	_	

#Text=To further investigate activation patterns across different thalamic regions, we used the Morel atlas to define 3 thalamic regions covering the mediodorsal nucleus (MD; 236 voxels), the pulvinar (PUL; 543 voxels) and the ventrolateral nucleus (VL; 361 voxels).
81-1	13345-13347	To	_	
81-2	13348-13355	further	_	
81-3	13356-13367	investigate	_	
81-4	13368-13378	activation	_	
81-5	13379-13387	patterns	_	
81-6	13388-13394	across	_	
81-7	13395-13404	different	_	
81-8	13405-13413	thalamic	_	
81-9	13414-13421	regions	_	
81-10	13421-13422	,	_	
81-11	13423-13425	we	_	
81-12	13426-13430	used	_	
81-13	13431-13434	the	_	
81-14	13435-13440	Morel	_	
81-15	13441-13446	atlas	_	
81-16	13447-13449	to	_	
81-17	13450-13456	define	_	
81-18	13457-13458	3	_	
81-19	13459-13467	thalamic	_	
81-20	13468-13475	regions	_	
81-21	13476-13484	covering	_	
81-22	13485-13488	the	_	
81-23	13489-13500	mediodorsal	_	
81-24	13501-13508	nucleus	_	
81-25	13509-13510	(	_	
81-26	13510-13512	MD	_	
81-27	13512-13513	;	_	
81-28	13514-13517	236	_	
81-29	13518-13524	voxels	_	
81-30	13524-13525	)	_	
81-31	13525-13526	,	_	
81-32	13527-13530	the	_	
81-33	13531-13539	pulvinar	_	
81-34	13540-13541	(	_	
81-35	13541-13544	PUL	_	
81-36	13544-13545	;	_	
81-37	13546-13549	543	_	
81-38	13550-13556	voxels	_	
81-39	13556-13557	)	_	
81-40	13558-13561	and	_	
81-41	13562-13565	the	_	
81-42	13566-13579	ventrolateral	_	
81-43	13580-13587	nucleus	_	
81-44	13588-13589	(	_	
81-45	13589-13591	VL	_	
81-46	13591-13592	;	_	
81-47	13593-13596	361	_	
81-48	13597-13603	voxels	_	
81-49	13603-13604	)	_	
81-50	13604-13605	.	_	

#Text=These 4 thalamus ROIs are presented in Supplementary Figure 1.
82-1	13606-13611	These	_	
82-2	13612-13613	4	_	
82-3	13614-13622	thalamus	_	
82-4	13623-13627	ROIs	_	
82-5	13628-13631	are	_	
82-6	13632-13641	presented	_	
82-7	13642-13644	in	_	
82-8	13645-13658	Supplementary	_	
82-9	13659-13665	Figure	_	
82-10	13666-13667	1	_	
82-11	13667-13668	.	_	

#Text=To correct for multiple thalamic regions, we report Bonferroni corrected p-values based on 3 tests conducted.
83-1	13669-13671	To	_	
83-2	13672-13679	correct	_	
83-3	13680-13683	for	_	
83-4	13684-13692	multiple	_	
83-5	13693-13701	thalamic	_	
83-6	13702-13709	regions	_	
83-7	13709-13710	,	_	
83-8	13711-13713	we	_	
83-9	13714-13720	report	_	
83-10	13721-13731	Bonferroni	_	
83-11	13732-13741	corrected	_	
83-12	13742-13750	p-values	_	
83-13	13751-13756	based	_	
83-14	13757-13759	on	_	
83-15	13760-13761	3	_	
83-16	13762-13767	tests	_	
83-17	13768-13777	conducted	_	
83-18	13777-13778	.	_	

#Text=To ensure that these effects were not driven by differences in performance, a secondary set of analyses including only high performing subjects was also conducted (see Supplementary Table 3).
84-1	13779-13781	To	_	
84-2	13782-13788	ensure	_	
84-3	13789-13793	that	_	
84-4	13794-13799	these	_	
84-5	13800-13807	effects	_	
84-6	13808-13812	were	_	
84-7	13813-13816	not	_	
84-8	13817-13823	driven	_	
84-9	13824-13826	by	_	
84-10	13827-13838	differences	_	
84-11	13839-13841	in	_	
84-12	13842-13853	performance	_	
84-13	13853-13854	,	_	
84-14	13855-13856	a	_	
84-15	13857-13866	secondary	_	
84-16	13867-13870	set	_	
84-17	13871-13873	of	_	
84-18	13874-13882	analyses	_	
84-19	13883-13892	including	_	
84-20	13893-13897	only	_	
84-21	13898-13902	high	_	
84-22	13903-13913	performing	_	
84-23	13914-13922	subjects	_	
84-24	13923-13926	was	_	
84-25	13927-13931	also	_	
84-26	13932-13941	conducted	_	
84-27	13942-13943	(	_	
84-28	13943-13946	see	_	
84-29	13947-13960	Supplementary	_	
84-30	13961-13966	Table	_	
84-31	13967-13968	3	_	
84-32	13968-13969	)	_	
84-33	13969-13970	.	_	

#Text=Beta-series Connectivity
#Text=Task connectivity was conducted using the beta-series correlation analysis method.
85-1	13971-13982	Beta-series	_	
85-2	13983-13995	Connectivity	_	
85-3	13996-14000	Task	_	
85-4	14001-14013	connectivity	_	
85-5	14014-14017	was	_	
85-6	14018-14027	conducted	_	
85-7	14028-14033	using	_	
85-8	14034-14037	the	_	
85-9	14038-14049	beta-series	_	
85-10	14050-14061	correlation	_	
85-11	14062-14070	analysis	_	
85-12	14071-14077	method	_	
85-13	14077-14078	.	_	

#Text=Beta-series connectivity refers to a method of examining task connectivity by isolating a brain region’s response to an event in a task (e.g. cue presentation) and then characterizing the covariance between task response in other brain regions, separately for each condition of interest.
86-1	14079-14090	Beta-series	_	
86-2	14091-14103	connectivity	_	
86-3	14104-14110	refers	_	
86-4	14111-14113	to	_	
86-5	14114-14115	a	_	
86-6	14116-14122	method	_	
86-7	14123-14125	of	_	
86-8	14126-14135	examining	_	
86-9	14136-14140	task	_	
86-10	14141-14153	connectivity	_	
86-11	14154-14156	by	_	
86-12	14157-14166	isolating	_	
86-13	14167-14168	a	_	
86-14	14169-14174	brain	_	
86-15	14175-14181	region	_	
86-16	14181-14182	’	_	
86-17	14182-14183	s	_	
86-18	14184-14192	response	_	
86-19	14193-14195	to	_	
86-20	14196-14198	an	_	
86-21	14199-14204	event	_	
86-22	14205-14207	in	_	
86-23	14208-14209	a	_	
86-24	14210-14214	task	_	
86-25	14215-14216	(	_	
86-26	14216-14219	e.g	_	
86-27	14219-14220	.	_	
86-28	14221-14224	cue	_	
86-29	14225-14237	presentation	_	
86-30	14237-14238	)	_	
86-31	14239-14242	and	_	
86-32	14243-14247	then	_	
86-33	14248-14262	characterizing	_	
86-34	14263-14266	the	_	
86-35	14267-14277	covariance	_	
86-36	14278-14285	between	_	
86-37	14286-14290	task	_	
86-38	14291-14299	response	_	
86-39	14300-14302	in	_	
86-40	14303-14308	other	_	
86-41	14309-14314	brain	_	
86-42	14315-14322	regions	_	
86-43	14322-14323	,	_	
86-44	14324-14334	separately	_	
86-45	14335-14338	for	_	
86-46	14339-14343	each	_	
86-47	14344-14353	condition	_	
86-48	14354-14356	of	_	
86-49	14357-14365	interest	_	
86-50	14365-14366	.	_	

#Text=Beta-series differs from the more conventional psychophysiological interactions (PPI) method for investigating task connectivity in that power is derived from the number of trials/events presented, rather than based on time course correlations.
87-1	14367-14378	Beta-series	_	
87-2	14379-14386	differs	_	
87-3	14387-14391	from	_	
87-4	14392-14395	the	_	
87-5	14396-14400	more	_	
87-6	14401-14413	conventional	_	
87-7	14414-14433	psychophysiological	_	
87-8	14434-14446	interactions	_	
87-9	14447-14448	(	_	
87-10	14448-14451	PPI	_	
87-11	14451-14452	)	_	
87-12	14453-14459	method	_	
87-13	14460-14463	for	_	
87-14	14464-14477	investigating	_	
87-15	14478-14482	task	_	
87-16	14483-14495	connectivity	_	
87-17	14496-14498	in	_	
87-18	14499-14503	that	_	
87-19	14504-14509	power	_	
87-20	14510-14512	is	_	
87-21	14513-14520	derived	_	
87-22	14521-14525	from	_	
87-23	14526-14529	the	_	
87-24	14530-14536	number	_	
87-25	14537-14539	of	_	
87-26	14540-14546	trials	_	
87-27	14546-14547	/	_	
87-28	14547-14553	events	_	
87-29	14554-14563	presented	_	
87-30	14563-14564	,	_	
87-31	14565-14571	rather	_	
87-32	14572-14576	than	_	
87-33	14577-14582	based	_	
87-34	14583-14585	on	_	
87-35	14586-14590	time	_	
87-36	14591-14597	course	_	
87-37	14598-14610	correlations	_	
87-38	14610-14611	.	_	

#Text=In designs with many trials (>30) and short events, beta-series provides superior power to detect connectivity than PPI.
88-1	14612-14614	In	_	
88-2	14615-14622	designs	_	
88-3	14623-14627	with	_	
88-4	14628-14632	many	_	
88-5	14633-14639	trials	_	
88-6	14640-14641	(	_	
88-7	14641-14642	>	_	
88-8	14642-14644	30	_	
88-9	14644-14645	)	_	
88-10	14646-14649	and	_	
88-11	14650-14655	short	_	
88-12	14656-14662	events	_	
88-13	14662-14663	,	_	
88-14	14664-14675	beta-series	_	
88-15	14676-14684	provides	_	
88-16	14685-14693	superior	_	
88-17	14694-14699	power	_	
88-18	14700-14702	to	_	
88-19	14703-14709	detect	_	
88-20	14710-14722	connectivity	_	
88-21	14723-14727	than	_	
88-22	14728-14731	PPI	_	
88-23	14731-14732	.	_	

#Text=We constructed a GLM model including a regressor per trial to compute a separate parameter estimate (beta value) for each trial, resulting in 120 covariates of interest entered into the GLM (60 Single and 60 Dual trials).
89-1	14733-14735	We	_	
89-2	14736-14747	constructed	_	
89-3	14748-14749	a	_	
89-4	14750-14753	GLM	_	
89-5	14754-14759	model	_	
89-6	14760-14769	including	_	
89-7	14770-14771	a	_	
89-8	14772-14781	regressor	_	
89-9	14782-14785	per	_	
89-10	14786-14791	trial	_	
89-11	14792-14794	to	_	
89-12	14795-14802	compute	_	
89-13	14803-14804	a	_	
89-14	14805-14813	separate	_	
89-15	14814-14823	parameter	_	
89-16	14824-14832	estimate	_	
89-17	14833-14834	(	_	
89-18	14834-14838	beta	_	
89-19	14839-14844	value	_	
89-20	14844-14845	)	_	
89-21	14846-14849	for	_	
89-22	14850-14854	each	_	
89-23	14855-14860	trial	_	
89-24	14860-14861	,	_	
89-25	14862-14871	resulting	_	
89-26	14872-14874	in	_	
89-27	14875-14878	120	_	
89-28	14879-14889	covariates	_	
89-29	14890-14892	of	_	
89-30	14893-14901	interest	_	
89-31	14902-14909	entered	_	
89-32	14910-14914	into	_	
89-33	14915-14918	the	_	
89-34	14919-14922	GLM	_	
89-35	14923-14924	(	_	
89-36	14924-14926	60	_	
89-37	14927-14933	Single	_	
89-38	14934-14937	and	_	
89-39	14938-14940	60	_	
89-40	14941-14945	Dual	_	
89-41	14946-14952	trials	_	
89-42	14952-14953	)	_	
89-43	14953-14954	.	_	

#Text=The GLM also included covariates of no interest to model the effects of shifting signal levels across runs and 6 motion parameters.
90-1	14955-14958	The	_	
90-2	14959-14962	GLM	_	
90-3	14963-14967	also	_	
90-4	14968-14976	included	_	
90-5	14977-14987	covariates	_	
90-6	14988-14990	of	_	
90-7	14991-14993	no	_	
90-8	14994-15002	interest	_	
90-9	15003-15005	to	_	
90-10	15006-15011	model	_	
90-11	15012-15015	the	_	
90-12	15016-15023	effects	_	
90-13	15024-15026	of	_	
90-14	15027-15035	shifting	_	
90-15	15036-15042	signal	_	
90-16	15043-15049	levels	_	
90-17	15050-15056	across	_	
90-18	15057-15061	runs	_	
90-19	15062-15065	and	_	
90-20	15066-15067	6	_	
90-21	15068-15074	motion	_	
90-22	15075-15085	parameters	_	
90-23	15085-15086	.	_	

#Text=This GLM resulted in a unique set of 120 beta values for each voxel in the brain.
91-1	15087-15091	This	_	
91-2	15092-15095	GLM	_	
91-3	15096-15104	resulted	_	
91-4	15105-15107	in	_	
91-5	15108-15109	a	_	
91-6	15110-15116	unique	_	
91-7	15117-15120	set	_	
91-8	15121-15123	of	_	
91-9	15124-15127	120	_	
91-10	15128-15132	beta	_	
91-11	15133-15139	values	_	
91-12	15140-15143	for	_	
91-13	15144-15148	each	_	
91-14	15149-15154	voxel	_	
91-15	15155-15157	in	_	
91-16	15158-15161	the	_	
91-17	15162-15167	brain	_	
91-18	15167-15168	.	_	

#Text=Beta values from correct trials were sorted into Single and Dual ‘beta series’ for each voxel in the brain.
92-1	15169-15173	Beta	_	
92-2	15174-15180	values	_	
92-3	15181-15185	from	_	
92-4	15186-15193	correct	_	
92-5	15194-15200	trials	_	
92-6	15201-15205	were	_	
92-7	15206-15212	sorted	_	
92-8	15213-15217	into	_	
92-9	15218-15224	Single	_	
92-10	15225-15228	and	_	
92-11	15229-15233	Dual	_	
92-12	15234-15235	‘	_	
92-13	15235-15239	beta	_	
92-14	15240-15246	series	_	
92-15	15246-15247	’	_	
92-16	15248-15251	for	_	
92-17	15252-15256	each	_	
92-18	15257-15262	voxel	_	
92-19	15263-15265	in	_	
92-20	15266-15269	the	_	
92-21	15270-15275	brain	_	
92-22	15275-15276	.	_	

#Text=The task-based thalamus region from the between groups comparison of the Dual>Single contrast was used as a seed.
93-1	15277-15280	The	_	
93-2	15281-15291	task-based	_	
93-3	15292-15300	thalamus	_	
93-4	15301-15307	region	_	
93-5	15308-15312	from	_	
93-6	15313-15316	the	_	
93-7	15317-15324	between	_	
93-8	15325-15331	groups	_	
93-9	15332-15342	comparison	_	
93-10	15343-15345	of	_	
93-11	15346-15349	the	_	
93-12	15350-15354	Dual	_	
93-13	15354-15355	>	_	
93-14	15355-15361	Single	_	
93-15	15362-15370	contrast	_	
93-16	15371-15374	was	_	
93-17	15375-15379	used	_	
93-18	15380-15382	as	_	
93-19	15383-15384	a	_	
93-20	15385-15389	seed	_	
93-21	15389-15390	.	_	

#Text=Connectivity between this thalamus seed and each PFC ROI was calculated for the Dual and Single conditions by correlating their respective beta series.
94-1	15391-15403	Connectivity	_	
94-2	15404-15411	between	_	
94-3	15412-15416	this	_	
94-4	15417-15425	thalamus	_	
94-5	15426-15430	seed	_	
94-6	15431-15434	and	_	
94-7	15435-15439	each	_	
94-8	15440-15443	PFC	_	
94-9	15444-15447	ROI	_	
94-10	15448-15451	was	_	
94-11	15452-15462	calculated	_	
94-12	15463-15466	for	_	
94-13	15467-15470	the	_	
94-14	15471-15475	Dual	_	
94-15	15476-15479	and	_	
94-16	15480-15486	Single	_	
94-17	15487-15497	conditions	_	
94-18	15498-15500	by	_	
94-19	15501-15512	correlating	_	
94-20	15513-15518	their	_	
94-21	15519-15529	respective	_	
94-22	15530-15534	beta	_	
94-23	15535-15541	series	_	
94-24	15541-15542	.	_	

#Text=Additional analyses examining beta series connectivity from the MD, PUL and VL to the left LPFC are included in Supplementary Figure 2.
95-1	15543-15553	Additional	_	
95-2	15554-15562	analyses	_	
95-3	15563-15572	examining	_	
95-4	15573-15577	beta	_	
95-5	15578-15584	series	_	
95-6	15585-15597	connectivity	_	
95-7	15598-15602	from	_	
95-8	15603-15606	the	_	
95-9	15607-15609	MD	_	
95-10	15609-15610	,	_	
95-11	15611-15614	PUL	_	
95-12	15615-15618	and	_	
95-13	15619-15621	VL	_	
95-14	15622-15624	to	_	
95-15	15625-15628	the	_	
95-16	15629-15633	left	_	
95-17	15634-15638	LPFC	_	
95-18	15639-15642	are	_	
95-19	15643-15651	included	_	
95-20	15652-15654	in	_	
95-21	15655-15668	Supplementary	_	
95-22	15669-15675	Figure	_	
95-23	15676-15677	2	_	
95-24	15677-15678	.	_	

#Text=Results
#Text=Task performance
#Text=See Table 2 for accuracy and reaction time values.
96-1	15679-15686	Results	_	
96-2	15687-15691	Task	_	
96-3	15692-15703	performance	_	
96-4	15704-15707	See	_	
96-5	15708-15713	Table	_	
96-6	15714-15715	2	_	
96-7	15716-15719	for	_	
96-8	15720-15728	accuracy	_	
96-9	15729-15732	and	_	
96-10	15733-15741	reaction	_	
96-11	15742-15746	time	_	
96-12	15747-15753	values	_	
96-13	15753-15754	.	_	

#Text=The ANOVA for accuracy indicated a significant main effect of condition (F(1,37)=32.80, p<0.001), with both groups showing lower accuracy during the Dual condition, but no significant effect of group (F(1,37)=0.35, p=0.56) or group × condition interaction (F(1,37)=0.18, p=0.68).
97-1	15755-15758	The	_	
97-2	15759-15764	ANOVA	_	
97-3	15765-15768	for	_	
97-4	15769-15777	accuracy	_	
97-5	15778-15787	indicated	_	
97-6	15788-15789	a	_	
97-7	15790-15801	significant	_	
97-8	15802-15806	main	_	
97-9	15807-15813	effect	_	
97-10	15814-15816	of	_	
97-11	15817-15826	condition	_	
97-12	15827-15828	(	_	
97-13	15828-15829	F	_	
97-14	15829-15830	(	_	
97-15	15830-15834	1,37	_	
97-16	15834-15835	)	_	
97-17	15835-15836	=	_	
97-18	15836-15841	32.80	_	
97-19	15841-15842	,	_	
97-20	15843-15844	p	_	
97-21	15844-15845	<	_	
97-22	15845-15850	0.001	_	
97-23	15850-15851	)	_	
97-24	15851-15852	,	_	
97-25	15853-15857	with	_	
97-26	15858-15862	both	_	
97-27	15863-15869	groups	_	
97-28	15870-15877	showing	_	
97-29	15878-15883	lower	_	
97-30	15884-15892	accuracy	_	
97-31	15893-15899	during	_	
97-32	15900-15903	the	_	
97-33	15904-15908	Dual	_	
97-34	15909-15918	condition	_	
97-35	15918-15919	,	_	
97-36	15920-15923	but	_	
97-37	15924-15926	no	_	
97-38	15927-15938	significant	_	
97-39	15939-15945	effect	_	
97-40	15946-15948	of	_	
97-41	15949-15954	group	_	
97-42	15955-15956	(	_	
97-43	15956-15957	F	_	
97-44	15957-15958	(	_	
97-45	15958-15962	1,37	_	
97-46	15962-15963	)	_	
97-47	15963-15964	=	_	
97-48	15964-15968	0.35	_	
97-49	15968-15969	,	_	
97-50	15970-15971	p	_	
97-51	15971-15972	=	_	
97-52	15972-15976	0.56	_	
97-53	15976-15977	)	_	
97-54	15978-15980	or	_	
97-55	15981-15986	group	_	
97-56	15987-15988	×	_	
97-57	15989-15998	condition	_	
97-58	15999-16010	interaction	_	
97-59	16011-16012	(	_	
97-60	16012-16013	F	_	
97-61	16013-16014	(	_	
97-62	16014-16018	1,37	_	
97-63	16018-16019	)	_	
97-64	16019-16020	=	_	
97-65	16020-16024	0.18	_	
97-66	16024-16025	,	_	
97-67	16026-16027	p	_	
97-68	16027-16028	=	_	
97-69	16028-16032	0.68	_	
97-70	16032-16033	)	_	
97-71	16033-16034	.	_	

#Text=The ANOVA for reaction time (RT) indicated that both groups (Single=1203±169 ms, Dual=1461±242 ms) had slower RTs for the Dual compared to the Single condition (F(1,37)=195.68, p<0.001), and the schizophrenia group showed a trend towards slower RTs compared to the healthy group (F(1,37)=3.38, p=0.07).
98-1	16035-16038	The	_	
98-2	16039-16044	ANOVA	_	
98-3	16045-16048	for	_	
98-4	16049-16057	reaction	_	
98-5	16058-16062	time	_	
98-6	16063-16064	(	_	
98-7	16064-16066	RT	_	
98-8	16066-16067	)	_	
98-9	16068-16077	indicated	_	
98-10	16078-16082	that	_	
98-11	16083-16087	both	_	
98-12	16088-16094	groups	_	
98-13	16095-16096	(	_	
98-14	16096-16102	Single	_	
98-15	16102-16103	=	_	
98-16	16103-16107	1203	_	
98-17	16107-16108	±	_	
98-18	16108-16111	169	_	
98-19	16112-16114	ms	_	
98-20	16114-16115	,	_	
98-21	16116-16120	Dual	_	
98-22	16120-16121	=	_	
98-23	16121-16125	1461	_	
98-24	16125-16126	±	_	
98-25	16126-16129	242	_	
98-26	16130-16132	ms	_	
98-27	16132-16133	)	_	
98-28	16134-16137	had	_	
98-29	16138-16144	slower	_	
98-30	16145-16148	RTs	_	
98-31	16149-16152	for	_	
98-32	16153-16156	the	_	
98-33	16157-16161	Dual	_	
98-34	16162-16170	compared	_	
98-35	16171-16173	to	_	
98-36	16174-16177	the	_	
98-37	16178-16184	Single	_	
98-38	16185-16194	condition	_	
98-39	16195-16196	(	_	
98-40	16196-16197	F	_	
98-41	16197-16198	(	_	
98-42	16198-16202	1,37	_	
98-43	16202-16203	)	_	
98-44	16203-16204	=	_	
98-45	16204-16210	195.68	_	
98-46	16210-16211	,	_	
98-47	16212-16213	p	_	
98-48	16213-16214	<	_	
98-49	16214-16219	0.001	_	
98-50	16219-16220	)	_	
98-51	16220-16221	,	_	
98-52	16222-16225	and	_	
98-53	16226-16229	the	_	
98-54	16230-16243	schizophrenia	_	
98-55	16244-16249	group	_	
98-56	16250-16256	showed	_	
98-57	16257-16258	a	_	
98-58	16259-16264	trend	_	
98-59	16265-16272	towards	_	
98-60	16273-16279	slower	_	
98-61	16280-16283	RTs	_	
98-62	16284-16292	compared	_	
98-63	16293-16295	to	_	
98-64	16296-16299	the	_	
98-65	16300-16307	healthy	_	
98-66	16308-16313	group	_	
98-67	16314-16315	(	_	
98-68	16315-16316	F	_	
98-69	16316-16317	(	_	
98-70	16317-16321	1,37	_	
98-71	16321-16322	)	_	
98-72	16322-16323	=	_	
98-73	16323-16327	3.38	_	
98-74	16327-16328	,	_	
98-75	16329-16330	p	_	
98-76	16330-16331	=	_	
98-77	16331-16335	0.07	_	
98-78	16335-16336	)	_	
98-79	16336-16337	.	_	

#Text=No significant group × condition interaction (F(1,37)=1.71, p=0.20) was found (Figure 1B).
99-1	16338-16340	No	_	
99-2	16341-16352	significant	_	
99-3	16353-16358	group	_	
99-4	16359-16360	×	_	
99-5	16361-16370	condition	_	
99-6	16371-16382	interaction	_	
99-7	16383-16384	(	_	
99-8	16384-16385	F	_	
99-9	16385-16386	(	_	
99-10	16386-16390	1,37	_	
99-11	16390-16391	)	_	
99-12	16391-16392	=	_	
99-13	16392-16396	1.71	_	
99-14	16396-16397	,	_	
99-15	16398-16399	p	_	
99-16	16399-16400	=	_	
99-17	16400-16404	0.20	_	
99-18	16404-16405	)	_	
99-19	16406-16409	was	_	
99-20	16410-16415	found	_	
99-21	16416-16417	(	_	
99-22	16417-16423	Figure	_	
99-23	16424-16426	1B	_	
99-24	16426-16427	)	_	
99-25	16427-16428	.	_	

#Text=Cognitive demand related activation differences across the whole brain and PFC
#Text=As shown in Figure 2A, healthy individuals showed significant differences for the Dual>Single contrast in the pre-SMA, SMA, anterior cingulate, bilateral FEF, premotor cortex, LPFC, inferior frontal gyrus, insula, sensorimotor cortex, superior and inferior parietal lobule, visual cortex, retrosplenial cortex, superior temporal gyrus, thalamus, putamen, cerebellum, right dorsolateral prefrontal cortex and left intraparietal sulcus (p<0.05, FDR).
100-1	16429-16438	Cognitive	_	
100-2	16439-16445	demand	_	
100-3	16446-16453	related	_	
100-4	16454-16464	activation	_	
100-5	16465-16476	differences	_	
100-6	16477-16483	across	_	
100-7	16484-16487	the	_	
100-8	16488-16493	whole	_	
100-9	16494-16499	brain	_	
100-10	16500-16503	and	_	
100-11	16504-16507	PFC	_	
100-12	16508-16510	As	_	
100-13	16511-16516	shown	_	
100-14	16517-16519	in	_	
100-15	16520-16526	Figure	_	
100-16	16527-16529	2A	_	
100-17	16529-16530	,	_	
100-18	16531-16538	healthy	_	
100-19	16539-16550	individuals	_	
100-20	16551-16557	showed	_	
100-21	16558-16569	significant	_	
100-22	16570-16581	differences	_	
100-23	16582-16585	for	_	
100-24	16586-16589	the	_	
100-25	16590-16594	Dual	_	
100-26	16594-16595	>	_	
100-27	16595-16601	Single	_	
100-28	16602-16610	contrast	_	
100-29	16611-16613	in	_	
100-30	16614-16617	the	_	
100-31	16618-16625	pre-SMA	_	
100-32	16625-16626	,	_	
100-33	16627-16630	SMA	_	
100-34	16630-16631	,	_	
100-35	16632-16640	anterior	_	
100-36	16641-16650	cingulate	_	
100-37	16650-16651	,	_	
100-38	16652-16661	bilateral	_	
100-39	16662-16665	FEF	_	
100-40	16665-16666	,	_	
100-41	16667-16675	premotor	_	
100-42	16676-16682	cortex	_	
100-43	16682-16683	,	_	
100-44	16684-16688	LPFC	_	
100-45	16688-16689	,	_	
100-46	16690-16698	inferior	_	
100-47	16699-16706	frontal	_	
100-48	16707-16712	gyrus	_	
100-49	16712-16713	,	_	
100-50	16714-16720	insula	_	
100-51	16720-16721	,	_	
100-52	16722-16734	sensorimotor	_	
100-53	16735-16741	cortex	_	
100-54	16741-16742	,	_	
100-55	16743-16751	superior	_	
100-56	16752-16755	and	_	
100-57	16756-16764	inferior	_	
100-58	16765-16773	parietal	_	
100-59	16774-16780	lobule	_	
100-60	16780-16781	,	_	
100-61	16782-16788	visual	_	
100-62	16789-16795	cortex	_	
100-63	16795-16796	,	_	
100-64	16797-16810	retrosplenial	_	
100-65	16811-16817	cortex	_	
100-66	16817-16818	,	_	
100-67	16819-16827	superior	_	
100-68	16828-16836	temporal	_	
100-69	16837-16842	gyrus	_	
100-70	16842-16843	,	_	
100-71	16844-16852	thalamus	_	
100-72	16852-16853	,	_	
100-73	16854-16861	putamen	_	
100-74	16861-16862	,	_	
100-75	16863-16873	cerebellum	_	
100-76	16873-16874	,	_	
100-77	16875-16880	right	_	
100-78	16881-16893	dorsolateral	_	
100-79	16894-16904	prefrontal	_	
100-80	16905-16911	cortex	_	
100-81	16912-16915	and	_	
100-82	16916-16920	left	_	
100-83	16921-16934	intraparietal	_	
100-84	16935-16941	sulcus	_	
100-85	16942-16943	(	_	
100-86	16943-16944	p	_	
100-87	16944-16945	<	_	
100-88	16945-16949	0.05	_	
100-89	16949-16950	,	_	
100-90	16951-16954	FDR	_	
100-91	16954-16955	)	_	
100-92	16955-16956	.	_	

#Text=The schizophrenia group showed significant differences in similar regions, including the pre-SMA/SMA, mid-cingulate, bilateral LPFC, FEF, premotor cortex, sensorimotor cortex, insula, superior temporal gyrus, thalamus, visual cortex, cerebellum, the left superior and inferior parietal lobules, intraparietal sulcus, pallidum, putamen, retrosplenial cortex and the right inferior frontal gyrus (p<0.05, FDR).
101-1	16957-16960	The	_	
101-2	16961-16974	schizophrenia	_	
101-3	16975-16980	group	_	
101-4	16981-16987	showed	_	
101-5	16988-16999	significant	_	
101-6	17000-17011	differences	_	
101-7	17012-17014	in	_	
101-8	17015-17022	similar	_	
101-9	17023-17030	regions	_	
101-10	17030-17031	,	_	
101-11	17032-17041	including	_	
101-12	17042-17045	the	_	
101-13	17046-17053	pre-SMA	_	
101-14	17053-17054	/	_	
101-15	17054-17057	SMA	_	
101-16	17057-17058	,	_	
101-17	17059-17072	mid-cingulate	_	
101-18	17072-17073	,	_	
101-19	17074-17083	bilateral	_	
101-20	17084-17088	LPFC	_	
101-21	17088-17089	,	_	
101-22	17090-17093	FEF	_	
101-23	17093-17094	,	_	
101-24	17095-17103	premotor	_	
101-25	17104-17110	cortex	_	
101-26	17110-17111	,	_	
101-27	17112-17124	sensorimotor	_	
101-28	17125-17131	cortex	_	
101-29	17131-17132	,	_	
101-30	17133-17139	insula	_	
101-31	17139-17140	,	_	
101-32	17141-17149	superior	_	
101-33	17150-17158	temporal	_	
101-34	17159-17164	gyrus	_	
101-35	17164-17165	,	_	
101-36	17166-17174	thalamus	_	
101-37	17174-17175	,	_	
101-38	17176-17182	visual	_	
101-39	17183-17189	cortex	_	
101-40	17189-17190	,	_	
101-41	17191-17201	cerebellum	_	
101-42	17201-17202	,	_	
101-43	17203-17206	the	_	
101-44	17207-17211	left	_	
101-45	17212-17220	superior	_	
101-46	17221-17224	and	_	
101-47	17225-17233	inferior	_	
101-48	17234-17242	parietal	_	
101-49	17243-17250	lobules	_	
101-50	17250-17251	,	_	
101-51	17252-17265	intraparietal	_	
101-52	17266-17272	sulcus	_	
101-53	17272-17273	,	_	
101-54	17274-17282	pallidum	_	
101-55	17282-17283	,	_	
101-56	17284-17291	putamen	_	
101-57	17291-17292	,	_	
101-58	17293-17306	retrosplenial	_	
101-59	17307-17313	cortex	_	
101-60	17314-17317	and	_	
101-61	17318-17321	the	_	
101-62	17322-17327	right	_	
101-63	17328-17336	inferior	_	
101-64	17337-17344	frontal	_	
101-65	17345-17350	gyrus	_	
101-66	17351-17352	(	_	
101-67	17352-17353	p	_	
101-68	17353-17354	<	_	
101-69	17354-17358	0.05	_	
101-70	17358-17359	,	_	
101-71	17360-17363	FDR	_	
101-72	17363-17364	)	_	
101-73	17364-17365	.	_	

#Text=No significant between group differences were observed.
102-1	17366-17368	No	_	
102-2	17369-17380	significant	_	
102-3	17381-17388	between	_	
102-4	17389-17394	group	_	
102-5	17395-17406	differences	_	
102-6	17407-17411	were	_	
102-7	17412-17420	observed	_	
102-8	17420-17421	.	_	

#Text=See Supplementary Table 1 for complete results.
103-1	17422-17425	See	_	
103-2	17426-17439	Supplementary	_	
103-3	17440-17445	Table	_	
103-4	17446-17447	1	_	
103-5	17448-17451	for	_	
103-6	17452-17460	complete	_	
103-7	17461-17468	results	_	
103-8	17468-17469	.	_	

#Text=ROI analyses were conducted by extracting average activation signal from the 4 PFC clusters defined from the Dual>Single contrast collapsed across all subjects.
104-1	17470-17473	ROI	_	
104-2	17474-17482	analyses	_	
104-3	17483-17487	were	_	
104-4	17488-17497	conducted	_	
104-5	17498-17500	by	_	
104-6	17501-17511	extracting	_	
104-7	17512-17519	average	_	
104-8	17520-17530	activation	_	
104-9	17531-17537	signal	_	
104-10	17538-17542	from	_	
104-11	17543-17546	the	_	
104-12	17547-17548	4	_	
104-13	17549-17552	PFC	_	
104-14	17553-17561	clusters	_	
104-15	17562-17569	defined	_	
104-16	17570-17574	from	_	
104-17	17575-17578	the	_	
104-18	17579-17583	Dual	_	
104-19	17583-17584	>	_	
104-20	17584-17590	Single	_	
104-21	17591-17599	contrast	_	
104-22	17600-17609	collapsed	_	
104-23	17610-17616	across	_	
104-24	17617-17620	all	_	
104-25	17621-17629	subjects	_	
104-26	17629-17630	.	_	

#Text=Condition differences were observed for the pre-SMA/SMA (F(1,37)=30.78, p<0.001), the left FEF (F(1,37)=33.99, p<0.001), the right LPFC (F(1,37)=27.07, p<0.001) and left LPFC (F(1,37)=16.81, p<0.001).
105-1	17631-17640	Condition	_	
105-2	17641-17652	differences	_	
105-3	17653-17657	were	_	
105-4	17658-17666	observed	_	
105-5	17667-17670	for	_	
105-6	17671-17674	the	_	
105-7	17675-17682	pre-SMA	_	
105-8	17682-17683	/	_	
105-9	17683-17686	SMA	_	
105-10	17687-17688	(	_	
105-11	17688-17689	F	_	
105-12	17689-17690	(	_	
105-13	17690-17694	1,37	_	
105-14	17694-17695	)	_	
105-15	17695-17696	=	_	
105-16	17696-17701	30.78	_	
105-17	17701-17702	,	_	
105-18	17703-17704	p	_	
105-19	17704-17705	<	_	
105-20	17705-17710	0.001	_	
105-21	17710-17711	)	_	
105-22	17711-17712	,	_	
105-23	17713-17716	the	_	
105-24	17717-17721	left	_	
105-25	17722-17725	FEF	_	
105-26	17726-17727	(	_	
105-27	17727-17728	F	_	
105-28	17728-17729	(	_	
105-29	17729-17733	1,37	_	
105-30	17733-17734	)	_	
105-31	17734-17735	=	_	
105-32	17735-17740	33.99	_	
105-33	17740-17741	,	_	
105-34	17742-17743	p	_	
105-35	17743-17744	<	_	
105-36	17744-17749	0.001	_	
105-37	17749-17750	)	_	
105-38	17750-17751	,	_	
105-39	17752-17755	the	_	
105-40	17756-17761	right	_	
105-41	17762-17766	LPFC	_	
105-42	17767-17768	(	_	
105-43	17768-17769	F	_	
105-44	17769-17770	(	_	
105-45	17770-17774	1,37	_	
105-46	17774-17775	)	_	
105-47	17775-17776	=	_	
105-48	17776-17781	27.07	_	
105-49	17781-17782	,	_	
105-50	17783-17784	p	_	
105-51	17784-17785	<	_	
105-52	17785-17790	0.001	_	
105-53	17790-17791	)	_	
105-54	17792-17795	and	_	
105-55	17796-17800	left	_	
105-56	17801-17805	LPFC	_	
105-57	17806-17807	(	_	
105-58	17807-17808	F	_	
105-59	17808-17809	(	_	
105-60	17809-17813	1,37	_	
105-61	17813-17814	)	_	
105-62	17814-17815	=	_	
105-63	17815-17820	16.81	_	
105-64	17820-17821	,	_	
105-65	17822-17823	p	_	
105-66	17823-17824	<	_	
105-67	17824-17829	0.001	_	
105-68	17829-17830	)	_	
105-69	17830-17831	.	_	

#Text=All PFC clusters showed greater activation in the Dual compared to the Single condition (Figure 3A, Supplementary Table 2).
106-1	17832-17835	All	_	
106-2	17836-17839	PFC	_	
106-3	17840-17848	clusters	_	
106-4	17849-17855	showed	_	
106-5	17856-17863	greater	_	
106-6	17864-17874	activation	_	
106-7	17875-17877	in	_	
106-8	17878-17881	the	_	
106-9	17882-17886	Dual	_	
106-10	17887-17895	compared	_	
106-11	17896-17898	to	_	
106-12	17899-17902	the	_	
106-13	17903-17909	Single	_	
106-14	17910-17919	condition	_	
106-15	17920-17921	(	_	
106-16	17921-17927	Figure	_	
106-17	17928-17930	3A	_	
106-18	17930-17931	,	_	
106-19	17932-17945	Supplementary	_	
106-20	17946-17951	Table	_	
106-21	17952-17953	2	_	
106-22	17953-17954	)	_	
106-23	17954-17955	.	_	

#Text=No region showed a significant group difference or group × condition interaction effect.
107-1	17956-17958	No	_	
107-2	17959-17965	region	_	
107-3	17966-17972	showed	_	
107-4	17973-17974	a	_	
107-5	17975-17986	significant	_	
107-6	17987-17992	group	_	
107-7	17993-18003	difference	_	
107-8	18004-18006	or	_	
107-9	18007-18012	group	_	
107-10	18013-18014	×	_	
107-11	18015-18024	condition	_	
107-12	18025-18036	interaction	_	
107-13	18037-18043	effect	_	
107-14	18043-18044	.	_	

#Text=Thalamic activation differences between healthy and schizophrenia groups
#Text=Voxelwise analyses of thalamus activation found significantly greater thalamus activation in the healthy compared to the schizophrenia group in the Dual>Single contrast (see Figure 2B; 20, −20, 6; cluster size = 270 voxels, p<0.05, FDRSVC).
108-1	18045-18053	Thalamic	_	
108-2	18054-18064	activation	_	
108-3	18065-18076	differences	_	
108-4	18077-18084	between	_	
108-5	18085-18092	healthy	_	
108-6	18093-18096	and	_	
108-7	18097-18110	schizophrenia	_	
108-8	18111-18117	groups	_	
108-9	18118-18127	Voxelwise	_	
108-10	18128-18136	analyses	_	
108-11	18137-18139	of	_	
108-12	18140-18148	thalamus	_	
108-13	18149-18159	activation	_	
108-14	18160-18165	found	_	
108-15	18166-18179	significantly	_	
108-16	18180-18187	greater	_	
108-17	18188-18196	thalamus	_	
108-18	18197-18207	activation	_	
108-19	18208-18210	in	_	
108-20	18211-18214	the	_	
108-21	18215-18222	healthy	_	
108-22	18223-18231	compared	_	
108-23	18232-18234	to	_	
108-24	18235-18238	the	_	
108-25	18239-18252	schizophrenia	_	
108-26	18253-18258	group	_	
108-27	18259-18261	in	_	
108-28	18262-18265	the	_	
108-29	18266-18270	Dual	_	
108-30	18270-18271	>	_	
108-31	18271-18277	Single	_	
108-32	18278-18286	contrast	_	
108-33	18287-18288	(	_	
108-34	18288-18291	see	_	
108-35	18292-18298	Figure	_	
108-36	18299-18301	2B	_	
108-37	18301-18302	;	_	
108-38	18303-18305	20	_	
108-39	18305-18306	,	_	
108-40	18307-18308	−	_	
108-41	18308-18310	20	_	
108-42	18310-18311	,	_	
108-43	18312-18313	6	_	
108-44	18313-18314	;	_	
108-45	18315-18322	cluster	_	
108-46	18323-18327	size	_	
108-47	18328-18329	=	_	
108-48	18330-18333	270	_	
108-49	18334-18340	voxels	_	
108-50	18340-18341	,	_	
108-51	18342-18343	p	_	
108-52	18343-18344	<	_	
108-53	18344-18348	0.05	_	
108-54	18348-18349	,	_	
108-55	18350-18356	FDRSVC	_	
108-56	18356-18357	)	_	
108-57	18357-18358	.	_	

#Text=ROI analyses were conducted by extracting average activation signals from 3 thalamic regions defined a-priori based on the Morel histological parcellation of the thalamus defined in MNI space.
109-1	18359-18362	ROI	_	
109-2	18363-18371	analyses	_	
109-3	18372-18376	were	_	
109-4	18377-18386	conducted	_	
109-5	18387-18389	by	_	
109-6	18390-18400	extracting	_	
109-7	18401-18408	average	_	
109-8	18409-18419	activation	_	
109-9	18420-18427	signals	_	
109-10	18428-18432	from	_	
109-11	18433-18434	3	_	
109-12	18435-18443	thalamic	_	
109-13	18444-18451	regions	_	
109-14	18452-18459	defined	_	
109-15	18460-18468	a-priori	_	
109-16	18469-18474	based	_	
109-17	18475-18477	on	_	
109-18	18478-18481	the	_	
109-19	18482-18487	Morel	_	
109-20	18488-18500	histological	_	
109-21	18501-18513	parcellation	_	
109-22	18514-18516	of	_	
109-23	18517-18520	the	_	
109-24	18521-18529	thalamus	_	
109-25	18530-18537	defined	_	
109-26	18538-18540	in	_	
109-27	18541-18544	MNI	_	
109-28	18545-18550	space	_	
109-29	18550-18551	.	_	

#Text=Mixed ANOVA of the MD ROI showed a significant main effect of condition (F(1,37)=29.25, p<0.001), and group (F(1,37)=12.28, p<0.01) but no significant group × condition interaction (F(1,37)=4.58, p=0.117).
110-1	18552-18557	Mixed	_	
110-2	18558-18563	ANOVA	_	
110-3	18564-18566	of	_	
110-4	18567-18570	the	_	
110-5	18571-18573	MD	_	
110-6	18574-18577	ROI	_	
110-7	18578-18584	showed	_	
110-8	18585-18586	a	_	
110-9	18587-18598	significant	_	
110-10	18599-18603	main	_	
110-11	18604-18610	effect	_	
110-12	18611-18613	of	_	
110-13	18614-18623	condition	_	
110-14	18624-18625	(	_	
110-15	18625-18626	F	_	
110-16	18626-18627	(	_	
110-17	18627-18631	1,37	_	
110-18	18631-18632	)	_	
110-19	18632-18633	=	_	
110-20	18633-18638	29.25	_	
110-21	18638-18639	,	_	
110-22	18640-18641	p	_	
110-23	18641-18642	<	_	
110-24	18642-18647	0.001	_	
110-25	18647-18648	)	_	
110-26	18648-18649	,	_	
110-27	18650-18653	and	_	
110-28	18654-18659	group	_	
110-29	18660-18661	(	_	
110-30	18661-18662	F	_	
110-31	18662-18663	(	_	
110-32	18663-18667	1,37	_	
110-33	18667-18668	)	_	
110-34	18668-18669	=	_	
110-35	18669-18674	12.28	_	
110-36	18674-18675	,	_	
110-37	18676-18677	p	_	
110-38	18677-18678	<	_	
110-39	18678-18682	0.01	_	
110-40	18682-18683	)	_	
110-41	18684-18687	but	_	
110-42	18688-18690	no	_	
110-43	18691-18702	significant	_	
110-44	18703-18708	group	_	
110-45	18709-18710	×	_	
110-46	18711-18720	condition	_	
110-47	18721-18732	interaction	_	
110-48	18733-18734	(	_	
110-49	18734-18735	F	_	
110-50	18735-18736	(	_	
110-51	18736-18740	1,37	_	
110-52	18740-18741	)	_	
110-53	18741-18742	=	_	
110-54	18742-18746	4.58	_	
110-55	18746-18747	,	_	
110-56	18748-18749	p	_	
110-57	18749-18750	=	_	
110-58	18750-18755	0.117	_	
110-59	18755-18756	)	_	
110-60	18756-18757	.	_	

#Text=The PUL ROI showed a significant main effect of condition (F(1,37)=9.41, p<0.05), but not group (F(1,37)=4.61, p=0.114) or group × condition interaction (F(1,37)=2.98, p=0.279).
111-1	18758-18761	The	_	
111-2	18762-18765	PUL	_	
111-3	18766-18769	ROI	_	
111-4	18770-18776	showed	_	
111-5	18777-18778	a	_	
111-6	18779-18790	significant	_	
111-7	18791-18795	main	_	
111-8	18796-18802	effect	_	
111-9	18803-18805	of	_	
111-10	18806-18815	condition	_	
111-11	18816-18817	(	_	
111-12	18817-18818	F	_	
111-13	18818-18819	(	_	
111-14	18819-18823	1,37	_	
111-15	18823-18824	)	_	
111-16	18824-18825	=	_	
111-17	18825-18829	9.41	_	
111-18	18829-18830	,	_	
111-19	18831-18832	p	_	
111-20	18832-18833	<	_	
111-21	18833-18837	0.05	_	
111-22	18837-18838	)	_	
111-23	18838-18839	,	_	
111-24	18840-18843	but	_	
111-25	18844-18847	not	_	
111-26	18848-18853	group	_	
111-27	18854-18855	(	_	
111-28	18855-18856	F	_	
111-29	18856-18857	(	_	
111-30	18857-18861	1,37	_	
111-31	18861-18862	)	_	
111-32	18862-18863	=	_	
111-33	18863-18867	4.61	_	
111-34	18867-18868	,	_	
111-35	18869-18870	p	_	
111-36	18870-18871	=	_	
111-37	18871-18876	0.114	_	
111-38	18876-18877	)	_	
111-39	18878-18880	or	_	
111-40	18881-18886	group	_	
111-41	18887-18888	×	_	
111-42	18889-18898	condition	_	
111-43	18899-18910	interaction	_	
111-44	18911-18912	(	_	
111-45	18912-18913	F	_	
111-46	18913-18914	(	_	
111-47	18914-18918	1,37	_	
111-48	18918-18919	)	_	
111-49	18919-18920	=	_	
111-50	18920-18924	2.98	_	
111-51	18924-18925	,	_	
111-52	18926-18927	p	_	
111-53	18927-18928	=	_	
111-54	18928-18933	0.279	_	
111-55	18933-18934	)	_	
111-56	18934-18935	.	_	

#Text=The VL ROI showed a significant effect of condition (F(1,37)=33.30, p<0.001), a trend toward a significant effect of group (F(1,37)=5.49, p=0.074), but no significant group × condition interaction (F(1,37)=1.30, p=0.265) (see Figure 3B, Supplementary Table 2).
112-1	18936-18939	The	_	
112-2	18940-18942	VL	_	
112-3	18943-18946	ROI	_	
112-4	18947-18953	showed	_	
112-5	18954-18955	a	_	
112-6	18956-18967	significant	_	
112-7	18968-18974	effect	_	
112-8	18975-18977	of	_	
112-9	18978-18987	condition	_	
112-10	18988-18989	(	_	
112-11	18989-18990	F	_	
112-12	18990-18991	(	_	
112-13	18991-18995	1,37	_	
112-14	18995-18996	)	_	
112-15	18996-18997	=	_	
112-16	18997-19002	33.30	_	
112-17	19002-19003	,	_	
112-18	19004-19005	p	_	
112-19	19005-19006	<	_	
112-20	19006-19011	0.001	_	
112-21	19011-19012	)	_	
112-22	19012-19013	,	_	
112-23	19014-19015	a	_	
112-24	19016-19021	trend	_	
112-25	19022-19028	toward	_	
112-26	19029-19030	a	_	
112-27	19031-19042	significant	_	
112-28	19043-19049	effect	_	
112-29	19050-19052	of	_	
112-30	19053-19058	group	_	
112-31	19059-19060	(	_	
112-32	19060-19061	F	_	
112-33	19061-19062	(	_	
112-34	19062-19066	1,37	_	
112-35	19066-19067	)	_	
112-36	19067-19068	=	_	
112-37	19068-19072	5.49	_	
112-38	19072-19073	,	_	
112-39	19074-19075	p	_	
112-40	19075-19076	=	_	
112-41	19076-19081	0.074	_	
112-42	19081-19082	)	_	
112-43	19082-19083	,	_	
112-44	19084-19087	but	_	
112-45	19088-19090	no	_	
112-46	19091-19102	significant	_	
112-47	19103-19108	group	_	
112-48	19109-19110	×	_	
112-49	19111-19120	condition	_	
112-50	19121-19132	interaction	_	
112-51	19133-19134	(	_	
112-52	19134-19135	F	_	
112-53	19135-19136	(	_	
112-54	19136-19140	1,37	_	
112-55	19140-19141	)	_	
112-56	19141-19142	=	_	
112-57	19142-19146	1.30	_	
112-58	19146-19147	,	_	
112-59	19148-19149	p	_	
112-60	19149-19150	=	_	
112-61	19150-19155	0.265	_	
112-62	19155-19156	)	_	
112-63	19157-19158	(	_	
112-64	19158-19161	see	_	
112-65	19162-19168	Figure	_	
112-66	19169-19171	3B	_	
112-67	19171-19172	,	_	
112-68	19173-19186	Supplementary	_	
112-69	19187-19192	Table	_	
112-70	19193-19194	2	_	
112-71	19194-19195	)	_	
112-72	19195-19196	.	_	

#Text=Thalamus-PFC connectivity
#Text=As we were interested in how thalamus-PFC connectivity was influenced by cognitive demand in schizophrenia, we performed a beta-series connectivity analysis using the cluster within the thalamus that showed a significant group × condition interaction as the seed region (See Figure 4).
113-1	19197-19209	Thalamus-PFC	_	
113-2	19210-19222	connectivity	_	
113-3	19223-19225	As	_	
113-4	19226-19228	we	_	
113-5	19229-19233	were	_	
113-6	19234-19244	interested	_	
113-7	19245-19247	in	_	
113-8	19248-19251	how	_	
113-9	19252-19264	thalamus-PFC	_	
113-10	19265-19277	connectivity	_	
113-11	19278-19281	was	_	
113-12	19282-19292	influenced	_	
113-13	19293-19295	by	_	
113-14	19296-19305	cognitive	_	
113-15	19306-19312	demand	_	
113-16	19313-19315	in	_	
113-17	19316-19329	schizophrenia	_	
113-18	19329-19330	,	_	
113-19	19331-19333	we	_	
113-20	19334-19343	performed	_	
113-21	19344-19345	a	_	
113-22	19346-19357	beta-series	_	
113-23	19358-19370	connectivity	_	
113-24	19371-19379	analysis	_	
113-25	19380-19385	using	_	
113-26	19386-19389	the	_	
113-27	19390-19397	cluster	_	
113-28	19398-19404	within	_	
113-29	19405-19408	the	_	
113-30	19409-19417	thalamus	_	
113-31	19418-19422	that	_	
113-32	19423-19429	showed	_	
113-33	19430-19431	a	_	
113-34	19432-19443	significant	_	
113-35	19444-19449	group	_	
113-36	19450-19451	×	_	
113-37	19452-19461	condition	_	
113-38	19462-19473	interaction	_	
113-39	19474-19476	as	_	
113-40	19477-19480	the	_	
113-41	19481-19485	seed	_	
113-42	19486-19492	region	_	
113-43	19493-19494	(	_	
113-44	19494-19497	See	_	
113-45	19498-19504	Figure	_	
113-46	19505-19506	4	_	
113-47	19506-19507	)	_	
113-48	19507-19508	.	_	

#Text=We investigated connectivity between this thalamus seed and the 4 task-based PFC ROIs that demonstrated greater BOLD response during Dual task condition compared to Single task condition (collapsed across subjects).
114-1	19509-19511	We	_	
114-2	19512-19524	investigated	_	
114-3	19525-19537	connectivity	_	
114-4	19538-19545	between	_	
114-5	19546-19550	this	_	
114-6	19551-19559	thalamus	_	
114-7	19560-19564	seed	_	
114-8	19565-19568	and	_	
114-9	19569-19572	the	_	
114-10	19573-19574	4	_	
114-11	19575-19585	task-based	_	
114-12	19586-19589	PFC	_	
114-13	19590-19594	ROIs	_	
114-14	19595-19599	that	_	
114-15	19600-19612	demonstrated	_	
114-16	19613-19620	greater	_	
114-17	19621-19625	BOLD	_	
114-18	19626-19634	response	_	
114-19	19635-19641	during	_	
114-20	19642-19646	Dual	_	
114-21	19647-19651	task	_	
114-22	19652-19661	condition	_	
114-23	19662-19670	compared	_	
114-24	19671-19673	to	_	
114-25	19674-19680	Single	_	
114-26	19681-19685	task	_	
114-27	19686-19695	condition	_	
114-28	19696-19697	(	_	
114-29	19697-19706	collapsed	_	
114-30	19707-19713	across	_	
114-31	19714-19722	subjects	_	
114-32	19722-19723	)	_	
114-33	19723-19724	.	_	

#Text=Connectivity between the thalamus and the left FEF, pre-SMA/SMA, right LPFC or left LPFC did not show a significant main effect of condition or group.
115-1	19725-19737	Connectivity	_	
115-2	19738-19745	between	_	
115-3	19746-19749	the	_	
115-4	19750-19758	thalamus	_	
115-5	19759-19762	and	_	
115-6	19763-19766	the	_	
115-7	19767-19771	left	_	
115-8	19772-19775	FEF	_	
115-9	19775-19776	,	_	
115-10	19777-19784	pre-SMA	_	
115-11	19784-19785	/	_	
115-12	19785-19788	SMA	_	
115-13	19788-19789	,	_	
115-14	19790-19795	right	_	
115-15	19796-19800	LPFC	_	
115-16	19801-19803	or	_	
115-17	19804-19808	left	_	
115-18	19809-19813	LPFC	_	
115-19	19814-19817	did	_	
115-20	19818-19821	not	_	
115-21	19822-19826	show	_	
115-22	19827-19828	a	_	
115-23	19829-19840	significant	_	
115-24	19841-19845	main	_	
115-25	19846-19852	effect	_	
115-26	19853-19855	of	_	
115-27	19856-19865	condition	_	
115-28	19866-19868	or	_	
115-29	19869-19874	group	_	
115-30	19874-19875	.	_	

#Text=Only connectivity between the thalamus and the left LPFC showed a significant group × condition interaction (F(1,37)=10.23, p<0.05), such that while the healthy group showed an increase in connectivity between the Single and Dual conditions, the schizophrenia group did not show such an increase (Figure 4, Supplementary Table 2).
116-1	19876-19880	Only	_	
116-2	19881-19893	connectivity	_	
116-3	19894-19901	between	_	
116-4	19902-19905	the	_	
116-5	19906-19914	thalamus	_	
116-6	19915-19918	and	_	
116-7	19919-19922	the	_	
116-8	19923-19927	left	_	
116-9	19928-19932	LPFC	_	
116-10	19933-19939	showed	_	
116-11	19940-19941	a	_	
116-12	19942-19953	significant	_	
116-13	19954-19959	group	_	
116-14	19960-19961	×	_	
116-15	19962-19971	condition	_	
116-16	19972-19983	interaction	_	
116-17	19984-19985	(	_	
116-18	19985-19986	F	_	
116-19	19986-19987	(	_	
116-20	19987-19991	1,37	_	
116-21	19991-19992	)	_	
116-22	19992-19993	=	_	
116-23	19993-19998	10.23	_	
116-24	19998-19999	,	_	
116-25	20000-20001	p	_	
116-26	20001-20002	<	_	
116-27	20002-20006	0.05	_	
116-28	20006-20007	)	_	
116-29	20007-20008	,	_	
116-30	20009-20013	such	_	
116-31	20014-20018	that	_	
116-32	20019-20024	while	_	
116-33	20025-20028	the	_	
116-34	20029-20036	healthy	_	
116-35	20037-20042	group	_	
116-36	20043-20049	showed	_	
116-37	20050-20052	an	_	
116-38	20053-20061	increase	_	
116-39	20062-20064	in	_	
116-40	20065-20077	connectivity	_	
116-41	20078-20085	between	_	
116-42	20086-20089	the	_	
116-43	20090-20096	Single	_	
116-44	20097-20100	and	_	
116-45	20101-20105	Dual	_	
116-46	20106-20116	conditions	_	
116-47	20116-20117	,	_	
116-48	20118-20121	the	_	
116-49	20122-20135	schizophrenia	_	
116-50	20136-20141	group	_	
116-51	20142-20145	did	_	
116-52	20146-20149	not	_	
116-53	20150-20154	show	_	
116-54	20155-20159	such	_	
116-55	20160-20162	an	_	
116-56	20163-20171	increase	_	
116-57	20172-20173	(	_	
116-58	20173-20179	Figure	_	
116-59	20180-20181	4	_	
116-60	20181-20182	,	_	
116-61	20183-20196	Supplementary	_	
116-62	20197-20202	Table	_	
116-63	20203-20204	2	_	
116-64	20204-20205	)	_	
116-65	20205-20206	.	_	

#Text=Beta-series connectivity results from our three Morel atlas ROIs are presented in Supplementary Figure 2.
117-1	20207-20218	Beta-series	_	
117-2	20219-20231	connectivity	_	
117-3	20232-20239	results	_	
117-4	20240-20244	from	_	
117-5	20245-20248	our	_	
117-6	20249-20254	three	_	
117-7	20255-20260	Morel	_	
117-8	20261-20266	atlas	_	
117-9	20267-20271	ROIs	_	
117-10	20272-20275	are	_	
117-11	20276-20285	presented	_	
117-12	20286-20288	in	_	
117-13	20289-20302	Supplementary	_	
117-14	20303-20309	Figure	_	
117-15	20310-20311	2	_	
117-16	20311-20312	.	_	

#Text=Discussion
#Text=We investigated modulation of thalamus and PFC function in schizophrenia patients using a dual task paradigm.
118-1	20313-20323	Discussion	_	
118-2	20324-20326	We	_	
118-3	20327-20339	investigated	_	
118-4	20340-20350	modulation	_	
118-5	20351-20353	of	_	
118-6	20354-20362	thalamus	_	
118-7	20363-20366	and	_	
118-8	20367-20370	PFC	_	
118-9	20371-20379	function	_	
118-10	20380-20382	in	_	
118-11	20383-20396	schizophrenia	_	
118-12	20397-20405	patients	_	
118-13	20406-20411	using	_	
118-14	20412-20413	a	_	
118-15	20414-20418	dual	_	
118-16	20419-20423	task	_	
118-17	20424-20432	paradigm	_	
118-18	20432-20433	.	_	

#Text=As hypothesized, we found that in both schizophrenia and healthy individuals, thalamus and PFC activation were modulated by cognitive demand, although only the thalamus showed reduced modulation of BOLD activation in response to cognitive demand in schizophrenia, with this difference only significant in the MD thalamus.
119-1	20434-20436	As	_	
119-2	20437-20449	hypothesized	_	
119-3	20449-20450	,	_	
119-4	20451-20453	we	_	
119-5	20454-20459	found	_	
119-6	20460-20464	that	_	
119-7	20465-20467	in	_	
119-8	20468-20472	both	_	
119-9	20473-20486	schizophrenia	_	
119-10	20487-20490	and	_	
119-11	20491-20498	healthy	_	
119-12	20499-20510	individuals	_	
119-13	20510-20511	,	_	
119-14	20512-20520	thalamus	_	
119-15	20521-20524	and	_	
119-16	20525-20528	PFC	_	
119-17	20529-20539	activation	_	
119-18	20540-20544	were	_	
119-19	20545-20554	modulated	_	
119-20	20555-20557	by	_	
119-21	20558-20567	cognitive	_	
119-22	20568-20574	demand	_	
119-23	20574-20575	,	_	
119-24	20576-20584	although	_	
119-25	20585-20589	only	_	
119-26	20590-20593	the	_	
119-27	20594-20602	thalamus	_	
119-28	20603-20609	showed	_	
119-29	20610-20617	reduced	_	
119-30	20618-20628	modulation	_	
119-31	20629-20631	of	_	
119-32	20632-20636	BOLD	_	
119-33	20637-20647	activation	_	
119-34	20648-20650	in	_	
119-35	20651-20659	response	_	
119-36	20660-20662	to	_	
119-37	20663-20672	cognitive	_	
119-38	20673-20679	demand	_	
119-39	20680-20682	in	_	
119-40	20683-20696	schizophrenia	_	
119-41	20696-20697	,	_	
119-42	20698-20702	with	_	
119-43	20703-20707	this	_	
119-44	20708-20718	difference	_	
119-45	20719-20723	only	_	
119-46	20724-20735	significant	_	
119-47	20736-20738	in	_	
119-48	20739-20742	the	_	
119-49	20743-20745	MD	_	
119-50	20746-20754	thalamus	_	
119-51	20754-20755	.	_	

#Text=Previous literature frequently showed concurrent dysfunction of the PFC and MD regions of the thalamus in patients performing cognitive tasks, as well as both showing decreased metabolism during cognition, with the MD thalamus particularly affected.
120-1	20756-20764	Previous	_	
120-2	20765-20775	literature	_	
120-3	20776-20786	frequently	_	
120-4	20787-20793	showed	_	
120-5	20794-20804	concurrent	_	
120-6	20805-20816	dysfunction	_	
120-7	20817-20819	of	_	
120-8	20820-20823	the	_	
120-9	20824-20827	PFC	_	
120-10	20828-20831	and	_	
120-11	20832-20834	MD	_	
120-12	20835-20842	regions	_	
120-13	20843-20845	of	_	
120-14	20846-20849	the	_	
120-15	20850-20858	thalamus	_	
120-16	20859-20861	in	_	
120-17	20862-20870	patients	_	
120-18	20871-20881	performing	_	
120-19	20882-20891	cognitive	_	
120-20	20892-20897	tasks	_	
120-21	20897-20898	,	_	
120-22	20899-20901	as	_	
120-23	20902-20906	well	_	
120-24	20907-20909	as	_	
120-25	20910-20914	both	_	
120-26	20915-20922	showing	_	
120-27	20923-20932	decreased	_	
120-28	20933-20943	metabolism	_	
120-29	20944-20950	during	_	
120-30	20951-20960	cognition	_	
120-31	20960-20961	,	_	
120-32	20962-20966	with	_	
120-33	20967-20970	the	_	
120-34	20971-20973	MD	_	
120-35	20974-20982	thalamus	_	
120-36	20983-20995	particularly	_	
120-37	20996-21004	affected	_	
120-38	21004-21005	.	_	

#Text=Interactions between the MD thalamus and PFC have been implicated in flexible, goal directed behaviors, and the MD thalamus has been particularly implicated in schizophrenia, showing greater volume reduction than other thalamic nuclei.
121-1	21006-21018	Interactions	_	
121-2	21019-21026	between	_	
121-3	21027-21030	the	_	
121-4	21031-21033	MD	_	
121-5	21034-21042	thalamus	_	
121-6	21043-21046	and	_	
121-7	21047-21050	PFC	_	
121-8	21051-21055	have	_	
121-9	21056-21060	been	_	
121-10	21061-21071	implicated	_	
121-11	21072-21074	in	_	
121-12	21075-21083	flexible	_	
121-13	21083-21084	,	_	
121-14	21085-21089	goal	_	
121-15	21090-21098	directed	_	
121-16	21099-21108	behaviors	_	
121-17	21108-21109	,	_	
121-18	21110-21113	and	_	
121-19	21114-21117	the	_	
121-20	21118-21120	MD	_	
121-21	21121-21129	thalamus	_	
121-22	21130-21133	has	_	
121-23	21134-21138	been	_	
121-24	21139-21151	particularly	_	
121-25	21152-21162	implicated	_	
121-26	21163-21165	in	_	
121-27	21166-21179	schizophrenia	_	
121-28	21179-21180	,	_	
121-29	21181-21188	showing	_	
121-30	21189-21196	greater	_	
121-31	21197-21203	volume	_	
121-32	21204-21213	reduction	_	
121-33	21214-21218	than	_	
121-34	21219-21224	other	_	
121-35	21225-21233	thalamic	_	
121-36	21234-21240	nuclei	_	
121-37	21240-21241	.	_	

#Text=Dual task paradigms in neurotypical individuals evoke a network of brain regions including the PFC and posterior parietal cortex that overlap with those observed in working memory tasks, commonly referred to as the task positive network.
122-1	21242-21246	Dual	_	
122-2	21247-21251	task	_	
122-3	21252-21261	paradigms	_	
122-4	21262-21264	in	_	
122-5	21265-21277	neurotypical	_	
122-6	21278-21289	individuals	_	
122-7	21290-21295	evoke	_	
122-8	21296-21297	a	_	
122-9	21298-21305	network	_	
122-10	21306-21308	of	_	
122-11	21309-21314	brain	_	
122-12	21315-21322	regions	_	
122-13	21323-21332	including	_	
122-14	21333-21336	the	_	
122-15	21337-21340	PFC	_	
122-16	21341-21344	and	_	
122-17	21345-21354	posterior	_	
122-18	21355-21363	parietal	_	
122-19	21364-21370	cortex	_	
122-20	21371-21375	that	_	
122-21	21376-21383	overlap	_	
122-22	21384-21388	with	_	
122-23	21389-21394	those	_	
122-24	21395-21403	observed	_	
122-25	21404-21406	in	_	
122-26	21407-21414	working	_	
122-27	21415-21421	memory	_	
122-28	21422-21427	tasks	_	
122-29	21427-21428	,	_	
122-30	21429-21437	commonly	_	
122-31	21438-21446	referred	_	
122-32	21447-21449	to	_	
122-33	21450-21452	as	_	
122-34	21453-21456	the	_	
122-35	21457-21461	task	_	
122-36	21462-21470	positive	_	
122-37	21471-21478	network	_	
122-38	21478-21479	.	_	

#Text=Disruption of PFC regions have been the focus of investigation in schizophrenia, with some studies showing increased activation, decreased activation, or no difference between groups, as in our study.
123-1	21480-21490	Disruption	_	
123-2	21491-21493	of	_	
123-3	21494-21497	PFC	_	
123-4	21498-21505	regions	_	
123-5	21506-21510	have	_	
123-6	21511-21515	been	_	
123-7	21516-21519	the	_	
123-8	21520-21525	focus	_	
123-9	21526-21528	of	_	
123-10	21529-21542	investigation	_	
123-11	21543-21545	in	_	
123-12	21546-21559	schizophrenia	_	
123-13	21559-21560	,	_	
123-14	21561-21565	with	_	
123-15	21566-21570	some	_	
123-16	21571-21578	studies	_	
123-17	21579-21586	showing	_	
123-18	21587-21596	increased	_	
123-19	21597-21607	activation	_	
123-20	21607-21608	,	_	
123-21	21609-21618	decreased	_	
123-22	21619-21629	activation	_	
123-23	21629-21630	,	_	
123-24	21631-21633	or	_	
123-25	21634-21636	no	_	
123-26	21637-21647	difference	_	
123-27	21648-21655	between	_	
123-28	21656-21662	groups	_	
123-29	21662-21663	,	_	
123-30	21664-21666	as	_	
123-31	21667-21669	in	_	
123-32	21670-21673	our	_	
123-33	21674-21679	study	_	
123-34	21679-21680	.	_	

#Text=There has been less focus on changes in other regions within this network in schizophrenia, though a recent study found decreased modulation of activity in the posterior parietal cortex with increased cognitive demand in schizophrenia.
124-1	21681-21686	There	_	
124-2	21687-21690	has	_	
124-3	21691-21695	been	_	
124-4	21696-21700	less	_	
124-5	21701-21706	focus	_	
124-6	21707-21709	on	_	
124-7	21710-21717	changes	_	
124-8	21718-21720	in	_	
124-9	21721-21726	other	_	
124-10	21727-21734	regions	_	
124-11	21735-21741	within	_	
124-12	21742-21746	this	_	
124-13	21747-21754	network	_	
124-14	21755-21757	in	_	
124-15	21758-21771	schizophrenia	_	
124-16	21771-21772	,	_	
124-17	21773-21779	though	_	
124-18	21780-21781	a	_	
124-19	21782-21788	recent	_	
124-20	21789-21794	study	_	
124-21	21795-21800	found	_	
124-22	21801-21810	decreased	_	
124-23	21811-21821	modulation	_	
124-24	21822-21824	of	_	
124-25	21825-21833	activity	_	
124-26	21834-21836	in	_	
124-27	21837-21840	the	_	
124-28	21841-21850	posterior	_	
124-29	21851-21859	parietal	_	
124-30	21860-21866	cortex	_	
124-31	21867-21871	with	_	
124-32	21872-21881	increased	_	
124-33	21882-21891	cognitive	_	
124-34	21892-21898	demand	_	
124-35	21899-21901	in	_	
124-36	21902-21915	schizophrenia	_	
124-37	21915-21916	.	_	

#Text=We found that an area within the thalamus covering the mediodorsal, lateral and posterior thalamus also showed reduced modulation by cognitive demand in schizophrenia, suggesting that regions within the task positive network other than the PFC are also disrupted in schizophrenia.
125-1	21917-21919	We	_	
125-2	21920-21925	found	_	
125-3	21926-21930	that	_	
125-4	21931-21933	an	_	
125-5	21934-21938	area	_	
125-6	21939-21945	within	_	
125-7	21946-21949	the	_	
125-8	21950-21958	thalamus	_	
125-9	21959-21967	covering	_	
125-10	21968-21971	the	_	
125-11	21972-21983	mediodorsal	_	
125-12	21983-21984	,	_	
125-13	21985-21992	lateral	_	
125-14	21993-21996	and	_	
125-15	21997-22006	posterior	_	
125-16	22007-22015	thalamus	_	
125-17	22016-22020	also	_	
125-18	22021-22027	showed	_	
125-19	22028-22035	reduced	_	
125-20	22036-22046	modulation	_	
125-21	22047-22049	by	_	
125-22	22050-22059	cognitive	_	
125-23	22060-22066	demand	_	
125-24	22067-22069	in	_	
125-25	22070-22083	schizophrenia	_	
125-26	22083-22084	,	_	
125-27	22085-22095	suggesting	_	
125-28	22096-22100	that	_	
125-29	22101-22108	regions	_	
125-30	22109-22115	within	_	
125-31	22116-22119	the	_	
125-32	22120-22124	task	_	
125-33	22125-22133	positive	_	
125-34	22134-22141	network	_	
125-35	22142-22147	other	_	
125-36	22148-22152	than	_	
125-37	22153-22156	the	_	
125-38	22157-22160	PFC	_	
125-39	22161-22164	are	_	
125-40	22165-22169	also	_	
125-41	22170-22179	disrupted	_	
125-42	22180-22182	in	_	
125-43	22183-22196	schizophrenia	_	
125-44	22196-22197	.	_	

#Text=In addition to thalamus activation, thalamus-PFC connectivity with the LPFC also showed reduced modulation by task demand in schizophrenia.
126-1	22198-22200	In	_	
126-2	22201-22209	addition	_	
126-3	22210-22212	to	_	
126-4	22213-22221	thalamus	_	
126-5	22222-22232	activation	_	
126-6	22232-22233	,	_	
126-7	22234-22246	thalamus-PFC	_	
126-8	22247-22259	connectivity	_	
126-9	22260-22264	with	_	
126-10	22265-22268	the	_	
126-11	22269-22273	LPFC	_	
126-12	22274-22278	also	_	
126-13	22279-22285	showed	_	
126-14	22286-22293	reduced	_	
126-15	22294-22304	modulation	_	
126-16	22305-22307	by	_	
126-17	22308-22312	task	_	
126-18	22313-22319	demand	_	
126-19	22320-22322	in	_	
126-20	22323-22336	schizophrenia	_	
126-21	22336-22337	.	_	

#Text=Compared to the right hemisphere, the left thalamus and the left PFC has shown reduced structural connectivity in schizophrenia.
127-1	22338-22346	Compared	_	
127-2	22347-22349	to	_	
127-3	22350-22353	the	_	
127-4	22354-22359	right	_	
127-5	22360-22370	hemisphere	_	
127-6	22370-22371	,	_	
127-7	22372-22375	the	_	
127-8	22376-22380	left	_	
127-9	22381-22389	thalamus	_	
127-10	22390-22393	and	_	
127-11	22394-22397	the	_	
127-12	22398-22402	left	_	
127-13	22403-22406	PFC	_	
127-14	22407-22410	has	_	
127-15	22411-22416	shown	_	
127-16	22417-22424	reduced	_	
127-17	22425-22435	structural	_	
127-18	22436-22448	connectivity	_	
127-19	22449-22451	in	_	
127-20	22452-22465	schizophrenia	_	
127-21	22465-22466	.	_	

#Text=This region of the PFC has previously been identified as an a-modal central bottleneck, important for resolving dual task competition.
128-1	22467-22471	This	_	
128-2	22472-22478	region	_	
128-3	22479-22481	of	_	
128-4	22482-22485	the	_	
128-5	22486-22489	PFC	_	
128-6	22490-22493	has	_	
128-7	22494-22504	previously	_	
128-8	22505-22509	been	_	
128-9	22510-22520	identified	_	
128-10	22521-22523	as	_	
128-11	22524-22526	an	_	
128-12	22527-22534	a-modal	_	
128-13	22535-22542	central	_	
128-14	22543-22553	bottleneck	_	
128-15	22553-22554	,	_	
128-16	22555-22564	important	_	
128-17	22565-22568	for	_	
128-18	22569-22578	resolving	_	
128-19	22579-22583	dual	_	
128-20	22584-22588	task	_	
128-21	22589-22600	competition	_	
128-22	22600-22601	.	_	

#Text=In studies of working memory load, only the left LPFC showed an interaction between working memory load and group such that patients showed lower activation increases with working memory load, as well as an interaction between working memory load and performance such that poorer performing patients showed decreased activation and higher performing patients showed increased activation compared to healthy individuals, with this effect most prominent in the left hemisphere.
129-1	22602-22604	In	_	
129-2	22605-22612	studies	_	
129-3	22613-22615	of	_	
129-4	22616-22623	working	_	
129-5	22624-22630	memory	_	
129-6	22631-22635	load	_	
129-7	22635-22636	,	_	
129-8	22637-22641	only	_	
129-9	22642-22645	the	_	
129-10	22646-22650	left	_	
129-11	22651-22655	LPFC	_	
129-12	22656-22662	showed	_	
129-13	22663-22665	an	_	
129-14	22666-22677	interaction	_	
129-15	22678-22685	between	_	
129-16	22686-22693	working	_	
129-17	22694-22700	memory	_	
129-18	22701-22705	load	_	
129-19	22706-22709	and	_	
129-20	22710-22715	group	_	
129-21	22716-22720	such	_	
129-22	22721-22725	that	_	
129-23	22726-22734	patients	_	
129-24	22735-22741	showed	_	
129-25	22742-22747	lower	_	
129-26	22748-22758	activation	_	
129-27	22759-22768	increases	_	
129-28	22769-22773	with	_	
129-29	22774-22781	working	_	
129-30	22782-22788	memory	_	
129-31	22789-22793	load	_	
129-32	22793-22794	,	_	
129-33	22795-22797	as	_	
129-34	22798-22802	well	_	
129-35	22803-22805	as	_	
129-36	22806-22808	an	_	
129-37	22809-22820	interaction	_	
129-38	22821-22828	between	_	
129-39	22829-22836	working	_	
129-40	22837-22843	memory	_	
129-41	22844-22848	load	_	
129-42	22849-22852	and	_	
129-43	22853-22864	performance	_	
129-44	22865-22869	such	_	
129-45	22870-22874	that	_	
129-46	22875-22881	poorer	_	
129-47	22882-22892	performing	_	
129-48	22893-22901	patients	_	
129-49	22902-22908	showed	_	
129-50	22909-22918	decreased	_	
129-51	22919-22929	activation	_	
129-52	22930-22933	and	_	
129-53	22934-22940	higher	_	
129-54	22941-22951	performing	_	
129-55	22952-22960	patients	_	
129-56	22961-22967	showed	_	
129-57	22968-22977	increased	_	
129-58	22978-22988	activation	_	
129-59	22989-22997	compared	_	
129-60	22998-23000	to	_	
129-61	23001-23008	healthy	_	
129-62	23009-23020	individuals	_	
129-63	23020-23021	,	_	
129-64	23022-23026	with	_	
129-65	23027-23031	this	_	
129-66	23032-23038	effect	_	
129-67	23039-23043	most	_	
129-68	23044-23053	prominent	_	
129-69	23054-23056	in	_	
129-70	23057-23060	the	_	
129-71	23061-23065	left	_	
129-72	23066-23076	hemisphere	_	
129-73	23076-23077	.	_	

#Text=No other PFC region tested showed a reduction in task-based modulation, suggesting that thalamocortical connectivity between the thalamus and the left LPFC may be particularly impaired in patients.
130-1	23078-23080	No	_	
130-2	23081-23086	other	_	
130-3	23087-23090	PFC	_	
130-4	23091-23097	region	_	
130-5	23098-23104	tested	_	
130-6	23105-23111	showed	_	
130-7	23112-23113	a	_	
130-8	23114-23123	reduction	_	
130-9	23124-23126	in	_	
130-10	23127-23137	task-based	_	
130-11	23138-23148	modulation	_	
130-12	23148-23149	,	_	
130-13	23150-23160	suggesting	_	
130-14	23161-23165	that	_	
130-15	23166-23181	thalamocortical	_	
130-16	23182-23194	connectivity	_	
130-17	23195-23202	between	_	
130-18	23203-23206	the	_	
130-19	23207-23215	thalamus	_	
130-20	23216-23219	and	_	
130-21	23220-23223	the	_	
130-22	23224-23228	left	_	
130-23	23229-23233	LPFC	_	
130-24	23234-23237	may	_	
130-25	23238-23240	be	_	
130-26	23241-23253	particularly	_	
130-27	23254-23262	impaired	_	
130-28	23263-23265	in	_	
130-29	23266-23274	patients	_	
130-30	23274-23275	.	_	

#Text=Studies of thalamocortical connectivity at rest consistently find reduced connectivity between the thalamus and prefrontal cortex.
131-1	23276-23283	Studies	_	
131-2	23284-23286	of	_	
131-3	23287-23302	thalamocortical	_	
131-4	23303-23315	connectivity	_	
131-5	23316-23318	at	_	
131-6	23319-23323	rest	_	
131-7	23324-23336	consistently	_	
131-8	23337-23341	find	_	
131-9	23342-23349	reduced	_	
131-10	23350-23362	connectivity	_	
131-11	23363-23370	between	_	
131-12	23371-23374	the	_	
131-13	23375-23383	thalamus	_	
131-14	23384-23387	and	_	
131-15	23388-23398	prefrontal	_	
131-16	23399-23405	cortex	_	
131-17	23405-23406	.	_	

#Text=Decreased thalamus-PFC resting state connectivity has been positively associated with cognition; although the association was relatively weak.
132-1	23407-23416	Decreased	_	
132-2	23417-23429	thalamus-PFC	_	
132-3	23430-23437	resting	_	
132-4	23438-23443	state	_	
132-5	23444-23456	connectivity	_	
132-6	23457-23460	has	_	
132-7	23461-23465	been	_	
132-8	23466-23476	positively	_	
132-9	23477-23487	associated	_	
132-10	23488-23492	with	_	
132-11	23493-23502	cognition	_	
132-12	23502-23503	;	_	
132-13	23504-23512	although	_	
132-14	23513-23516	the	_	
132-15	23517-23528	association	_	
132-16	23529-23532	was	_	
132-17	23533-23543	relatively	_	
132-18	23544-23548	weak	_	
132-19	23548-23549	.	_	

#Text=Further, thalamus-PFC connectivity increased after cognitive remediation training, but not computer skills training, with this increase positively associated with increases in cognitive scores (MATRICS scores), implicating resting state thalamocortical connectivity in cognitive function in schizophrenia.
133-1	23550-23557	Further	_	
133-2	23557-23558	,	_	
133-3	23559-23571	thalamus-PFC	_	
133-4	23572-23584	connectivity	_	
133-5	23585-23594	increased	_	
133-6	23595-23600	after	_	
133-7	23601-23610	cognitive	_	
133-8	23611-23622	remediation	_	
133-9	23623-23631	training	_	
133-10	23631-23632	,	_	
133-11	23633-23636	but	_	
133-12	23637-23640	not	_	
133-13	23641-23649	computer	_	
133-14	23650-23656	skills	_	
133-15	23657-23665	training	_	
133-16	23665-23666	,	_	
133-17	23667-23671	with	_	
133-18	23672-23676	this	_	
133-19	23677-23685	increase	_	
133-20	23686-23696	positively	_	
133-21	23697-23707	associated	_	
133-22	23708-23712	with	_	
133-23	23713-23722	increases	_	
133-24	23723-23725	in	_	
133-25	23726-23735	cognitive	_	
133-26	23736-23742	scores	_	
133-27	23743-23744	(	_	
133-28	23744-23751	MATRICS	_	
133-29	23752-23758	scores	_	
133-30	23758-23759	)	_	
133-31	23759-23760	,	_	
133-32	23761-23772	implicating	_	
133-33	23773-23780	resting	_	
133-34	23781-23786	state	_	
133-35	23787-23802	thalamocortical	_	
133-36	23803-23815	connectivity	_	
133-37	23816-23818	in	_	
133-38	23819-23828	cognitive	_	
133-39	23829-23837	function	_	
133-40	23838-23840	in	_	
133-41	23841-23854	schizophrenia	_	
133-42	23854-23855	.	_	

#Text=In contrast to resting state, few studies have investigated thalamocortical connectivity during cognitive tasks.
134-1	23856-23858	In	_	
134-2	23859-23867	contrast	_	
134-3	23868-23870	to	_	
134-4	23871-23878	resting	_	
134-5	23879-23884	state	_	
134-6	23884-23885	,	_	
134-7	23886-23889	few	_	
134-8	23890-23897	studies	_	
134-9	23898-23902	have	_	
134-10	23903-23915	investigated	_	
134-11	23916-23931	thalamocortical	_	
134-12	23932-23944	connectivity	_	
134-13	23945-23951	during	_	
134-14	23952-23961	cognitive	_	
134-15	23962-23967	tasks	_	
134-16	23967-23968	.	_	

#Text=Such studies typically find increased connectivity in patients during task.
135-1	23969-23973	Such	_	
135-2	23974-23981	studies	_	
135-3	23982-23991	typically	_	
135-4	23992-23996	find	_	
135-5	23997-24006	increased	_	
135-6	24007-24019	connectivity	_	
135-7	24020-24022	in	_	
135-8	24023-24031	patients	_	
135-9	24032-24038	during	_	
135-10	24039-24043	task	_	
135-11	24043-24044	.	_	

#Text=In a structural equation model including the dorsolateral and ventrolateral PFC, parietal cortex, thalamus and cerebellum during a working memory task, patients showed increased path coefficients between the thalamus and ventrolateral PFC in task compared to baseline.
136-1	24045-24047	In	_	
136-2	24048-24049	a	_	
136-3	24050-24060	structural	_	
136-4	24061-24069	equation	_	
136-5	24070-24075	model	_	
136-6	24076-24085	including	_	
136-7	24086-24089	the	_	
136-8	24090-24102	dorsolateral	_	
136-9	24103-24106	and	_	
136-10	24107-24120	ventrolateral	_	
136-11	24121-24124	PFC	_	
136-12	24124-24125	,	_	
136-13	24126-24134	parietal	_	
136-14	24135-24141	cortex	_	
136-15	24141-24142	,	_	
136-16	24143-24151	thalamus	_	
136-17	24152-24155	and	_	
136-18	24156-24166	cerebellum	_	
136-19	24167-24173	during	_	
136-20	24174-24175	a	_	
136-21	24176-24183	working	_	
136-22	24184-24190	memory	_	
136-23	24191-24195	task	_	
136-24	24195-24196	,	_	
136-25	24197-24205	patients	_	
136-26	24206-24212	showed	_	
136-27	24213-24222	increased	_	
136-28	24223-24227	path	_	
136-29	24228-24240	coefficients	_	
136-30	24241-24248	between	_	
136-31	24249-24252	the	_	
136-32	24253-24261	thalamus	_	
136-33	24262-24265	and	_	
136-34	24266-24279	ventrolateral	_	
136-35	24280-24283	PFC	_	
136-36	24284-24286	in	_	
136-37	24287-24291	task	_	
136-38	24292-24300	compared	_	
136-39	24301-24303	to	_	
136-40	24304-24312	baseline	_	
136-41	24312-24313	.	_	

#Text=In another study, patients showed lower connectivity from the right dorsolateral PFC to right thalamus, and greater connectivity from the dorsal anterior cingulate to thalamus during a cognitive control task.
137-1	24314-24316	In	_	
137-2	24317-24324	another	_	
137-3	24325-24330	study	_	
137-4	24330-24331	,	_	
137-5	24332-24340	patients	_	
137-6	24341-24347	showed	_	
137-7	24348-24353	lower	_	
137-8	24354-24366	connectivity	_	
137-9	24367-24371	from	_	
137-10	24372-24375	the	_	
137-11	24376-24381	right	_	
137-12	24382-24394	dorsolateral	_	
137-13	24395-24398	PFC	_	
137-14	24399-24401	to	_	
137-15	24402-24407	right	_	
137-16	24408-24416	thalamus	_	
137-17	24416-24417	,	_	
137-18	24418-24421	and	_	
137-19	24422-24429	greater	_	
137-20	24430-24442	connectivity	_	
137-21	24443-24447	from	_	
137-22	24448-24451	the	_	
137-23	24452-24458	dorsal	_	
137-24	24459-24467	anterior	_	
137-25	24468-24477	cingulate	_	
137-26	24478-24480	to	_	
137-27	24481-24489	thalamus	_	
137-28	24490-24496	during	_	
137-29	24497-24498	a	_	
137-30	24499-24508	cognitive	_	
137-31	24509-24516	control	_	
137-32	24517-24521	task	_	
137-33	24521-24522	.	_	

#Text=In addition, there was a significant positive correlation between right dorsolateral PFC-thalamus endogenous connectivity and fractional anisotropy (a measure of white matter integrity) in the white matter tract between the frontal cortex and thalamus, suggesting that changes in PFC-thalamus connectivity have an underlying structural basis.
138-1	24523-24525	In	_	
138-2	24526-24534	addition	_	
138-3	24534-24535	,	_	
138-4	24536-24541	there	_	
138-5	24542-24545	was	_	
138-6	24546-24547	a	_	
138-7	24548-24559	significant	_	
138-8	24560-24568	positive	_	
138-9	24569-24580	correlation	_	
138-10	24581-24588	between	_	
138-11	24589-24594	right	_	
138-12	24595-24607	dorsolateral	_	
138-13	24608-24620	PFC-thalamus	_	
138-14	24621-24631	endogenous	_	
138-15	24632-24644	connectivity	_	
138-16	24645-24648	and	_	
138-17	24649-24659	fractional	_	
138-18	24660-24670	anisotropy	_	
138-19	24671-24672	(	_	
138-20	24672-24673	a	_	
138-21	24674-24681	measure	_	
138-22	24682-24684	of	_	
138-23	24685-24690	white	_	
138-24	24691-24697	matter	_	
138-25	24698-24707	integrity	_	
138-26	24707-24708	)	_	
138-27	24709-24711	in	_	
138-28	24712-24715	the	_	
138-29	24716-24721	white	_	
138-30	24722-24728	matter	_	
138-31	24729-24734	tract	_	
138-32	24735-24742	between	_	
138-33	24743-24746	the	_	
138-34	24747-24754	frontal	_	
138-35	24755-24761	cortex	_	
138-36	24762-24765	and	_	
138-37	24766-24774	thalamus	_	
138-38	24774-24775	,	_	
138-39	24776-24786	suggesting	_	
138-40	24787-24791	that	_	
138-41	24792-24799	changes	_	
138-42	24800-24802	in	_	
138-43	24803-24815	PFC-thalamus	_	
138-44	24816-24828	connectivity	_	
138-45	24829-24833	have	_	
138-46	24834-24836	an	_	
138-47	24837-24847	underlying	_	
138-48	24848-24858	structural	_	
138-49	24859-24864	basis	_	
138-50	24864-24865	.	_	

#Text=In a single pulse transcranial magnetic stimulation (TMS) study, thalamic response after stimulation was significantly lower in patients compared to healthy controls, with the magnitude of the TMS-evoked response predicted by coupling between the thalamus and PFC, providing evidence of a direct association between evoked brain responses in the cortex and thalamic function and connectivity.
139-1	24866-24868	In	_	
139-2	24869-24870	a	_	
139-3	24871-24877	single	_	
139-4	24878-24883	pulse	_	
139-5	24884-24896	transcranial	_	
139-6	24897-24905	magnetic	_	
139-7	24906-24917	stimulation	_	
139-8	24918-24919	(	_	
139-9	24919-24922	TMS	_	
139-10	24922-24923	)	_	
139-11	24924-24929	study	_	
139-12	24929-24930	,	_	
139-13	24931-24939	thalamic	_	
139-14	24940-24948	response	_	
139-15	24949-24954	after	_	
139-16	24955-24966	stimulation	_	
139-17	24967-24970	was	_	
139-18	24971-24984	significantly	_	
139-19	24985-24990	lower	_	
139-20	24991-24993	in	_	
139-21	24994-25002	patients	_	
139-22	25003-25011	compared	_	
139-23	25012-25014	to	_	
139-24	25015-25022	healthy	_	
139-25	25023-25031	controls	_	
139-26	25031-25032	,	_	
139-27	25033-25037	with	_	
139-28	25038-25041	the	_	
139-29	25042-25051	magnitude	_	
139-30	25052-25054	of	_	
139-31	25055-25058	the	_	
139-32	25059-25069	TMS-evoked	_	
139-33	25070-25078	response	_	
139-34	25079-25088	predicted	_	
139-35	25089-25091	by	_	
139-36	25092-25100	coupling	_	
139-37	25101-25108	between	_	
139-38	25109-25112	the	_	
139-39	25113-25121	thalamus	_	
139-40	25122-25125	and	_	
139-41	25126-25129	PFC	_	
139-42	25129-25130	,	_	
139-43	25131-25140	providing	_	
139-44	25141-25149	evidence	_	
139-45	25150-25152	of	_	
139-46	25153-25154	a	_	
139-47	25155-25161	direct	_	
139-48	25162-25173	association	_	
139-49	25174-25181	between	_	
139-50	25182-25188	evoked	_	
139-51	25189-25194	brain	_	
139-52	25195-25204	responses	_	
139-53	25205-25207	in	_	
139-54	25208-25211	the	_	
139-55	25212-25218	cortex	_	
139-56	25219-25222	and	_	
139-57	25223-25231	thalamic	_	
139-58	25232-25240	function	_	
139-59	25241-25244	and	_	
139-60	25245-25257	connectivity	_	
139-61	25257-25258	.	_	

#Text=Our study adds to the literature by suggesting that thalamus-PFC connectivity during task is not a static increase, rather that the relationship may depend on cognitive demand.
140-1	25259-25262	Our	_	
140-2	25263-25268	study	_	
140-3	25269-25273	adds	_	
140-4	25274-25276	to	_	
140-5	25277-25280	the	_	
140-6	25281-25291	literature	_	
140-7	25292-25294	by	_	
140-8	25295-25305	suggesting	_	
140-9	25306-25310	that	_	
140-10	25311-25323	thalamus-PFC	_	
140-11	25324-25336	connectivity	_	
140-12	25337-25343	during	_	
140-13	25344-25348	task	_	
140-14	25349-25351	is	_	
140-15	25352-25355	not	_	
140-16	25356-25357	a	_	
140-17	25358-25364	static	_	
140-18	25365-25373	increase	_	
140-19	25373-25374	,	_	
140-20	25375-25381	rather	_	
140-21	25382-25386	that	_	
140-22	25387-25390	the	_	
140-23	25391-25403	relationship	_	
140-24	25404-25407	may	_	
140-25	25408-25414	depend	_	
140-26	25415-25417	on	_	
140-27	25418-25427	cognitive	_	
140-28	25428-25434	demand	_	
140-29	25434-25435	.	_	

#Text=Our investigation had several limitations.
141-1	25436-25439	Our	_	
141-2	25440-25453	investigation	_	
141-3	25454-25457	had	_	
141-4	25458-25465	several	_	
141-5	25466-25477	limitations	_	
141-6	25477-25478	.	_	

#Text=The current task only included two levels of difficulty, which precluded us from investigating non-linear changes in activation and connectivity.
142-1	25479-25482	The	_	
142-2	25483-25490	current	_	
142-3	25491-25495	task	_	
142-4	25496-25500	only	_	
142-5	25501-25509	included	_	
142-6	25510-25513	two	_	
142-7	25514-25520	levels	_	
142-8	25521-25523	of	_	
142-9	25524-25534	difficulty	_	
142-10	25534-25535	,	_	
142-11	25536-25541	which	_	
142-12	25542-25551	precluded	_	
142-13	25552-25554	us	_	
142-14	25555-25559	from	_	
142-15	25560-25573	investigating	_	
142-16	25574-25584	non-linear	_	
142-17	25585-25592	changes	_	
142-18	25593-25595	in	_	
142-19	25596-25606	activation	_	
142-20	25607-25610	and	_	
142-21	25611-25623	connectivity	_	
142-22	25623-25624	.	_	

#Text=Our design did not allow us to test if activation within the thalamus also demonstrates an inverted-U shaped activation pattern similar to the PFC.
143-1	25625-25628	Our	_	
143-2	25629-25635	design	_	
143-3	25636-25639	did	_	
143-4	25640-25643	not	_	
143-5	25644-25649	allow	_	
143-6	25650-25652	us	_	
143-7	25653-25655	to	_	
143-8	25656-25660	test	_	
143-9	25661-25663	if	_	
143-10	25664-25674	activation	_	
143-11	25675-25681	within	_	
143-12	25682-25685	the	_	
143-13	25686-25694	thalamus	_	
143-14	25695-25699	also	_	
143-15	25700-25712	demonstrates	_	
143-16	25713-25715	an	_	
143-17	25716-25726	inverted-U	_	
143-18	25727-25733	shaped	_	
143-19	25734-25744	activation	_	
143-20	25745-25752	pattern	_	
143-21	25753-25760	similar	_	
143-22	25761-25763	to	_	
143-23	25764-25767	the	_	
143-24	25768-25771	PFC	_	
143-25	25771-25772	.	_	

#Text=Another limitation of our design was our comparison of Dual compared to Single conditions.
144-1	25773-25780	Another	_	
144-2	25781-25791	limitation	_	
144-3	25792-25794	of	_	
144-4	25795-25798	our	_	
144-5	25799-25805	design	_	
144-6	25806-25809	was	_	
144-7	25810-25813	our	_	
144-8	25814-25824	comparison	_	
144-9	25825-25827	of	_	
144-10	25828-25832	Dual	_	
144-11	25833-25841	compared	_	
144-12	25842-25844	to	_	
144-13	25845-25851	Single	_	
144-14	25852-25862	conditions	_	
144-15	25862-25863	.	_	

#Text=Although our task was designed to investigate thalamic responses to cognitive demand, it is possible that different cognitive mechanisms may be required for Single and Dual conditions, therefore we cannot rule out the possibility that our results reflect differences in cognitive processes underlying the two conditions rather than cognitive demand.
145-1	25864-25872	Although	_	
145-2	25873-25876	our	_	
145-3	25877-25881	task	_	
145-4	25882-25885	was	_	
145-5	25886-25894	designed	_	
145-6	25895-25897	to	_	
145-7	25898-25909	investigate	_	
145-8	25910-25918	thalamic	_	
145-9	25919-25928	responses	_	
145-10	25929-25931	to	_	
145-11	25932-25941	cognitive	_	
145-12	25942-25948	demand	_	
145-13	25948-25949	,	_	
145-14	25950-25952	it	_	
145-15	25953-25955	is	_	
145-16	25956-25964	possible	_	
145-17	25965-25969	that	_	
145-18	25970-25979	different	_	
145-19	25980-25989	cognitive	_	
145-20	25990-26000	mechanisms	_	
145-21	26001-26004	may	_	
145-22	26005-26007	be	_	
145-23	26008-26016	required	_	
145-24	26017-26020	for	_	
145-25	26021-26027	Single	_	
145-26	26028-26031	and	_	
145-27	26032-26036	Dual	_	
145-28	26037-26047	conditions	_	
145-29	26047-26048	,	_	
145-30	26049-26058	therefore	_	
145-31	26059-26061	we	_	
145-32	26062-26068	cannot	_	
145-33	26069-26073	rule	_	
145-34	26074-26077	out	_	
145-35	26078-26081	the	_	
145-36	26082-26093	possibility	_	
145-37	26094-26098	that	_	
145-38	26099-26102	our	_	
145-39	26103-26110	results	_	
145-40	26111-26118	reflect	_	
145-41	26119-26130	differences	_	
145-42	26131-26133	in	_	
145-43	26134-26143	cognitive	_	
145-44	26144-26153	processes	_	
145-45	26154-26164	underlying	_	
145-46	26165-26168	the	_	
145-47	26169-26172	two	_	
145-48	26173-26183	conditions	_	
145-49	26184-26190	rather	_	
145-50	26191-26195	than	_	
145-51	26196-26205	cognitive	_	
145-52	26206-26212	demand	_	
145-53	26212-26213	.	_	

#Text=Additionally, most of our patients were on antipsychotic medication, therefore interpretation of our results must take into account medication effects.
146-1	26214-26226	Additionally	_	
146-2	26226-26227	,	_	
146-3	26228-26232	most	_	
146-4	26233-26235	of	_	
146-5	26236-26239	our	_	
146-6	26240-26248	patients	_	
146-7	26249-26253	were	_	
146-8	26254-26256	on	_	
146-9	26257-26270	antipsychotic	_	
146-10	26271-26281	medication	_	
146-11	26281-26282	,	_	
146-12	26283-26292	therefore	_	
146-13	26293-26307	interpretation	_	
146-14	26308-26310	of	_	
146-15	26311-26314	our	_	
146-16	26315-26322	results	_	
146-17	26323-26327	must	_	
146-18	26328-26332	take	_	
146-19	26333-26337	into	_	
146-20	26338-26345	account	_	
146-21	26346-26356	medication	_	
146-22	26357-26364	effects	_	
146-23	26364-26365	.	_	

#Text=Finally, statistical power to detect group effects was limited by the modest sample sizes.
147-1	26366-26373	Finally	_	
147-2	26373-26374	,	_	
147-3	26375-26386	statistical	_	
147-4	26387-26392	power	_	
147-5	26393-26395	to	_	
147-6	26396-26402	detect	_	
147-7	26403-26408	group	_	
147-8	26409-26416	effects	_	
147-9	26417-26420	was	_	
147-10	26421-26428	limited	_	
147-11	26429-26431	by	_	
147-12	26432-26435	the	_	
147-13	26436-26442	modest	_	
147-14	26443-26449	sample	_	
147-15	26450-26455	sizes	_	
147-16	26455-26456	.	_	

#Text=Several results, including task performance and differences in activation, reached trend significance suggesting that additional effects may have been detected if sample sizes were larger.
148-1	26457-26464	Several	_	
148-2	26465-26472	results	_	
148-3	26472-26473	,	_	
148-4	26474-26483	including	_	
148-5	26484-26488	task	_	
148-6	26489-26500	performance	_	
148-7	26501-26504	and	_	
148-8	26505-26516	differences	_	
148-9	26517-26519	in	_	
148-10	26520-26530	activation	_	
148-11	26530-26531	,	_	
148-12	26532-26539	reached	_	
148-13	26540-26545	trend	_	
148-14	26546-26558	significance	_	
148-15	26559-26569	suggesting	_	
148-16	26570-26574	that	_	
148-17	26575-26585	additional	_	
148-18	26586-26593	effects	_	
148-19	26594-26597	may	_	
148-20	26598-26602	have	_	
148-21	26603-26607	been	_	
148-22	26608-26616	detected	_	
148-23	26617-26619	if	_	
148-24	26620-26626	sample	_	
148-25	26627-26632	sizes	_	
148-26	26633-26637	were	_	
148-27	26638-26644	larger	_	
148-28	26644-26645	.	_	

#Text=In conclusion, patients are less able to appropriately modulate their thalamus activation and thalamus connectivity with the left LPFC based on task requirements.
149-1	26646-26648	In	_	
149-2	26649-26659	conclusion	_	
149-3	26659-26660	,	_	
149-4	26661-26669	patients	_	
149-5	26670-26673	are	_	
149-6	26674-26678	less	_	
149-7	26679-26683	able	_	
149-8	26684-26686	to	_	
149-9	26687-26700	appropriately	_	
149-10	26701-26709	modulate	_	
149-11	26710-26715	their	_	
149-12	26716-26724	thalamus	_	
149-13	26725-26735	activation	_	
149-14	26736-26739	and	_	
149-15	26740-26748	thalamus	_	
149-16	26749-26761	connectivity	_	
149-17	26762-26766	with	_	
149-18	26767-26770	the	_	
149-19	26771-26775	left	_	
149-20	26776-26780	LPFC	_	
149-21	26781-26786	based	_	
149-22	26787-26789	on	_	
149-23	26790-26794	task	_	
149-24	26795-26807	requirements	_	
149-25	26807-26808	.	_	

#Text=Supplementary Material
#Text=Disclosures: No commercial support was received for the preparation of this manuscript and the authors have no conflicts of interest to report.
150-1	26809-26822	Supplementary	_	
150-2	26823-26831	Material	_	
150-3	26832-26843	Disclosures	_	
150-4	26843-26844	:	_	
150-5	26845-26847	No	_	
150-6	26848-26858	commercial	_	
150-7	26859-26866	support	_	
150-8	26867-26870	was	_	
150-9	26871-26879	received	_	
150-10	26880-26883	for	_	
150-11	26884-26887	the	_	
150-12	26888-26899	preparation	_	
150-13	26900-26902	of	_	
150-14	26903-26907	this	_	
150-15	26908-26918	manuscript	_	
150-16	26919-26922	and	_	
150-17	26923-26926	the	_	
150-18	26927-26934	authors	_	
150-19	26935-26939	have	_	
150-20	26940-26942	no	_	
150-21	26943-26952	conflicts	_	
150-22	26953-26955	of	_	
150-23	26956-26964	interest	_	
150-24	26965-26967	to	_	
150-25	26968-26974	report	_	
150-26	26974-26975	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
151-1	26976-26980	This	_	
151-2	26981-26983	is	_	
151-3	26984-26985	a	_	
151-4	26986-26989	PDF	_	
151-5	26990-26994	file	_	
151-6	26995-26997	of	_	
151-7	26998-27000	an	_	
151-8	27001-27009	unedited	_	
151-9	27010-27020	manuscript	_	
151-10	27021-27025	that	_	
151-11	27026-27029	has	_	
151-12	27030-27034	been	_	
151-13	27035-27043	accepted	_	
151-14	27044-27047	for	_	
151-15	27048-27059	publication	_	
151-16	27059-27060	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
152-1	27061-27063	As	_	
152-2	27064-27065	a	_	
152-3	27066-27073	service	_	
152-4	27074-27076	to	_	
152-5	27077-27080	our	_	
152-6	27081-27090	customers	_	
152-7	27091-27093	we	_	
152-8	27094-27097	are	_	
152-9	27098-27107	providing	_	
152-10	27108-27112	this	_	
152-11	27113-27118	early	_	
152-12	27119-27126	version	_	
152-13	27127-27129	of	_	
152-14	27130-27133	the	_	
152-15	27134-27144	manuscript	_	
152-16	27144-27145	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
153-1	27146-27149	The	_	
153-2	27150-27160	manuscript	_	
153-3	27161-27165	will	_	
153-4	27166-27173	undergo	_	
153-5	27174-27185	copyediting	_	
153-6	27185-27186	,	_	
153-7	27187-27198	typesetting	_	
153-8	27198-27199	,	_	
153-9	27200-27203	and	_	
153-10	27204-27210	review	_	
153-11	27211-27213	of	_	
153-12	27214-27217	the	_	
153-13	27218-27227	resulting	_	
153-14	27228-27233	proof	_	
153-15	27234-27240	before	_	
153-16	27241-27243	it	_	
153-17	27244-27246	is	_	
153-18	27247-27256	published	_	
153-19	27257-27259	in	_	
153-20	27260-27263	its	_	
153-21	27264-27269	final	_	
153-22	27270-27277	citable	_	
153-23	27278-27282	form	_	
153-24	27282-27283	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
154-1	27284-27290	Please	_	
154-2	27291-27295	note	_	
154-3	27296-27300	that	_	
154-4	27301-27307	during	_	
154-5	27308-27311	the	_	
154-6	27312-27322	production	_	
154-7	27323-27330	process	_	
154-8	27331-27337	errors	_	
154-9	27338-27341	may	_	
154-10	27342-27344	be	_	
154-11	27345-27355	discovered	_	
154-12	27356-27361	which	_	
154-13	27362-27367	could	_	
154-14	27368-27374	affect	_	
154-15	27375-27378	the	_	
154-16	27379-27386	content	_	
154-17	27386-27387	,	_	
154-18	27388-27391	and	_	
154-19	27392-27395	all	_	
154-20	27396-27401	legal	_	
154-21	27402-27413	disclaimers	_	
154-22	27414-27418	that	_	
154-23	27419-27424	apply	_	
154-24	27425-27427	to	_	
154-25	27428-27431	the	_	
154-26	27432-27439	journal	_	
154-27	27440-27447	pertain	_	
154-28	27447-27448	.	_	

#Text=References
#Text=The mediodorsal thalamic nucleus and schizophrenia
#Text=The role of the thalamus in schizophrenia
#Text=Abnormalities of thalamic activation and cognition in schizophrenia
#Text=Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness
#Text=Mediodorsal and visual thalamic connectivity differ in schizophrenia and bipolar disorder with and without psychosis history
#Text=Experimental designs and processing strategies for fMRI studies involving overt verbal responses
#Text=Thalamus abnormalities during working memory in schizophrenia.
155-1	27449-27459	References	_	
155-2	27460-27463	The	_	
155-3	27464-27475	mediodorsal	_	
155-4	27476-27484	thalamic	_	
155-5	27485-27492	nucleus	_	
155-6	27493-27496	and	_	
155-7	27497-27510	schizophrenia	_	
155-8	27511-27514	The	_	
155-9	27515-27519	role	_	
155-10	27520-27522	of	_	
155-11	27523-27526	the	_	
155-12	27527-27535	thalamus	_	
155-13	27536-27538	in	_	
155-14	27539-27552	schizophrenia	_	
155-15	27553-27566	Abnormalities	_	
155-16	27567-27569	of	_	
155-17	27570-27578	thalamic	_	
155-18	27579-27589	activation	_	
155-19	27590-27593	and	_	
155-20	27594-27603	cognition	_	
155-21	27604-27606	in	_	
155-22	27607-27620	schizophrenia	_	
155-23	27621-27635	Characterizing	_	
155-24	27636-27652	thalamo-cortical	_	
155-25	27653-27665	disturbances	_	
155-26	27666-27668	in	_	
155-27	27669-27682	schizophrenia	_	
155-28	27683-27686	and	_	
155-29	27687-27694	bipolar	_	
155-30	27695-27702	illness	_	
155-31	27703-27714	Mediodorsal	_	
155-32	27715-27718	and	_	
155-33	27719-27725	visual	_	
155-34	27726-27734	thalamic	_	
155-35	27735-27747	connectivity	_	
155-36	27748-27754	differ	_	
155-37	27755-27757	in	_	
155-38	27758-27771	schizophrenia	_	
155-39	27772-27775	and	_	
155-40	27776-27783	bipolar	_	
155-41	27784-27792	disorder	_	
155-42	27793-27797	with	_	
155-43	27798-27801	and	_	
155-44	27802-27809	without	_	
155-45	27810-27819	psychosis	_	
155-46	27820-27827	history	_	
155-47	27828-27840	Experimental	_	
155-48	27841-27848	designs	_	
155-49	27849-27852	and	_	
155-50	27853-27863	processing	_	
155-51	27864-27874	strategies	_	
155-52	27875-27878	for	_	
155-53	27879-27883	fMRI	_	
155-54	27884-27891	studies	_	
155-55	27892-27901	involving	_	
155-56	27902-27907	overt	_	
155-57	27908-27914	verbal	_	
155-58	27915-27924	responses	_	
155-59	27925-27933	Thalamus	_	
155-60	27934-27947	abnormalities	_	
155-61	27948-27954	during	_	
155-62	27955-27962	working	_	
155-63	27963-27969	memory	_	
155-64	27970-27972	in	_	
155-65	27973-27986	schizophrenia	_	
155-66	27986-27987	.	_	

#Text=An fMRI study
#Text=Adaptive Pulvinar Circuitry Supports Visual Cognition
#Text=Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited
#Text=Basal ganglia-thalamocortical circuitry disruptions in schizophrenia during delayed response tasks
#Text=Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia
#Text=Phase-specific brain change of spatial working memory processing in genetic and ultra-high risk groups of schizophrenia
#Text=A comparison of statistical methods for detecting context-modulated functional connectivity in fMRI
#Text=An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
#Text=Isolation of a central bottleneck of information processing with time-resolved FMRI
#Text=Training improves multitasking performance by increasing the speed of information processing in human prefrontal cortex
#Text=
#Text=Prefrontal-Thalamic Anatomical Connectivity and Executive Cognitive Function in Schizophrenia
#Text=Review of thalamocortical resting-state fMRI studies in schizophrenia
#Text=Probing thalamic integrity in schizophrenia using concurrent transcranial magnetic stimulation and functional magnetic resonance imaging
#Text=Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging
#Text=The cortico-basal ganglia integrative network: the role of the thalamus
#Text=The place of the thalamus in frontal cortical-basal ganglia circuits
#Text=Posterior Parietal Cortex Dysfunction Is Central to Working Memory Storage and Broad Cognitive Deficits in Schizophrenia
#Text=Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia
#Text=Frontal-striatal-thalamic mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating
#Text=
#Text=Re-evaluating dorsolateral prefrontal cortex activation during working memory in schizophrenia
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=An event-related functional magnetic resonance imaging study of an auditory oddball task in schizophrenia
#Text=Thalamocortical connectivity during resting state in schizophrenia
#Text=A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics
#Text=Attention orienting dysfunction during salient novel stimulus processing in schizophrenia
#Text=Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia
#Text=Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives
#Text=Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings
#Text=Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia
#Text=The mediodorsal thalamus as a higher order thalamic relay nucleus important for learning and decision-making
#Text=Multiarchitectonic and stereotactic atlas of the human thalamus
#Text=The Morel stereotactic atlas of the human thalamus: atlas-to-MR registration of internally consistent canonical model
#Text=Cognitive Functions and Neurodevelopmental Disorders Involving the Prefrontal Cortex and Mediodorsal Thalamus
#Text=The Mediodorsal Thalamus: An Essential Partner of the Prefrontal Cortex for Cognition
#Text=Grey matter volume patterns in thalamic nuclei are associated with familial risk for schizophrenia
#Text=Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia
#Text=Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition
#Text=Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia
#Text=Measuring functional connectivity during distinct stages of a cognitive task
#Text=Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients
#Text=Altered effective connectivity in drug free schizophrenic patients
#Text=Inefficient executive cognitive control in schizophrenia is preceded by altered functional activation during information encoding: an fMRI study
#Text=Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study
#Text=Thalamo-cortical functional connectivity in schizophrenia and bipolar disorder
#Text=Amodal processing in human prefrontal cortex
#Text=A Unified attentional bottleneck in the human brain
#Text=Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia
#Text=Increased hippocampal, thalamic, and prefrontal hemodynamic response to an urban noise stimulus in schizophrenia
#Text=Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium
#Text=Structural and functional dysconnectivity of the fronto-thalamic system in schizophrenia: a DCM-DTI study
#Text=Structural basis of the fronto-thalamic dysconnectivity in schizophrenia: A combined DCM-VBM study
#Text=Disrupted thalamic restingstate functional networks in schizophrenia
#Text=
#Text=Low-Frequency BOLD Fluctuations Demonstrate Altered Thalamocortical Connectivity in Schizophrenia
#Text=Mapping Thalamocortical Functional Connectivity in Chronic and Early Stages of Psychotic Disorders
#Text=Thalamocortical dysconnectivity in schizophrenia
#Text=A) Task schematic.
156-1	27988-27990	An	_	
156-2	27991-27995	fMRI	_	
156-3	27996-28001	study	_	
156-4	28002-28010	Adaptive	_	
156-5	28011-28019	Pulvinar	_	
156-6	28020-28029	Circuitry	_	
156-7	28030-28038	Supports	_	
156-8	28039-28045	Visual	_	
156-9	28046-28055	Cognition	_	
156-10	28056-28069	Physiological	_	
156-11	28070-28081	dysfunction	_	
156-12	28082-28084	of	_	
156-13	28085-28088	the	_	
156-14	28089-28101	dorsolateral	_	
156-15	28102-28112	prefrontal	_	
156-16	28113-28119	cortex	_	
156-17	28120-28122	in	_	
156-18	28123-28136	schizophrenia	_	
156-19	28137-28146	revisited	_	
156-20	28147-28152	Basal	_	
156-21	28153-28176	ganglia-thalamocortical	_	
156-22	28177-28186	circuitry	_	
156-23	28187-28198	disruptions	_	
156-24	28199-28201	in	_	
156-25	28202-28215	schizophrenia	_	
156-26	28216-28222	during	_	
156-27	28223-28230	delayed	_	
156-28	28231-28239	response	_	
156-29	28240-28245	tasks	_	
156-30	28246-28258	Dorsolateral	_	
156-31	28259-28269	prefrontal	_	
156-32	28270-28276	cortex	_	
156-33	28277-28285	activity	_	
156-34	28286-28292	during	_	
156-35	28293-28304	maintenance	_	
156-36	28305-28308	and	_	
156-37	28309-28321	manipulation	_	
156-38	28322-28324	of	_	
156-39	28325-28336	information	_	
156-40	28337-28339	in	_	
156-41	28340-28347	working	_	
156-42	28348-28354	memory	_	
156-43	28355-28357	in	_	
156-44	28358-28366	patients	_	
156-45	28367-28371	with	_	
156-46	28372-28385	schizophrenia	_	
156-47	28386-28400	Phase-specific	_	
156-48	28401-28406	brain	_	
156-49	28407-28413	change	_	
156-50	28414-28416	of	_	
156-51	28417-28424	spatial	_	
156-52	28425-28432	working	_	
156-53	28433-28439	memory	_	
156-54	28440-28450	processing	_	
156-55	28451-28453	in	_	
156-56	28454-28461	genetic	_	
156-57	28462-28465	and	_	
156-58	28466-28476	ultra-high	_	
156-59	28477-28481	risk	_	
156-60	28482-28488	groups	_	
156-61	28489-28491	of	_	
156-62	28492-28505	schizophrenia	_	
156-63	28506-28507	A	_	
156-64	28508-28518	comparison	_	
156-65	28519-28521	of	_	
156-66	28522-28533	statistical	_	
156-67	28534-28541	methods	_	
156-68	28542-28545	for	_	
156-69	28546-28555	detecting	_	
156-70	28556-28573	context-modulated	_	
156-71	28574-28584	functional	_	
156-72	28585-28597	connectivity	_	
156-73	28598-28600	in	_	
156-74	28601-28605	fMRI	_	
156-75	28606-28608	An	_	
156-76	28609-28618	automated	_	
156-77	28619-28627	labeling	_	
156-78	28628-28634	system	_	
156-79	28635-28638	for	_	
156-80	28639-28650	subdividing	_	
156-81	28651-28654	the	_	
156-82	28655-28660	human	_	
156-83	28661-28669	cerebral	_	
156-84	28670-28676	cortex	_	
156-85	28677-28679	on	_	
156-86	28680-28683	MRI	_	
156-87	28684-28689	scans	_	
156-88	28690-28694	into	_	
156-89	28695-28700	gyral	_	
156-90	28701-28706	based	_	
156-91	28707-28714	regions	_	
156-92	28715-28717	of	_	
156-93	28718-28726	interest	_	
156-94	28727-28736	Isolation	_	
156-95	28737-28739	of	_	
156-96	28740-28741	a	_	
156-97	28742-28749	central	_	
156-98	28750-28760	bottleneck	_	
156-99	28761-28763	of	_	
156-100	28764-28775	information	_	
156-101	28776-28786	processing	_	
156-102	28787-28791	with	_	
156-103	28792-28805	time-resolved	_	
156-104	28806-28810	FMRI	_	
156-105	28811-28819	Training	_	
156-106	28820-28828	improves	_	
156-107	28829-28841	multitasking	_	
156-108	28842-28853	performance	_	
156-109	28854-28856	by	_	
156-110	28857-28867	increasing	_	
156-111	28868-28871	the	_	
156-112	28872-28877	speed	_	
156-113	28878-28880	of	_	
156-114	28881-28892	information	_	
156-115	28893-28903	processing	_	
156-116	28904-28906	in	_	
156-117	28907-28912	human	_	
156-118	28913-28923	prefrontal	_	
156-119	28924-28930	cortex	_	
156-120	28932-28951	Prefrontal-Thalamic	_	
156-121	28952-28962	Anatomical	_	
156-122	28963-28975	Connectivity	_	
156-123	28976-28979	and	_	
156-124	28980-28989	Executive	_	
156-125	28990-28999	Cognitive	_	
156-126	29000-29008	Function	_	
156-127	29009-29011	in	_	
156-128	29012-29025	Schizophrenia	_	
156-129	29026-29032	Review	_	
156-130	29033-29035	of	_	
156-131	29036-29051	thalamocortical	_	
156-132	29052-29065	resting-state	_	
156-133	29066-29070	fMRI	_	
156-134	29071-29078	studies	_	
156-135	29079-29081	in	_	
156-136	29082-29095	schizophrenia	_	
156-137	29096-29103	Probing	_	
156-138	29104-29112	thalamic	_	
156-139	29113-29122	integrity	_	
156-140	29123-29125	in	_	
156-141	29126-29139	schizophrenia	_	
156-142	29140-29145	using	_	
156-143	29146-29156	concurrent	_	
156-144	29157-29169	transcranial	_	
156-145	29170-29178	magnetic	_	
156-146	29179-29190	stimulation	_	
156-147	29191-29194	and	_	
156-148	29195-29205	functional	_	
156-149	29206-29214	magnetic	_	
156-150	29215-29224	resonance	_	
156-151	29225-29232	imaging	_	
156-152	29233-29239	Visual	_	
156-153	29240-29249	attention	_	
156-154	29250-29259	circuitry	_	
156-155	29260-29262	in	_	
156-156	29263-29276	schizophrenia	_	
156-157	29277-29289	investigated	_	
156-158	29290-29294	with	_	
156-159	29295-29302	oddball	_	
156-160	29303-29316	event-related	_	
156-161	29317-29327	functional	_	
156-162	29328-29336	magnetic	_	
156-163	29337-29346	resonance	_	
156-164	29347-29354	imaging	_	
156-165	29355-29358	The	_	
156-166	29359-29372	cortico-basal	_	
156-167	29373-29380	ganglia	_	
156-168	29381-29392	integrative	_	
156-169	29393-29400	network	_	
156-170	29400-29401	:	_	
156-171	29402-29405	the	_	
156-172	29406-29410	role	_	
156-173	29411-29413	of	_	
156-174	29414-29417	the	_	
156-175	29418-29426	thalamus	_	
156-176	29427-29430	The	_	
156-177	29431-29436	place	_	
156-178	29437-29439	of	_	
156-179	29440-29443	the	_	
156-180	29444-29452	thalamus	_	
156-181	29453-29455	in	_	
156-182	29456-29463	frontal	_	
156-183	29464-29478	cortical-basal	_	
156-184	29479-29486	ganglia	_	
156-185	29487-29495	circuits	_	
156-186	29496-29505	Posterior	_	
156-187	29506-29514	Parietal	_	
156-188	29515-29521	Cortex	_	
156-189	29522-29533	Dysfunction	_	
156-190	29534-29536	Is	_	
156-191	29537-29544	Central	_	
156-192	29545-29547	to	_	
156-193	29548-29555	Working	_	
156-194	29556-29562	Memory	_	
156-195	29563-29570	Storage	_	
156-196	29571-29574	and	_	
156-197	29575-29580	Broad	_	
156-198	29581-29590	Cognitive	_	
156-199	29591-29599	Deficits	_	
156-200	29600-29602	in	_	
156-201	29603-29616	Schizophrenia	_	
156-202	29617-29625	Abnormal	_	
156-203	29626-29633	glucose	_	
156-204	29634-29644	metabolism	_	
156-205	29645-29647	in	_	
156-206	29648-29651	the	_	
156-207	29652-29663	mediodorsal	_	
156-208	29664-29671	nucleus	_	
156-209	29672-29674	of	_	
156-210	29675-29678	the	_	
156-211	29679-29687	thalamus	_	
156-212	29688-29690	in	_	
156-213	29691-29704	schizophrenia	_	
156-214	29705-29730	Frontal-striatal-thalamic	_	
156-215	29731-29742	mediodorsal	_	
156-216	29743-29750	nucleus	_	
156-217	29751-29762	dysfunction	_	
156-218	29763-29765	in	_	
156-219	29766-29788	schizophrenia-spectrum	_	
156-220	29789-29797	patients	_	
156-221	29798-29804	during	_	
156-222	29805-29817	sensorimotor	_	
156-223	29818-29824	gating	_	
156-224	29826-29839	Re-evaluating	_	
156-225	29840-29852	dorsolateral	_	
156-226	29853-29863	prefrontal	_	
156-227	29864-29870	cortex	_	
156-228	29871-29881	activation	_	
156-229	29882-29888	during	_	
156-230	29889-29896	working	_	
156-231	29897-29903	memory	_	
156-232	29904-29906	in	_	
156-233	29907-29920	schizophrenia	_	
156-234	29921-29924	The	_	
156-235	29925-29933	positive	_	
156-236	29934-29937	and	_	
156-237	29938-29946	negative	_	
156-238	29947-29955	syndrome	_	
156-239	29956-29961	scale	_	
156-240	29962-29963	(	_	
156-241	29963-29968	PANSS	_	
156-242	29968-29969	)	_	
156-243	29970-29973	for	_	
156-244	29974-29987	schizophrenia	_	
156-245	29988-29990	An	_	
156-246	29991-30004	event-related	_	
156-247	30005-30015	functional	_	
156-248	30016-30024	magnetic	_	
156-249	30025-30034	resonance	_	
156-250	30035-30042	imaging	_	
156-251	30043-30048	study	_	
156-252	30049-30051	of	_	
156-253	30052-30054	an	_	
156-254	30055-30063	auditory	_	
156-255	30064-30071	oddball	_	
156-256	30072-30076	task	_	
156-257	30077-30079	in	_	
156-258	30080-30093	schizophrenia	_	
156-259	30094-30109	Thalamocortical	_	
156-260	30110-30122	connectivity	_	
156-261	30123-30129	during	_	
156-262	30130-30137	resting	_	
156-263	30138-30143	state	_	
156-264	30144-30146	in	_	
156-265	30147-30160	schizophrenia	_	
156-266	30161-30162	A	_	
156-267	30163-30167	fMRI	_	
156-268	30168-30181	investigation	_	
156-269	30182-30184	of	_	
156-270	30185-30192	startle	_	
156-271	30193-30199	gating	_	
156-272	30200-30208	deficits	_	
156-273	30209-30211	in	_	
156-274	30212-30225	schizophrenia	_	
156-275	30226-30234	patients	_	
156-276	30235-30242	treated	_	
156-277	30243-30247	with	_	
156-278	30248-30255	typical	_	
156-279	30256-30258	or	_	
156-280	30259-30267	atypical	_	
156-281	30268-30282	antipsychotics	_	
156-282	30283-30292	Attention	_	
156-283	30293-30302	orienting	_	
156-284	30303-30314	dysfunction	_	
156-285	30315-30321	during	_	
156-286	30322-30329	salient	_	
156-287	30330-30335	novel	_	
156-288	30336-30344	stimulus	_	
156-289	30345-30355	processing	_	
156-290	30356-30358	in	_	
156-291	30359-30372	schizophrenia	_	
156-292	30373-30381	Thalamic	_	
156-293	30382-30385	and	_	
156-294	30386-30396	prefrontal	_	
156-295	30397-30400	FDG	_	
156-296	30401-30407	uptake	_	
156-297	30408-30410	in	_	
156-298	30411-30416	never	_	
156-299	30417-30426	medicated	_	
156-300	30427-30435	patients	_	
156-301	30436-30440	with	_	
156-302	30441-30454	schizophrenia	_	
156-303	30455-30468	Resting-state	_	
156-304	30469-30474	brain	_	
156-305	30475-30483	function	_	
156-306	30484-30486	in	_	
156-307	30487-30500	schizophrenia	_	
156-308	30501-30504	and	_	
156-309	30505-30514	psychotic	_	
156-310	30515-30522	bipolar	_	
156-311	30523-30531	probands	_	
156-312	30532-30535	and	_	
156-313	30536-30541	their	_	
156-314	30542-30554	first-degree	_	
156-315	30555-30564	relatives	_	
156-316	30565-30575	Prefrontal	_	
156-317	30576-30582	cortex	_	
156-318	30583-30594	dysfunction	_	
156-319	30595-30601	during	_	
156-320	30602-30609	working	_	
156-321	30610-30616	memory	_	
156-322	30617-30628	performance	_	
156-323	30629-30631	in	_	
156-324	30632-30645	schizophrenia	_	
156-325	30645-30646	:	_	
156-326	30647-30658	reconciling	_	
156-327	30659-30669	discrepant	_	
156-328	30670-30678	findings	_	
156-329	30679-30692	Meta-analysis	_	
156-330	30693-30695	of	_	
156-331	30696-30698	41	_	
156-332	30699-30709	functional	_	
156-333	30710-30722	neuroimaging	_	
156-334	30723-30730	studies	_	
156-335	30731-30733	of	_	
156-336	30734-30743	executive	_	
156-337	30744-30752	function	_	
156-338	30753-30755	in	_	
156-339	30756-30769	schizophrenia	_	
156-340	30770-30773	The	_	
156-341	30774-30785	mediodorsal	_	
156-342	30786-30794	thalamus	_	
156-343	30795-30797	as	_	
156-344	30798-30799	a	_	
156-345	30800-30806	higher	_	
156-346	30807-30812	order	_	
156-347	30813-30821	thalamic	_	
156-348	30822-30827	relay	_	
156-349	30828-30835	nucleus	_	
156-350	30836-30845	important	_	
156-351	30846-30849	for	_	
156-352	30850-30858	learning	_	
156-353	30859-30862	and	_	
156-354	30863-30878	decision-making	_	
156-355	30879-30897	Multiarchitectonic	_	
156-356	30898-30901	and	_	
156-357	30902-30914	stereotactic	_	
156-358	30915-30920	atlas	_	
156-359	30921-30923	of	_	
156-360	30924-30927	the	_	
156-361	30928-30933	human	_	
156-362	30934-30942	thalamus	_	
156-363	30943-30946	The	_	
156-364	30947-30952	Morel	_	
156-365	30953-30965	stereotactic	_	
156-366	30966-30971	atlas	_	
156-367	30972-30974	of	_	
156-368	30975-30978	the	_	
156-369	30979-30984	human	_	
156-370	30985-30993	thalamus	_	
156-371	30993-30994	:	_	
156-372	30995-31006	atlas-to-MR	_	
156-373	31007-31019	registration	_	
156-374	31020-31022	of	_	
156-375	31023-31033	internally	_	
156-376	31034-31044	consistent	_	
156-377	31045-31054	canonical	_	
156-378	31055-31060	model	_	
156-379	31061-31070	Cognitive	_	
156-380	31071-31080	Functions	_	
156-381	31081-31084	and	_	
156-382	31085-31103	Neurodevelopmental	_	
156-383	31104-31113	Disorders	_	
156-384	31114-31123	Involving	_	
156-385	31124-31127	the	_	
156-386	31128-31138	Prefrontal	_	
156-387	31139-31145	Cortex	_	
156-388	31146-31149	and	_	
156-389	31150-31161	Mediodorsal	_	
156-390	31162-31170	Thalamus	_	
156-391	31171-31174	The	_	
156-392	31175-31186	Mediodorsal	_	
156-393	31187-31195	Thalamus	_	
156-394	31195-31196	:	_	
156-395	31197-31199	An	_	
156-396	31200-31209	Essential	_	
156-397	31210-31217	Partner	_	
156-398	31218-31220	of	_	
156-399	31221-31224	the	_	
156-400	31225-31235	Prefrontal	_	
156-401	31236-31242	Cortex	_	
156-402	31243-31246	for	_	
156-403	31247-31256	Cognition	_	
156-404	31257-31261	Grey	_	
156-405	31262-31268	matter	_	
156-406	31269-31275	volume	_	
156-407	31276-31284	patterns	_	
156-408	31285-31287	in	_	
156-409	31288-31296	thalamic	_	
156-410	31297-31303	nuclei	_	
156-411	31304-31307	are	_	
156-412	31308-31318	associated	_	
156-413	31319-31323	with	_	
156-414	31324-31332	familial	_	
156-415	31333-31337	risk	_	
156-416	31338-31341	for	_	
156-417	31342-31355	schizophrenia	_	
156-418	31356-31366	Prefrontal	_	
156-419	31367-31373	cortex	_	
156-420	31374-31385	dysfunction	_	
156-421	31386-31394	mediates	_	
156-422	31395-31403	deficits	_	
156-423	31404-31406	in	_	
156-424	31407-31414	working	_	
156-425	31415-31421	memory	_	
156-426	31422-31425	and	_	
156-427	31426-31435	prepotent	_	
156-428	31436-31446	responding	_	
156-429	31447-31449	in	_	
156-430	31450-31463	schizophrenia	_	
156-431	31464-31484	Levels-of-processing	_	
156-432	31485-31491	effect	_	
156-433	31492-31494	on	_	
156-434	31495-31509	frontotemporal	_	
156-435	31510-31518	function	_	
156-436	31519-31521	in	_	
156-437	31522-31535	schizophrenia	_	
156-438	31536-31542	during	_	
156-439	31543-31547	word	_	
156-440	31548-31556	encoding	_	
156-441	31557-31560	and	_	
156-442	31561-31572	recognition	_	
156-443	31573-31582	Increases	_	
156-444	31583-31585	in	_	
156-445	31586-31595	Intrinsic	_	
156-446	31596-31611	Thalamocortical	_	
156-447	31612-31624	Connectivity	_	
156-448	31625-31628	and	_	
156-449	31629-31636	Overall	_	
156-450	31637-31646	Cognition	_	
156-451	31647-31656	Following	_	
156-452	31657-31666	Cognitive	_	
156-453	31667-31678	Remediation	_	
156-454	31679-31681	in	_	
156-455	31682-31689	Chronic	_	
156-456	31690-31703	Schizophrenia	_	
156-457	31704-31713	Measuring	_	
156-458	31714-31724	functional	_	
156-459	31725-31737	connectivity	_	
156-460	31738-31744	during	_	
156-461	31745-31753	distinct	_	
156-462	31754-31760	stages	_	
156-463	31761-31763	of	_	
156-464	31764-31765	a	_	
156-465	31766-31775	cognitive	_	
156-466	31776-31780	task	_	
156-467	31781-31790	Decreased	_	
156-468	31791-31799	cerebral	_	
156-469	31800-31810	activation	_	
156-470	31811-31817	during	_	
156-471	31818-31821	CPT	_	
156-472	31822-31833	performance	_	
156-473	31833-31834	:	_	
156-474	31835-31845	structural	_	
156-475	31846-31849	and	_	
156-476	31850-31860	functional	_	
156-477	31861-31869	deficits	_	
156-478	31870-31872	in	_	
156-479	31873-31886	schizophrenic	_	
156-480	31887-31895	patients	_	
156-481	31896-31903	Altered	_	
156-482	31904-31913	effective	_	
156-483	31914-31926	connectivity	_	
156-484	31927-31929	in	_	
156-485	31930-31934	drug	_	
156-486	31935-31939	free	_	
156-487	31940-31953	schizophrenic	_	
156-488	31954-31962	patients	_	
156-489	31963-31974	Inefficient	_	
156-490	31975-31984	executive	_	
156-491	31985-31994	cognitive	_	
156-492	31995-32002	control	_	
156-493	32003-32005	in	_	
156-494	32006-32019	schizophrenia	_	
156-495	32020-32022	is	_	
156-496	32023-32031	preceded	_	
156-497	32032-32034	by	_	
156-498	32035-32042	altered	_	
156-499	32043-32053	functional	_	
156-500	32054-32064	activation	_	
156-501	32065-32071	during	_	
156-502	32072-32083	information	_	
156-503	32084-32092	encoding	_	
156-504	32092-32093	:	_	
156-505	32094-32096	an	_	
156-506	32097-32101	fMRI	_	
156-507	32102-32107	study	_	
156-508	32108-32114	Neural	_	
156-509	32115-32125	correlates	_	
156-510	32126-32128	of	_	
156-511	32129-32136	working	_	
156-512	32137-32143	memory	_	
156-513	32144-32155	dysfunction	_	
156-514	32156-32158	in	_	
156-515	32159-32172	first-episode	_	
156-516	32173-32186	schizophrenia	_	
156-517	32187-32195	patients	_	
156-518	32195-32196	:	_	
156-519	32197-32199	an	_	
156-520	32200-32204	fMRI	_	
156-521	32205-32217	multi-center	_	
156-522	32218-32223	study	_	
156-523	32224-32240	Thalamo-cortical	_	
156-524	32241-32251	functional	_	
156-525	32252-32264	connectivity	_	
156-526	32265-32267	in	_	
156-527	32268-32281	schizophrenia	_	
156-528	32282-32285	and	_	
156-529	32286-32293	bipolar	_	
156-530	32294-32302	disorder	_	
156-531	32303-32309	Amodal	_	
156-532	32310-32320	processing	_	
156-533	32321-32323	in	_	
156-534	32324-32329	human	_	
156-535	32330-32340	prefrontal	_	
156-536	32341-32347	cortex	_	
156-537	32348-32349	A	_	
156-538	32350-32357	Unified	_	
156-539	32358-32369	attentional	_	
156-540	32370-32380	bottleneck	_	
156-541	32381-32383	in	_	
156-542	32384-32387	the	_	
156-543	32388-32393	human	_	
156-544	32394-32399	brain	_	
156-545	32400-32409	Increased	_	
156-546	32410-32421	hemodynamic	_	
156-547	32422-32430	response	_	
156-548	32431-32433	in	_	
156-549	32434-32437	the	_	
156-550	32438-32449	hippocampus	_	
156-551	32449-32450	,	_	
156-552	32451-32459	thalamus	_	
156-553	32460-32463	and	_	
156-554	32464-32474	prefrontal	_	
156-555	32475-32481	cortex	_	
156-556	32482-32488	during	_	
156-557	32489-32497	abnormal	_	
156-558	32498-32505	sensory	_	
156-559	32506-32512	gating	_	
156-560	32513-32515	in	_	
156-561	32516-32529	schizophrenia	_	
156-562	32530-32539	Increased	_	
156-563	32540-32551	hippocampal	_	
156-564	32551-32552	,	_	
156-565	32553-32561	thalamic	_	
156-566	32561-32562	,	_	
156-567	32563-32566	and	_	
156-568	32567-32577	prefrontal	_	
156-569	32578-32589	hemodynamic	_	
156-570	32590-32598	response	_	
156-571	32599-32601	to	_	
156-572	32602-32604	an	_	
156-573	32605-32610	urban	_	
156-574	32611-32616	noise	_	
156-575	32617-32625	stimulus	_	
156-576	32626-32628	in	_	
156-577	32629-32642	schizophrenia	_	
156-578	32643-32654	Subcortical	_	
156-579	32655-32660	brain	_	
156-580	32661-32667	volume	_	
156-581	32668-32681	abnormalities	_	
156-582	32682-32684	in	_	
156-583	32685-32689	2028	_	
156-584	32690-32701	individuals	_	
156-585	32702-32706	with	_	
156-586	32707-32720	schizophrenia	_	
156-587	32721-32724	and	_	
156-588	32725-32729	2540	_	
156-589	32730-32737	healthy	_	
156-590	32738-32746	controls	_	
156-591	32747-32750	via	_	
156-592	32751-32754	the	_	
156-593	32755-32761	ENIGMA	_	
156-594	32762-32772	consortium	_	
156-595	32773-32783	Structural	_	
156-596	32784-32787	and	_	
156-597	32788-32798	functional	_	
156-598	32799-32814	dysconnectivity	_	
156-599	32815-32817	of	_	
156-600	32818-32821	the	_	
156-601	32822-32837	fronto-thalamic	_	
156-602	32838-32844	system	_	
156-603	32845-32847	in	_	
156-604	32848-32861	schizophrenia	_	
156-605	32861-32862	:	_	
156-606	32863-32864	a	_	
156-607	32865-32872	DCM-DTI	_	
156-608	32873-32878	study	_	
156-609	32879-32889	Structural	_	
156-610	32890-32895	basis	_	
156-611	32896-32898	of	_	
156-612	32899-32902	the	_	
156-613	32903-32918	fronto-thalamic	_	
156-614	32919-32934	dysconnectivity	_	
156-615	32935-32937	in	_	
156-616	32938-32951	schizophrenia	_	
156-617	32951-32952	:	_	
156-618	32953-32954	A	_	
156-619	32955-32963	combined	_	
156-620	32964-32971	DCM-VBM	_	
156-621	32972-32977	study	_	
156-622	32978-32987	Disrupted	_	
156-623	32988-32996	thalamic	_	
156-624	32997-33009	restingstate	_	
156-625	33010-33020	functional	_	
156-626	33021-33029	networks	_	
156-627	33030-33032	in	_	
156-628	33033-33046	schizophrenia	_	
156-629	33048-33061	Low-Frequency	_	
156-630	33062-33066	BOLD	_	
156-631	33067-33079	Fluctuations	_	
156-632	33080-33091	Demonstrate	_	
156-633	33092-33099	Altered	_	
156-634	33100-33115	Thalamocortical	_	
156-635	33116-33128	Connectivity	_	
156-636	33129-33131	in	_	
156-637	33132-33145	Schizophrenia	_	
156-638	33146-33153	Mapping	_	
156-639	33154-33169	Thalamocortical	_	
156-640	33170-33180	Functional	_	
156-641	33181-33193	Connectivity	_	
156-642	33194-33196	in	_	
156-643	33197-33204	Chronic	_	
156-644	33205-33208	and	_	
156-645	33209-33214	Early	_	
156-646	33215-33221	Stages	_	
156-647	33222-33224	of	_	
156-648	33225-33234	Psychotic	_	
156-649	33235-33244	Disorders	_	
156-650	33245-33260	Thalamocortical	_	
156-651	33261-33276	dysconnectivity	_	
156-652	33277-33279	in	_	
156-653	33280-33293	schizophrenia	_	
156-654	33294-33295	A	_	
156-655	33295-33296	)	_	
156-656	33297-33301	Task	_	
156-657	33302-33311	schematic	_	
156-658	33311-33312	.	_	

#Text=For Single trials, participants responded to one of two images with a learned motor response or one of two audio tones with a learned vocal response, on Dual trials, both visual and audio cues were presented simultaneously and participants were requested to perform both responses.
157-1	33313-33316	For	_	
157-2	33317-33323	Single	_	
157-3	33324-33330	trials	_	
157-4	33330-33331	,	_	
157-5	33332-33344	participants	_	
157-6	33345-33354	responded	_	
157-7	33355-33357	to	_	
157-8	33358-33361	one	_	
157-9	33362-33364	of	_	
157-10	33365-33368	two	_	
157-11	33369-33375	images	_	
157-12	33376-33380	with	_	
157-13	33381-33382	a	_	
157-14	33383-33390	learned	_	
157-15	33391-33396	motor	_	
157-16	33397-33405	response	_	
157-17	33406-33408	or	_	
157-18	33409-33412	one	_	
157-19	33413-33415	of	_	
157-20	33416-33419	two	_	
157-21	33420-33425	audio	_	
157-22	33426-33431	tones	_	
157-23	33432-33436	with	_	
157-24	33437-33438	a	_	
157-25	33439-33446	learned	_	
157-26	33447-33452	vocal	_	
157-27	33453-33461	response	_	
157-28	33461-33462	,	_	
157-29	33463-33465	on	_	
157-30	33466-33470	Dual	_	
157-31	33471-33477	trials	_	
157-32	33477-33478	,	_	
157-33	33479-33483	both	_	
157-34	33484-33490	visual	_	
157-35	33491-33494	and	_	
157-36	33495-33500	audio	_	
157-37	33501-33505	cues	_	
157-38	33506-33510	were	_	
157-39	33511-33520	presented	_	
157-40	33521-33535	simultaneously	_	
157-41	33536-33539	and	_	
157-42	33540-33552	participants	_	
157-43	33553-33557	were	_	
157-44	33558-33567	requested	_	
157-45	33568-33570	to	_	
157-46	33571-33578	perform	_	
157-47	33579-33583	both	_	
157-48	33584-33593	responses	_	
157-49	33593-33594	.	_	

#Text=B) Behavioral performance.
158-1	33595-33596	B	_	
158-2	33596-33597	)	_	
158-3	33598-33608	Behavioral	_	
158-4	33609-33620	performance	_	
158-5	33620-33621	.	_	

#Text=Single condition accuracy ranged from 70 to 100% for CON and 60 to 100% for SCZ.
159-1	33622-33628	Single	_	
159-2	33629-33638	condition	_	
159-3	33639-33647	accuracy	_	
159-4	33648-33654	ranged	_	
159-5	33655-33659	from	_	
159-6	33660-33662	70	_	
159-7	33663-33665	to	_	
159-8	33666-33670	100%	_	
159-9	33671-33674	for	_	
159-10	33675-33678	CON	_	
159-11	33679-33682	and	_	
159-12	33683-33685	60	_	
159-13	33686-33688	to	_	
159-14	33689-33693	100%	_	
159-15	33694-33697	for	_	
159-16	33698-33701	SCZ	_	
159-17	33701-33702	.	_	

#Text=Dual condition accuracy ranged from 42 to 100% for CON and from 23 to 100% for SCZ.
160-1	33703-33707	Dual	_	
160-2	33708-33717	condition	_	
160-3	33718-33726	accuracy	_	
160-4	33727-33733	ranged	_	
160-5	33734-33738	from	_	
160-6	33739-33741	42	_	
160-7	33742-33744	to	_	
160-8	33745-33749	100%	_	
160-9	33750-33753	for	_	
160-10	33754-33757	CON	_	
160-11	33758-33761	and	_	
160-12	33762-33766	from	_	
160-13	33767-33769	23	_	
160-14	33770-33772	to	_	
160-15	33773-33777	100%	_	
160-16	33778-33781	for	_	
160-17	33782-33785	SCZ	_	
160-18	33785-33786	.	_	

#Text=No significant group differences were found for either accuracy or reaction time.
161-1	33787-33789	No	_	
161-2	33790-33801	significant	_	
161-3	33802-33807	group	_	
161-4	33808-33819	differences	_	
161-5	33820-33824	were	_	
161-6	33825-33830	found	_	
161-7	33831-33834	for	_	
161-8	33835-33841	either	_	
161-9	33842-33850	accuracy	_	
161-10	33851-33853	or	_	
161-11	33854-33862	reaction	_	
161-12	33863-33867	time	_	
161-13	33867-33868	.	_	

#Text=Abbreviations CON=Healthy control group; SCZ=Schizophrenia group.
162-1	33869-33882	Abbreviations	_	
162-2	33883-33886	CON	_	
162-3	33886-33887	=	_	
162-4	33887-33894	Healthy	_	
162-5	33895-33902	control	_	
162-6	33903-33908	group	_	
162-7	33908-33909	;	_	
162-8	33910-33913	SCZ	_	
162-9	33913-33914	=	_	
162-10	33914-33927	Schizophrenia	_	
162-11	33928-33933	group	_	
162-12	33933-33934	.	_	

#Text=A) Whole brain voxelwise analysis of brain regions showing differences in Dual>Single contrast in healthy individuals (CON), schizophrenia patients (SCZ) and CON>SCZ difference.
163-1	33935-33936	A	_	
163-2	33936-33937	)	_	
163-3	33938-33943	Whole	_	
163-4	33944-33949	brain	_	
163-5	33950-33959	voxelwise	_	
163-6	33960-33968	analysis	_	
163-7	33969-33971	of	_	
163-8	33972-33977	brain	_	
163-9	33978-33985	regions	_	
163-10	33986-33993	showing	_	
163-11	33994-34005	differences	_	
163-12	34006-34008	in	_	
163-13	34009-34013	Dual	_	
163-14	34013-34014	>	_	
163-15	34014-34020	Single	_	
163-16	34021-34029	contrast	_	
163-17	34030-34032	in	_	
163-18	34033-34040	healthy	_	
163-19	34041-34052	individuals	_	
163-20	34053-34054	(	_	
163-21	34054-34057	CON	_	
163-22	34057-34058	)	_	
163-23	34058-34059	,	_	
163-24	34060-34073	schizophrenia	_	
163-25	34074-34082	patients	_	
163-26	34083-34084	(	_	
163-27	34084-34087	SCZ	_	
163-28	34087-34088	)	_	
163-29	34089-34092	and	_	
163-30	34093-34096	CON	_	
163-31	34096-34097	>	_	
163-32	34097-34100	SCZ	_	
163-33	34101-34111	difference	_	
163-34	34111-34112	.	_	

#Text=Voxel-wise threshold of p<0.005.
164-1	34113-34123	Voxel-wise	_	
164-2	34124-34133	threshold	_	
164-3	34134-34136	of	_	
164-4	34137-34138	p	_	
164-5	34138-34139	<	_	
164-6	34139-34144	0.005	_	
164-7	34144-34145	.	_	

#Text=See Supplement Table 1 for clusterwise significance.
165-1	34146-34149	See	_	
165-2	34150-34160	Supplement	_	
165-3	34161-34166	Table	_	
165-4	34167-34168	1	_	
165-5	34169-34172	for	_	
165-6	34173-34184	clusterwise	_	
165-7	34185-34197	significance	_	
165-8	34197-34198	.	_	

#Text=B) Dual>Single contrast masked with the Harvard-Oxford bilateral thalamus to show thalamus specific activation differences between CON and SCZ.
166-1	34199-34200	B	_	
166-2	34200-34201	)	_	
166-3	34202-34206	Dual	_	
166-4	34206-34207	>	_	
166-5	34207-34213	Single	_	
166-6	34214-34222	contrast	_	
166-7	34223-34229	masked	_	
166-8	34230-34234	with	_	
166-9	34235-34238	the	_	
166-10	34239-34253	Harvard-Oxford	_	
166-11	34254-34263	bilateral	_	
166-12	34264-34272	thalamus	_	
166-13	34273-34275	to	_	
166-14	34276-34280	show	_	
166-15	34281-34289	thalamus	_	
166-16	34290-34298	specific	_	
166-17	34299-34309	activation	_	
166-18	34310-34321	differences	_	
166-19	34322-34329	between	_	
166-20	34330-34333	CON	_	
166-21	34334-34337	and	_	
166-22	34338-34341	SCZ	_	
166-23	34341-34342	.	_	

#Text=Voxel-wise threshold p<0.005, cluster significant at FDR < 0.05SVC.
167-1	34343-34353	Voxel-wise	_	
167-2	34354-34363	threshold	_	
167-3	34364-34365	p	_	
167-4	34365-34366	<	_	
167-5	34366-34371	0.005	_	
167-6	34371-34372	,	_	
167-7	34373-34380	cluster	_	
167-8	34381-34392	significant	_	
167-9	34393-34395	at	_	
167-10	34396-34399	FDR	_	
167-11	34400-34401	<	_	
167-12	34402-34409	0.05SVC	_	
167-13	34409-34410	.	_	

#Text=Activation patterns in (A) prefrontal cortex (PFC) and (B) thalamus regions of interest (ROIs) All ROIs showed significant condition effects (p<0.001), only the MD showed significant group differences (F(1,37)=12.28, p<0.01) Abbreviations: FEF=frontal eye fields; pre-SMA=presupplementary motor area; LPFC=lateral prefrontal cortex; MD=mediodorsal thalamus; PUL=pulvinar; VL=ventrolateral thalamus.
168-1	34411-34421	Activation	_	
168-2	34422-34430	patterns	_	
168-3	34431-34433	in	_	
168-4	34434-34435	(	_	
168-5	34435-34436	A	_	
168-6	34436-34437	)	_	
168-7	34438-34448	prefrontal	_	
168-8	34449-34455	cortex	_	
168-9	34456-34457	(	_	
168-10	34457-34460	PFC	_	
168-11	34460-34461	)	_	
168-12	34462-34465	and	_	
168-13	34466-34467	(	_	
168-14	34467-34468	B	_	
168-15	34468-34469	)	_	
168-16	34470-34478	thalamus	_	
168-17	34479-34486	regions	_	
168-18	34487-34489	of	_	
168-19	34490-34498	interest	_	
168-20	34499-34500	(	_	
168-21	34500-34504	ROIs	_	
168-22	34504-34505	)	_	
168-23	34506-34509	All	_	
168-24	34510-34514	ROIs	_	
168-25	34515-34521	showed	_	
168-26	34522-34533	significant	_	
168-27	34534-34543	condition	_	
168-28	34544-34551	effects	_	
168-29	34552-34553	(	_	
168-30	34553-34554	p	_	
168-31	34554-34555	<	_	
168-32	34555-34560	0.001	_	
168-33	34560-34561	)	_	
168-34	34561-34562	,	_	
168-35	34563-34567	only	_	
168-36	34568-34571	the	_	
168-37	34572-34574	MD	_	
168-38	34575-34581	showed	_	
168-39	34582-34593	significant	_	
168-40	34594-34599	group	_	
168-41	34600-34611	differences	_	
168-42	34612-34613	(	_	
168-43	34613-34614	F	_	
168-44	34614-34615	(	_	
168-45	34615-34619	1,37	_	
168-46	34619-34620	)	_	
168-47	34620-34621	=	_	
168-48	34621-34626	12.28	_	
168-49	34626-34627	,	_	
168-50	34628-34629	p	_	
168-51	34629-34630	<	_	
168-52	34630-34634	0.01	_	
168-53	34634-34635	)	_	
168-54	34636-34649	Abbreviations	_	
168-55	34649-34650	:	_	
168-56	34651-34654	FEF	_	
168-57	34654-34655	=	_	
168-58	34655-34662	frontal	_	
168-59	34663-34666	eye	_	
168-60	34667-34673	fields	_	
168-61	34673-34674	;	_	
168-62	34675-34682	pre-SMA	_	
168-63	34682-34683	=	_	
168-64	34683-34699	presupplementary	_	
168-65	34700-34705	motor	_	
168-66	34706-34710	area	_	
168-67	34710-34711	;	_	
168-68	34712-34716	LPFC	_	
168-69	34716-34717	=	_	
168-70	34717-34724	lateral	_	
168-71	34725-34735	prefrontal	_	
168-72	34736-34742	cortex	_	
168-73	34742-34743	;	_	
168-74	34744-34746	MD	_	
168-75	34746-34747	=	_	
168-76	34747-34758	mediodorsal	_	
168-77	34759-34767	thalamus	_	
168-78	34767-34768	;	_	
168-79	34769-34772	PUL	_	
168-80	34772-34773	=	_	
168-81	34773-34781	pulvinar	_	
168-82	34781-34782	;	_	
168-83	34783-34785	VL	_	
168-84	34785-34786	=	_	
168-85	34786-34799	ventrolateral	_	
168-86	34800-34808	thalamus	_	
168-87	34808-34809	.	_	

#Text=Connectivity between thalamic regions (i.e. seed) that demonstrated reduced taskbased activation in schizophrenia compared to healthy controls and prefrontal cortex regions of interest.
169-1	34810-34822	Connectivity	_	
169-2	34823-34830	between	_	
169-3	34831-34839	thalamic	_	
169-4	34840-34847	regions	_	
169-5	34848-34849	(	_	
169-6	34849-34852	i.e	_	
169-7	34852-34853	.	_	
169-8	34854-34858	seed	_	
169-9	34858-34859	)	_	
169-10	34860-34864	that	_	
169-11	34865-34877	demonstrated	_	
169-12	34878-34885	reduced	_	
169-13	34886-34895	taskbased	_	
169-14	34896-34906	activation	_	
169-15	34907-34909	in	_	
169-16	34910-34923	schizophrenia	_	
169-17	34924-34932	compared	_	
169-18	34933-34935	to	_	
169-19	34936-34943	healthy	_	
169-20	34944-34952	controls	_	
169-21	34953-34956	and	_	
169-22	34957-34967	prefrontal	_	
169-23	34968-34974	cortex	_	
169-24	34975-34982	regions	_	
169-25	34983-34985	of	_	
169-26	34986-34994	interest	_	
169-27	34994-34995	.	_	

#Text=The LPFC showed a significant interaction effect (F(1,37)=10.23, p<0.05, Bonferroni corrected for 4 tests), indicating our schizophrenia group did not show the cognitive demand related modulation of functional connectivity observed in our healthy group.
170-1	34996-34999	The	_	
170-2	35000-35004	LPFC	_	
170-3	35005-35011	showed	_	
170-4	35012-35013	a	_	
170-5	35014-35025	significant	_	
170-6	35026-35037	interaction	_	
170-7	35038-35044	effect	_	
170-8	35045-35046	(	_	
170-9	35046-35047	F	_	
170-10	35047-35048	(	_	
170-11	35048-35052	1,37	_	
170-12	35052-35053	)	_	
170-13	35053-35054	=	_	
170-14	35054-35059	10.23	_	
170-15	35059-35060	,	_	
170-16	35061-35062	p	_	
170-17	35062-35063	<	_	
170-18	35063-35067	0.05	_	
170-19	35067-35068	,	_	
170-20	35069-35079	Bonferroni	_	
170-21	35080-35089	corrected	_	
170-22	35090-35093	for	_	
170-23	35094-35095	4	_	
170-24	35096-35101	tests	_	
170-25	35101-35102	)	_	
170-26	35102-35103	,	_	
170-27	35104-35114	indicating	_	
170-28	35115-35118	our	_	
170-29	35119-35132	schizophrenia	_	
170-30	35133-35138	group	_	
170-31	35139-35142	did	_	
170-32	35143-35146	not	_	
170-33	35147-35151	show	_	
170-34	35152-35155	the	_	
170-35	35156-35165	cognitive	_	
170-36	35166-35172	demand	_	
170-37	35173-35180	related	_	
170-38	35181-35191	modulation	_	
170-39	35192-35194	of	_	
170-40	35195-35205	functional	_	
170-41	35206-35218	connectivity	_	
170-42	35219-35227	observed	_	
170-43	35228-35230	in	_	
170-44	35231-35234	our	_	
170-45	35235-35242	healthy	_	
170-46	35243-35248	group	_	
170-47	35248-35249	.	_	

#Text=No other main effects or interaction were significant.
171-1	35250-35252	No	_	
171-2	35253-35258	other	_	
171-3	35259-35263	main	_	
171-4	35264-35271	effects	_	
171-5	35272-35274	or	_	
171-6	35275-35286	interaction	_	
171-7	35287-35291	were	_	
171-8	35292-35303	significant	_	
171-9	35303-35304	.	_	

#Text=Abbreviations: FEF=frontal eye fields; pre-SMA=presupplementary motor area; LPFC=lateral prefrontal cortex.
172-1	35305-35318	Abbreviations	_	
172-2	35318-35319	:	_	
172-3	35320-35323	FEF	_	
172-4	35323-35324	=	_	
172-5	35324-35331	frontal	_	
172-6	35332-35335	eye	_	
172-7	35336-35342	fields	_	
172-8	35342-35343	;	_	
172-9	35344-35351	pre-SMA	_	
172-10	35351-35352	=	_	
172-11	35352-35368	presupplementary	_	
172-12	35369-35374	motor	_	
172-13	35375-35379	area	_	
172-14	35379-35380	;	_	
172-15	35381-35385	LPFC	_	
172-16	35385-35386	=	_	
172-17	35386-35393	lateral	_	
172-18	35394-35404	prefrontal	_	
172-19	35405-35411	cortex	_	
172-20	35411-35412	.	_	

#Text=Sample Demographics
#Text=\tCON\tSCZ\tStatistics\t \tVariable\tn=19\tn=20\tt/x2\tdf\tp\t \tSex (M:F)\t8:11\t10:10\t0.24\t37\t.621\t \tEthnicity (W:AA)\t14:5\t12:8\t.82\t37\t.365\t \tHandedness (L:R:A)\t3:15:1\t2:17:1\t.30\t37\t.861\t \tSmoking (Y:N)\t3:16\t7:13\t1.89\t37\t.170\t \t\tMean\tSD\tMean\tSD\t\t\t\t \t\t\t\t\t\t \tAge\t41.05\t8.8\t40.45\t11.9\t0.18\t37\t.858\t \tEducation\t16.42\t2.1\t13.80\t2.3\t3.72\t37\t<.001\t \tMaternal Education\t12.74\t2.2\t13.16\t3.3\t−0.47\t36\t.642\t \tPaternal Education\t13.84\t3.3\t13.16\t4.1\t0.57\t36\t.573\t \tWTAR\t109.32\t11.3\t102.70\t14.0\t1.63\t37\t.111\t \tPANSS Positive\t--\t13.8\t6.1\t--\t--\t--\t \tPANSS Negative\t--\t14.7\t5.6\t--\t--\t--\t \tPANSS General\t--\t26.9\t7.8\t--\t--\t--\t \tAge of Onset\t--\t22.2\t5.6\t--\t--\t--\t \tCPZ equivalent\t--\t387\t262.3\t--\t--\t--\t \t
#Text=Abbreviations: CON=Healthy Controls; SCZ=Schizophrenia Spectrum Disorder; AA=African American; A=Ambidextrous; CPZ=Chlorpromazine; df=Degrees of Freedom; F=Female; L=Left; M=Male; N=no; PANSS=Positive and Negative Syndrome Scale; R=Right; W=White; WTAR=Wechsler Test of Adult Reading; Y=yes
#Text=Task performance
#Text=\tCON\tSCZ\t \t\tSingle\tDual\tSingle\tDual\t \t\t\t \tAccuracy\t90.2±10.1\t78.3±20.4\t87.8±14.0\t74.0±26.4\t \tReaction Time\t1062±157\t1374±233\t1203±169\t1461±242
173-1	35413-35419	Sample	_	
173-2	35420-35432	Demographics	_	
173-3	35434-35437	CON	_	
173-4	35438-35441	SCZ	_	
173-5	35442-35452	Statistics	_	
173-6	35455-35463	Variable	_	
173-7	35464-35465	n	_	
173-8	35465-35466	=	_	
173-9	35466-35468	19	_	
173-10	35469-35470	n	_	
173-11	35470-35471	=	_	
173-12	35471-35473	20	_	
173-13	35474-35475	t	_	
173-14	35475-35476	/	_	
173-15	35476-35478	x2	_	
173-16	35479-35481	df	_	
173-17	35482-35483	p	_	
173-18	35486-35489	Sex	_	
173-19	35490-35491	(	_	
173-20	35491-35492	M	_	
173-21	35492-35493	:	_	
173-22	35493-35494	F	_	
173-23	35494-35495	)	_	
173-24	35496-35497	8	_	
173-25	35497-35498	:	_	
173-26	35498-35500	11	_	
173-27	35501-35503	10	_	
173-28	35503-35504	:	_	
173-29	35504-35506	10	_	
173-30	35507-35511	0.24	_	
173-31	35512-35514	37	_	
173-32	35515-35519	.621	_	
173-33	35522-35531	Ethnicity	_	
173-34	35532-35533	(	_	
173-35	35533-35534	W	_	
173-36	35534-35535	:	_	
173-37	35535-35537	AA	_	
173-38	35537-35538	)	_	
173-39	35539-35541	14	_	
173-40	35541-35542	:	_	
173-41	35542-35543	5	_	
173-42	35544-35546	12	_	
173-43	35546-35547	:	_	
173-44	35547-35548	8	_	
173-45	35549-35552	.82	_	
173-46	35553-35555	37	_	
173-47	35556-35560	.365	_	
173-48	35563-35573	Handedness	_	
173-49	35574-35575	(	_	
173-50	35575-35576	L	_	
173-51	35576-35577	:	_	
173-52	35577-35578	R	_	
173-53	35578-35579	:	_	
173-54	35579-35580	A	_	
173-55	35580-35581	)	_	
173-56	35582-35583	3	_	
173-57	35583-35584	:	_	
173-58	35584-35586	15	_	
173-59	35586-35587	:	_	
173-60	35587-35588	1	_	
173-61	35589-35590	2	_	
173-62	35590-35591	:	_	
173-63	35591-35593	17	_	
173-64	35593-35594	:	_	
173-65	35594-35595	1	_	
173-66	35596-35599	.30	_	
173-67	35600-35602	37	_	
173-68	35603-35607	.861	_	
173-69	35610-35617	Smoking	_	
173-70	35618-35619	(	_	
173-71	35619-35620	Y	_	
173-72	35620-35621	:	_	
173-73	35621-35622	N	_	
173-74	35622-35623	)	_	
173-75	35624-35625	3	_	
173-76	35625-35626	:	_	
173-77	35626-35628	16	_	
173-78	35629-35630	7	_	
173-79	35630-35631	:	_	
173-80	35631-35633	13	_	
173-81	35634-35638	1.89	_	
173-82	35639-35641	37	_	
173-83	35642-35646	.170	_	
173-84	35650-35654	Mean	_	
173-85	35655-35657	SD	_	
173-86	35658-35662	Mean	_	
173-87	35663-35665	SD	_	
173-88	35678-35681	Age	_	
173-89	35682-35687	41.05	_	
173-90	35688-35691	8.8	_	
173-91	35692-35697	40.45	_	
173-92	35698-35702	11.9	_	
173-93	35703-35707	0.18	_	
173-94	35708-35710	37	_	
173-95	35711-35715	.858	_	
173-96	35718-35727	Education	_	
173-97	35728-35733	16.42	_	
173-98	35734-35737	2.1	_	
173-99	35738-35743	13.80	_	
173-100	35744-35747	2.3	_	
173-101	35748-35752	3.72	_	
173-102	35753-35755	37	_	
173-103	35756-35757	<	_	
173-104	35757-35761	.001	_	
173-105	35764-35772	Maternal	_	
173-106	35773-35782	Education	_	
173-107	35783-35788	12.74	_	
173-108	35789-35792	2.2	_	
173-109	35793-35798	13.16	_	
173-110	35799-35802	3.3	_	
173-111	35803-35804	−	_	
173-112	35804-35808	0.47	_	
173-113	35809-35811	36	_	
173-114	35812-35816	.642	_	
173-115	35819-35827	Paternal	_	
173-116	35828-35837	Education	_	
173-117	35838-35843	13.84	_	
173-118	35844-35847	3.3	_	
173-119	35848-35853	13.16	_	
173-120	35854-35857	4.1	_	
173-121	35858-35862	0.57	_	
173-122	35863-35865	36	_	
173-123	35866-35870	.573	_	
173-124	35873-35877	WTAR	_	
173-125	35878-35884	109.32	_	
173-126	35885-35889	11.3	_	
173-127	35890-35896	102.70	_	
173-128	35897-35901	14.0	_	
173-129	35902-35906	1.63	_	
173-130	35907-35909	37	_	
173-131	35910-35914	.111	_	
173-132	35917-35922	PANSS	_	
173-133	35923-35931	Positive	_	
173-134	35932-35933	-	_	
173-135	35933-35934	-	_	
173-136	35935-35939	13.8	_	
173-137	35940-35943	6.1	_	
173-138	35944-35945	-	_	
173-139	35945-35946	-	_	
173-140	35947-35948	-	_	
173-141	35948-35949	-	_	
173-142	35950-35951	-	_	
173-143	35951-35952	-	_	
173-144	35955-35960	PANSS	_	
173-145	35961-35969	Negative	_	
173-146	35970-35971	-	_	
173-147	35971-35972	-	_	
173-148	35973-35977	14.7	_	
173-149	35978-35981	5.6	_	
173-150	35982-35983	-	_	
173-151	35983-35984	-	_	
173-152	35985-35986	-	_	
173-153	35986-35987	-	_	
173-154	35988-35989	-	_	
173-155	35989-35990	-	_	
173-156	35993-35998	PANSS	_	
173-157	35999-36006	General	_	
173-158	36007-36008	-	_	
173-159	36008-36009	-	_	
173-160	36010-36014	26.9	_	
173-161	36015-36018	7.8	_	
173-162	36019-36020	-	_	
173-163	36020-36021	-	_	
173-164	36022-36023	-	_	
173-165	36023-36024	-	_	
173-166	36025-36026	-	_	
173-167	36026-36027	-	_	
173-168	36030-36033	Age	_	
173-169	36034-36036	of	_	
173-170	36037-36042	Onset	_	
173-171	36043-36044	-	_	
173-172	36044-36045	-	_	
173-173	36046-36050	22.2	_	
173-174	36051-36054	5.6	_	
173-175	36055-36056	-	_	
173-176	36056-36057	-	_	
173-177	36058-36059	-	_	
173-178	36059-36060	-	_	
173-179	36061-36062	-	_	
173-180	36062-36063	-	_	
173-181	36066-36069	CPZ	_	
173-182	36070-36080	equivalent	_	
173-183	36081-36082	-	_	
173-184	36082-36083	-	_	
173-185	36084-36087	387	_	
173-186	36088-36093	262.3	_	
173-187	36094-36095	-	_	
173-188	36095-36096	-	_	
173-189	36097-36098	-	_	
173-190	36098-36099	-	_	
173-191	36100-36101	-	_	
173-192	36101-36102	-	_	
173-193	36106-36119	Abbreviations	_	
173-194	36119-36120	:	_	
173-195	36121-36124	CON	_	
173-196	36124-36125	=	_	
173-197	36125-36132	Healthy	_	
173-198	36133-36141	Controls	_	
173-199	36141-36142	;	_	
173-200	36143-36146	SCZ	_	
173-201	36146-36147	=	_	
173-202	36147-36160	Schizophrenia	_	
173-203	36161-36169	Spectrum	_	
173-204	36170-36178	Disorder	_	
173-205	36178-36179	;	_	
173-206	36180-36182	AA	_	
173-207	36182-36183	=	_	
173-208	36183-36190	African	_	
173-209	36191-36199	American	_	
173-210	36199-36200	;	_	
173-211	36201-36202	A	_	
173-212	36202-36203	=	_	
173-213	36203-36215	Ambidextrous	_	
173-214	36215-36216	;	_	
173-215	36217-36220	CPZ	_	
173-216	36220-36221	=	_	
173-217	36221-36235	Chlorpromazine	_	
173-218	36235-36236	;	_	
173-219	36237-36239	df	_	
173-220	36239-36240	=	_	
173-221	36240-36247	Degrees	_	
173-222	36248-36250	of	_	
173-223	36251-36258	Freedom	_	
173-224	36258-36259	;	_	
173-225	36260-36261	F	_	
173-226	36261-36262	=	_	
173-227	36262-36268	Female	_	
173-228	36268-36269	;	_	
173-229	36270-36271	L	_	
173-230	36271-36272	=	_	
173-231	36272-36276	Left	_	
173-232	36276-36277	;	_	
173-233	36278-36279	M	_	
173-234	36279-36280	=	_	
173-235	36280-36284	Male	_	
173-236	36284-36285	;	_	
173-237	36286-36287	N	_	
173-238	36287-36288	=	_	
173-239	36288-36290	no	_	
173-240	36290-36291	;	_	
173-241	36292-36297	PANSS	_	
173-242	36297-36298	=	_	
173-243	36298-36306	Positive	_	
173-244	36307-36310	and	_	
173-245	36311-36319	Negative	_	
173-246	36320-36328	Syndrome	_	
173-247	36329-36334	Scale	_	
173-248	36334-36335	;	_	
173-249	36336-36337	R	_	
173-250	36337-36338	=	_	
173-251	36338-36343	Right	_	
173-252	36343-36344	;	_	
173-253	36345-36346	W	_	
173-254	36346-36347	=	_	
173-255	36347-36352	White	_	
173-256	36352-36353	;	_	
173-257	36354-36358	WTAR	_	
173-258	36358-36359	=	_	
173-259	36359-36367	Wechsler	_	
173-260	36368-36372	Test	_	
173-261	36373-36375	of	_	
173-262	36376-36381	Adult	_	
173-263	36382-36389	Reading	_	
173-264	36389-36390	;	_	
173-265	36391-36392	Y	_	
173-266	36392-36393	=	_	
173-267	36393-36396	yes	_	
173-268	36397-36401	Task	_	
173-269	36402-36413	performance	_	
173-270	36415-36418	CON	_	
173-271	36419-36422	SCZ	_	
173-272	36426-36432	Single	_	
173-273	36433-36437	Dual	_	
173-274	36438-36444	Single	_	
173-275	36445-36449	Dual	_	
173-276	36456-36464	Accuracy	_	
173-277	36465-36469	90.2	_	
173-278	36469-36470	±	_	
173-279	36470-36474	10.1	_	
173-280	36475-36479	78.3	_	
173-281	36479-36480	±	_	
173-282	36480-36484	20.4	_	
173-283	36485-36489	87.8	_	
173-284	36489-36490	±	_	
173-285	36490-36494	14.0	_	
173-286	36495-36499	74.0	_	
173-287	36499-36500	±	_	
173-288	36500-36504	26.4	_	
173-289	36507-36515	Reaction	_	
173-290	36516-36520	Time	_	
173-291	36521-36525	1062	_	
173-292	36525-36526	±	_	
173-293	36526-36529	157	_	
173-294	36530-36534	1374	_	
173-295	36534-36535	±	_	
173-296	36535-36538	233	_	
173-297	36539-36543	1203	_	
173-298	36543-36544	±	_	
173-299	36544-36547	169	_	
173-300	36548-36552	1461	_	
173-301	36552-36553	±	_	
173-302	36553-36556	242	_	
